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SCIENTIFIC OPINION 
Scientific Opinion on the hazard assessment of endocrine disruptors: 
Scientific criteria for identification of endocrine disruptors and 
appropriateness of existing test methods for assessing effects mediated by 
these substances on human health and the environment
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EFSA Scientific Committee
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Upon  request  of  the  European  Commission,  the  Scientific  Committee  (SC)  of  the  European  Food  Safety 
Authority reviewed existing information related to the testing and assessment of endocrine active substances 
(EASs)  and  endocrine  disruptors  (EDs).  This  work  was  conducted  by  a  working  group  of  experts  in 
endocrinology, risk assessment and toxicology, together with observers from other EU agencies, namely EMA, 
ECHA and EEA. To distinguish between EDs and other groups of substances with different modes of action, it 
was concluded that an ED is defined by three criteria: the presence of i) an adverse effect in an intact organism 
or a (sub)population; ii) an endocrine activity; and iii) a plausible causal relationship between the two. As 
scientific criteria for adversity have not been generally defined, specific criteria for endocrine disrupting effects 
could  not  be  identified.  Hence,  expert  judgement  is  required  to  assess  on  a  case-by-case  basis  the 
(eco)toxicological relevance of changes at the molecular to individual and/or (sub)population level following 
exposure to an EAS. The SC concluded that a reasonably complete suite of standardised assays for testing the 
effects  of  EASs  is  (or  will  soon  be)  available  for  the  oestrogenic,  androgenic,  thyroid  and  steroidogenic 
modalities in mammals and fish, with fewer tests for birds and amphibians. Shortcomings in current tests and for 
other endocrine modalities and species were reviewed. Critical effect, severity, (ir)reversibility and potency 
aspects are part of the hazard characterisation of EDs. To inform on risk and level of concern for the purpose of 
risk management decisions, risk assessment (taking into account hazard and exposure data/predictions) makes 
best use of available information. Levels of concern are not determined exclusively by risk assessment but also 
by protection goals set by the risk management.  
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SUMMARY 
Following  a  request from  the  European  Commission  (EC),  the  Scientific  Committee  (SC)  of  the 
European Safety Authority (EFSA) was asked to deliver a scientific opinion on the hazard assessment 
of endocrine disruptors (EDs). More specifically  the SC was asked  to advise on i) the scientific 
criteria to distinguish between EDs and other groups of substances with different modes of action, ii) 
the criteria to distinguish between physiological modulation and adverse effects on humans and on the 
ecosystem as a result of exposure to endocrine active substances (EASs), and iii) to review existing 
test methods and discuss their appropriateness for the identification and characterisation of effects 
mediated by EASs. 
The SC defines an EAS as a substance having the inherent ability to interact or interfere with one or 
more components of the endocrine system resulting in a biological effect, but need not necessarily 
cause adverse effects. Therefore, the SC considers endocrine activity as a collection of modes of 
action, potentially leading to adverse outcomes, rather than a (eco)toxicological hazard in itself. The 
SC  endorsed  the  WHO/IPCS  2002  definition  of  an  ED  implying  that  there  must  be  reasonable 
evidence  for  a  biologically  plausible  causal  relationship  between  the  endocrine  activity  and  the 
induced  adverse  effect(s)  seen  in  an  intact  organism  or  a  (sub)population  for  a  substance  to  be 
identified as an ED. 
Assessment of adversity is not unique to endocrine related effects. Scientific criteria for assessment of 
adversity have not been  generally defined. In  general, but not always, transient, inconsistent and 
minor  fluctuations  at  the  biochemical  and  molecular  level  may  be  considered  adaptive,  i.e.  non-
adverse. Changes at the cell-, organ-, organism-, or (sub)population-level resulting in pathology or 
functional impairment in vivo, as well as altered timing of development, may be considered adverse. It 
is therefore difficult to propose ED-specific criteria for adversity and expert judgement in a weight-of-
evidence approach is needed to assess substances for possible endocrine disrupting properties. 
The  Organisation  for  Economic  Co-operation  and  Development  (OECD)  revised  Conceptual 
Framework (CF) provides a guide to the data sources, the OECD test guidelines and standardised test 
methods available, under development or proposed for the evaluation of chemicals for EASs/EDs. 
Information on endocrine activity can be obtained from existing information, read-across, in silico 
tools, in vitro and in vivo screening assays (Levels 1, 2 and 3 of the CF), or from other mechanistic 
investigations. A prerequisite for an EAS to be regarded as an ED is the need to identify the adverse 
effect. For this, test methods with apical endpoints (Levels 4 and 5 of the CF) can be used together 
with existing information, read-across and other in vivo (eco)toxicity tests that provide information on 
apical  endpoints.  Therefore,  in  principle,  no  single assay  is  likely  to  provide  all  the  information 
needed to decide whether a substance is an ED because of the need to provide both mechanistic and 
apical information. 
Taken  together,  but  bearing  in  mind  the  recommendations  made  in  this  opinion,  a  reasonably 
complete suite of standardised assays (for testing the effects of EASs) is (or will soon be) available for 
the oestrogen, androgen, thyroid, or steroidogenesis (EATS) modalities in mammals and fish, with 
fewer tests available for birds and amphibians. While downstream effects of disruption of some non-
EATS pathways/modalities may be detectable in some of the standardised apical vertebrate assays, it 
is important to recognise that standardised mechanistic assays for non-EATS modalities relevant to 
mammals,  fish  and  other  vertebrates  are  not  or  not  yet  available.  For  invertebrates,  standardised 
mechanistic assays are lacking from the OECD testing suite, mainly due to poor understanding of 
invertebrate endocrinology. Finally, a range of major taxa, e.g. reptiles or echinoderms have not yet 
been considered by OECD for any endocrine assay development. It is unknown at present whether it 
will be possible to read-across to untested groups from tests with other taxa. 
The SC identified the need for further development of screens and test methods, particularly with 
regard  to  non-EATS  modalities  that  may  be  associated  with  adverse  effects  in  humans  or  the 
environment. Identification/Characterisation of EDs: scientific criteria and test methods 
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The SC discussed a number of general aspects related to the testing of substances (independently of 
whether these are EASs or substances with other modes of action): 
  Exposure  of  organs  and  tissues  to  certain  substances  at  critical  point(s)  during  their 
development can result in irreversible change of the organ/tissue. The SC noted that, although 
some of the tests in the OECD CF do cover exposure during critical periods of development 
in utero, current mammalian tests may not cover effects that might be induced by exposure 
during fetal or pubertal development, but may emerge during later life stages. Fish lifecycle 
tests cover all relevant windows of exposure and can be expected to reveal the longer-term 
effects of developmental exposures at all stages of the lifecycle. 
  The SC recognises that combined exposure to multiple EASs could occur in such a way that 
combined  toxicity  could  arise.  The  issue  of  combined  toxicity  resulting  from  combined 
exposure to multiple substances will be addressed by EFSA in a separate activity. 
  The SC noted the lack of consensus in the scientific community with regard to the existence 
and/or relevance of low-dose effects and non-monotonic dose response curves (NMDRCs) in 
(eco)toxicology  in  connection  with  endocrine  activity,  endocrine  disruption  or  other 
endpoints/modes of actions.  
 
The SC recommends as a follow up activity to clarify in a broader context the issues of biological 
thresholds and criteria for adversity, combined exposure to multiple substances and NMDRCs.  
The SC also underlines the need for the further development of testing strategies to generate adequate 
data for the identification and assessment of endocrine disrupting properties. An example has been 
developed in outline for fish species by the OECD. 
The SC discussed several aspects that can be considered for hazard characterisation of EDs. The SC is 
of  the  opinion  that  hazard  characterisation  (e.g.  establishment  of  a  health-/ecotoxicology-based 
guidance  value)  should  be  based  on  the  effect  leading  to  the  lowest  health/ecotoxicology-based 
guidance value, irrespective of the mode of action. Such a health/ecotoxicology-based guidance value 
would also protect against endocrine-mediated effects occurring at higher doses. With regard to the 
use of severity, (ir)reversibility and potency for the hazard characterisation of EDs, the SC considers 
that to inform on a level of concern for endocrine disrupting substances, these elements should be 
evaluated  in  relation  to  the  degree,  duration  and  timing  of  exposure.  Levels  of  concern  are  not 
determined exclusively by risk assessment but also by protection goals set by the risk management. 
In  conclusion,  EDs,  of  natural  or  synthetic  origin,  can  be  identified  according  to  three  criteria: 
endocrine activity, adversity of effects and a plausible link between endocrine activity and adverse 
effect. The SC considers that a reasonably complete suite of assays is (or will soon be) available to 
identify and characterise the important hazards of EATS substances in mammals and fish, with fewer 
tests available for birds and amphibians. Furthermore, these evaluation methods should, in principle, 
be fit for the purpose of establishing safe doses/concentrations of EDs if (1) certain aspects (e.g. 
follow up of exposure in critical windows of susceptibility to later life stages) are addressed and (2) 
used with all available information in a weight-of-evidence approach. It should also be noted that 
standardised  mechanistic  assays  for  non-EATS  modalities  relevant  to  mammals,  fish  and  other 
vertebrates are not yet available. For invertebrates, relevant mechanistic assays are lacking from the 
OECD testing suite. Finally, a range of major taxa e.g. reptiles or echinoderms, have not yet been 
considered by the OECD for any endocrine assay development. 
Furthermore, to inform on risk and level of concern for the purpose of risk management decisions it is 
the opinion of the SC that risk assessment (taking into account hazard and exposure data/predictions) 
makes best use of available information. EDs can therefore be treated like most other substances of 
concern for human health and the environment, i.e. be subject to risk assessment and not only to 
hazard assessment. Identification/Characterisation of EDs: scientific criteria and test methods 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
 
The endocrine system plays a crucial role in maintaining human homeostasis and is often affected by 
exogenous stimuli. A range of synthetic as well as naturally occurring agents have been identified as 
interacting  with  the  endocrine  system.  If  the  interaction  of  these  exogenous  substances  with  the 
endocrine  system  leads  to  adverse  health  effect  in  an  intact  organism  or  its  progeny  or  (sub) 
populations, these substances are referred to as „endocrine disruptors‟
4 (EDs). 
Given the range of the EU legislation under which these substances are regulated (such as plant 
protection  products,  biocides,  pharmaceuticals,  cosmetics,  chemicals),  the  European  Commission 
(EC) published its proposed Community Strategy for Endocrine Disruptors
5 in 1993. The European 
Parliament called on the EC in 1998 to examine many research and regulatory questions related to 
endocrine disruption. 
The Community Strategy called for the establishment of  „a  list  of  substances  requiring  priority 
evaluation („ED priority list‟) of their role in endocrine disruption and to identify inter alia substances 
which can already be addressed under existing legislation, gaps in knowledge and specific cases of 
consumer  use  for  special  consideration‟.  On  the  basis  of  independent  reviews  of  peer-reviewed 
scientific literature, and in consultation with the Commission‟s Scientific Committee on Toxicity, 
Ecotoxicity and the Environment, a candidate list of 553 synthetic chemicals and 9 hormones was 
published in 2000, together with a series of actions proposed to further evaluate the role of these 
substances  in  endocrine  disruption.  The  final  long-term  goals  of  the  Community  Strategy  are 
„legislative  actions‟  to  control  substances  having  harmful  effects  on  humans,  wildlife  and/or  the 
environment.  
In  recognition  of  the  need  to  address  the  problem  of  endocrine  disruptors,  many  pieces  of  EU 
legislation contain specific provisions on this issue, e.g. REACH, Food and Feed legislation, Plant 
Protection  Products  Regulation,  Biocides  Regulation,  Regulation  on  cosmetics,  Water  Framework 
Directive and others. Currently, the main focus both within the EU and internationally is to agree on 
approaches for the identification and risk assessment of endocrine disruptors. 
 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
 
In the light of the above, EFSA is asked to advise the Commission on the following questions: 
1) What scientific criteria may be used to distinguish between EDs and other groups of chemicals with 
different modes of action? The answer should examine the following: low-dose effects, including non-
monotonic dose response, critical windows of susceptibility, threshold effects etc. 
2) What scientific criteria may be used to distinguish between physiological modulation (adaptive 
response) and adverse effects on humans and on the ecosystem as a result of exposure to endocrine 
active substances? 
3) Are the existing toxicity testing methods appropriate for the identification and characterisation of 
effects mediated by endocrine active substances (both humans and ecosystem should be considered)? 
                                                       
4  "An  endocrine  disruptor  is  an  exogenous  substance  or  mixture  that  alters  function(s)  of  the  endocrine  system  and 
consequently  causes  adverse  health  effects  in  an  intact  organism,  or  its  progeny,  or  (sub)populations.",  International 
Programme on Chemical Safety (IPCS). 2002. Global Assessment of the State-of-the-Science of Endocrine Disruptors. 
WHO (World Health Organization), Geneva, Switzerland. 
5  http://europa.eu/legislation_summaries/internal_market/single_market_for_goods/chemical_products/l21277_en.htm  Identification/Characterisation of EDs: scientific criteria and test methods 
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In  developing  this  opinion,  EFSA  is  requested  to  take  account  of  the  latest  available  published 
scientific  information,  including  the  final  report  „State  of  the  Art  Assessment  of  Endocrine 
Disrupters‟(Kortenkamp et al., 2011). 
With  a  view  to  ensuring  consistency,  other  Scientific  Advisory  Bodies,  including  the  European 
Medicines  Agency  (EMA),  the  European  Chemical  Agency  (ECHA),  the  European  Environment 
Agency (EEA) and the European Commission Scientific Committees (SCCS, SCHER and SCENIHR) 
should be involved during the preparation of the opinion. 
The Commission would ask the EFSA to provide its final opinion to the present request by March 
2013. 
 
CLARIFICATIONS TO THE TERMS OF REFERENCE 
 
Following clarification of the problem formulation between EFSA and the EC, it was agreed that this 
EFSA opinion would take stock of the available information related to the three specific questions 
posed by the Commission in the terms of reference, namely  
i)  What scientific criteria should be used to identify EDs,  
ii)  What is an adverse effect and how can it be distinguished from physiological modulation, and  
iii)  Are existing toxicity testing methods appropriately covering the effects of endocrine active 
substances?  The  opinion  will  be  based  on  an  evaluation  of  existing  information,  current 
insights  and  scientific  activities  on  „endocrine  disruptors‟,  from  European  and  other 
international parties. 
 
METHODOLOGY 
 
Composition of the working group tasked with drafting the opinion 
EFSA  followed  its  specific  Standard  Operating  Procedure  detailing  the  steps  necessary  for 
establishing, updating or closing a scientific working group. This procedure describes for example the 
process for appointing the Chair, the identification of the areas of expertise that need to be covered 
and the way experts with matching profiles are sought at EFSA or in the EFSA Expert Database. The 
areas of expertise considered to be relevant for this mandate are endocrinology (general, human and 
environmental), and risk assessment and toxicology (general, human and environmental). Experts with 
up-to-date knowledge of (OECD) test methods for endocrine disruptors were also sought.  
As requested in the mandate received from the EC, other Scientific Advisory Bodies were approached 
to ensure consistency. This led to the identification of additional experts with a profile matching the 
above mentioned areas of expertise and who participate in advisory committees of the EC Scientific 
Committees (SCCS, SCHER, SCENIHR), EMA and EEA to join the working group in their personal 
capacity. In addition, representatives from the EC‟s Directorate-General for Health and Consumers 
and the Joint Research Centre – involved in the ongoing review of the EC‟s current strategy on EDs 
coordinated by the EC‟s Directorate-General for the Environment – , as well as EMA, EEA and 
ECHA were invited to participate as observers.  Identification/Characterisation of EDs: scientific criteria and test methods 
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In  addition,  the  EFSA  Scientific  Committee  Unit  ensured  links  with  experts  involved  with 
international organisations working on endocrine  active substances, such as OECD and WHO.  A 
hearing expert was invited to present and discuss during the 4
th meeting of the working group the 
WHO/UNEP draft update of the global assessment of the state of the science of endocrine disruptors.  
In accordance with the Decision of the Executive Director concerning the selection of experts
6, the 
declarations of interests of all  short-listed experts were checked for absence of conflicts of interest 
before they could be invited to participate in the working group to contribute in their personal 
capacity, as an observer or as  a hearing expert. A list of the members of the working group and the 
observers, as well as their declarations of interest were made available on EFSA‟s website
7. 
 
Sources of information 
The  development  of  this  opinion  was  initiated  by  compiling  important  documentation  previously 
published by various national, European and other international parties that have worked on the topic 
of endocrine active substances. In addition, EFSA asked its national focal points to contribute existing 
documents such as national position papers or reviews on endocrine active substances. In responding 
to the EC mandate, the SC took stock of the various (sometimes controversial) views from the various 
experts and fora. The SC acknowledges their informative value for the scientific issues discussed in 
this opinion. 
EFSA did not carry out a systematic literature review on endocrine active substances or endocrine 
disruptors.  A  non-exhaustive  overview  of  the  information  that  was  reviewed  for  this  opinion  is 
provided in Appendix A.  
 
Methodologies and approaches used to evaluate the information collected 
The SC and its working group applied the general principles for the evaluation of all information 
gathered to address the questions posed by the European Commission. These principles are described 
in the 2009 Guidance Document of the Scientific Committee on transparency in the scientific aspects 
of the risk assessments carried out by EFSA (EFSA, 2009a).  
                                                       
6  Decision of the Executive Director concerning the selection of members of the Scientific Committee, Scientific Panels and 
external  experts  to  assist  EFSA  with  its  scientific  work  (available  at 
http://www.efsa.europa.eu/en/keydocs/docs/expertselection.pdf)  
7  See http://www.efsa.europa.eu/en/sc/scwgs.htm and https://ess.efsa.europa.eu/doi/doiweb/wg/678310  Identification/Characterisation of EDs: scientific criteria and test methods 
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ASSESSMENT 
 
1.  Introduction  
 
Many substances released into the environment through human activity are capable of interfering with 
the  endocrine  or  hormone  systems  of  animals  and  humans,  which  regulate  the  metabolism  and 
function of the body. Such endocrine active substances (EASs) occur in a variety of chemical classes 
including  synthetic  drugs,  pesticides,  compounds  used  in  industry  and  in  consumer  products, 
industrial by-products and pollutants, including some metals. However, one should keep in mind that 
there is also a large number of EASs of natural origin occurring in plants consumed as food or feed, 
and also some secondary metabolites from fungi that may contaminate food and feed are known to 
express endocrine-like activity. Examples of naturally occurring EASs are oestrogenic compounds in 
soy (e.g. genistein and daidzein), mycotoxins (e.g. zearalenone) in cereals, goitrogens in cabbage with 
the potential to inhibit iodine uptake (glucosinates), and glycirrhizine in liquorice with the potential to 
disturb the mineralocorticoid system.  
The term „endocrine disruptor (ED)‟ was first used at the Wingspread Conference in Wisconsin, USA 
in 1991 for those EASs, which may lead to an adverse health effect (Colborn and Corlie, 1992). 
WHO/IPCS  developed  a  widely  accepted  definition,  which  is  discussed  later  in  this  opinion 
(WHO/IPCS, 2002).  
According  to  the  above  Wingspread  Conference  Statement  on  “chemically-induced  alterations  in 
sexual development: the wildlife/human connection”, the public concern regarding EDs was originally 
linked to observations  of reproductive and developmental toxicity in wildlife. These observations 
included  reduced  fertility,  birth  defects  and  sexual  and  behavioural  developmental  disorders. 
Furthermore, the public concern was also originally linked to cancer of the reproductive organs in 
female  offspring,  caused  by  the  use  of  synthetic  oestrogens  in  women  during  pregnancy  (e.g. 
diethylstilbestrol (DES)). Though effects may vary between species and compounds, the Conference 
Statement identified four main issues arising from exposure to EDs of synthetic and natural origin: (1) 
they may have effects on the embryo, fetus or perinatal organism different from those on the adult 
organism;  (2)  effects  are  often  manifested  in  offspring,  not  in  the  exposed  parent;  (3)  timing  of 
exposure in the developing organism is critical in determining future impact and character; and (4) 
although critical exposure may occur during embryonic development, obvious manifestations may not 
occur until maturity (Bern et al., 1992). A number of reports (Kortenkamp et al., 2011; EEA, 2012; 
WHO/UNEP, 2013) have recently analysed in detail the evidence for endocrine disruption in humans, 
wildlife  and  animal  models.  The  reader  is  referred  to  these  papers  for  detailed  and  updated 
information. 
However, it should be noted that the above mentioned issues related to reproduction and development 
are not specific to EDs and that the endocrine system extends far beyond those. Furthermore, the 
endocrine system includes many additional signalling systems in humans and animals involving a vast 
number  of  hormonal  or  signalling  factors,  which  are  divided  into  5  major  classes:  amino  acid 
derivatives, small neuropeptides, large proteins, steroid hormones and vitamin derivatives (Jameson, 
2010). In addition, numerous peptide growth factors share actions with hormones. For this reason, 
hormonal aspects of metabolic regulation and neurodevelopment have also recently been included in 
the endocrine system.  
Substances that may exert their adverse effects by endocrine-related modes of action are relevant to 
various sectors of EFSA‟s activities. An EFSA technical report developed by a cross-EFSA task force 
was published in 2010 to clarify the state-of-play and to make recommendations for scientific and 
communication issues (EFSA, 2010). In that report, the term „endocrine active substance‟ was used to Identification/Characterisation of EDs: scientific criteria and test methods 
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cover all substances that in some way may interfere with the endocrine system, but not necessarily 
cause adverse effects.  
 
1.1.  Scope of this opinion 
 
The standard risk assessment paradigm consists of four steps, namely hazard identification, hazard 
characterisation, exposure assessment and risk characterisation, of which the latter is an integration of 
the first three steps (EC, 2000; WHO/IPCS, 2009). In its present mandate on EDs, the European 
Commission  (EC)  poses  questions  in  the  terms  of  reference  related  to  the  potential  hazards  (i.e. 
inherent properties) of a substance. This opinion therefore focuses on the first two steps of the risk 
assessment paradigm, namely how to identify and characterise hazards mediated by EASs.  
There is a significant body of scientific evidence that some exogenous natural and synthetic chemicals 
can interfere with the function of animal endocrine systems (EFSA, 2010). While plant hormones are 
also well characterised, and there may be examples of natural or synthetic chemicals interacting with 
plant hormone function, the scope of this scientific opinion is the wildlife and human health effects of 
EDs; it does not include interference with plant hormone systems. 
The first and second points of the agreed terms of reference are addressed under section 3: Criteria for 
identifying  endocrine  disruptors.  The  third  point  is  discussed  under  section  4:  Availability  and 
appropriateness  of  test  methods  for  identifying  and  characterising  effects  mediated  by  endocrine 
active substances. It is not the purpose of this opinion to develop testing strategies for EDs. 
Due to the limited timeframe for the development of this opinion, a number of concepts mentioned in 
the original request of the ED could only be briefly discussed in this opinion: 
  Thresholds  aspects  are  considered  in  section  3.1,  when  discussing  criteria  to  distinguish 
endocrine disruption from endocrine modulation. 
  Low-dose effects, non-monotonic dose response curves, critical windows of susceptibility, 
and combined exposure to multiple substances are briefly discussed under section 4, when 
considering the appropriateness of test methods. 
  Critical  effect,  consideration  of  severity,  (ir)reversibility  and  potency  are  part  of  hazard 
characterisation (see section 5: Elements of hazard characterisation of EDs). 
   
1.2.  Overview of provisions for endocrine disruptors in EU legislation  
 
The  background  information  provided  by  the  EC  mentions  various  legislative  acts  that  contain 
specific provisions on endocrine disruption. Further summaries of these are given in Appendix B. 
Because of the broad use of endocrine active substances, the overview of relevant legislations goes 
beyond EFSA‟s remit (risk assessment of food and feed) and covers other areas such as medicines, 
cosmetics, industrial chemicals and biocides. Some of the proposed concepts such as „zero tolerance‟, 
„negligible level of exposure‟, or „levels of concern‟ are related to risk management and are therefore 
beyond the scope of this opinion.  
The Scientific Committee (SC) notes that Regulation (EC) No 1107/2009 on plant protection products 
includes  specific  provisions  to  approve  an  active  substance,  safener  or  synergist,  “if  it  is  not 
considered to have endocrine disrupting properties that may cause adverse effects in humans / on 
non-target  organisms  unless  the  exposure……is  negligible”.  It  follows  from  this  wording  that  a 
hazard-based approach is prescribed in the European Union for the regulation of plant protection 
substances exhibiting endocrine disruptive properties.  A similar approach is taken for biocides in Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    11 
Regulation  (EC)  No  528/2012.  A  different  approach  is  taken  in  the  USA  and  Japan,  where  risk 
assessment of all EASs is to be conducted, i.e. consideration of both hazard and exposure. 
 
2.  Definitions and terminology 
 
A variety of inter-related terms have been used to describe the phenomenon of endocrine-mediated 
effects, and while these may reflect the perspectives of different stakeholders, they also have varying 
scientific interpretations. As an example, two such terms are used in the terms of reference for this 
mandate: „endocrine disruptor‟, used in part i), and „endocrine active substance‟, used in part ii) and 
iii). This section is aimed at clarifying the meaning of and relationships between these terms.  
 
Endocrine system 
The endocrine system regulates the metabolism and function of the body and is further described by 
WHO/IPCS  (WHO/IPCS,  2002;  WHO,  2012)  and  on  the  US  EPA  website
8. As an inter -related 
system, the endocrine system influences almost every cell, organ, and function  of an organism. It 
regulates, with the use of numerous chemical messengers, various vital functions such as metabolism, 
growth and development, tissue function,  or mood, from conception through adulthood and into old 
age. This includes for example the development of the brain and nervous system, the growth and 
function of the reproductive system,  or the regulation  of blood sugar level. In order to  fulfil these 
functions, the endocrine system uses cycles and negative feedback  loops, regulating the secretion of 
almost all hormones. The cycles of secretion of chemical messengers, whose duration can range from 
hours to months, maintain physiological and homeostatic control.  Once a receptor and a hormone 
bind, the receptor carries out the hormone's instructions by either  leading to alteration of the cell's 
existing  proteins  or  alteration  of  gene  expression.  Both  of  these  actions  can  create  reactions 
throughout the body.  Endocrine system diseases and disorders  occur  when one or more of  the 
system‟s  components  are  not  working  well.  For  example,  a  hormonal  imbalance  may  develop  if 
hormones are released in too great or too small amounts, or if there are not enough receptors or 
binding sites.  
 
Endocrine activity and endocrine active substance 
In the scientific report on endocrine active substances (EFSA, 2010), EFSA defined an EAS as: 
 
“any  chemical  that  can  interact  directly  or  indirectly  with  the  endocrine  system,  and 
subsequently result in an effect on the endocrine system, target organs and tissues.”  
 
Perhaps  the  most  familiar  and  well-characterised  example  of  such  an  interaction  is  binding  of  a 
substance  to  a  hormone  receptor,  e.g.  the  oestrogen  receptor  (ER).  Such  substances  may  exhibit 
agonist or antagonist activity (or both) in relation to the receptor, depending on the nature of its 
interaction with the ligand-binding site of the receptor. Other ways that a substance might exhibit 
endocrine activity include interference with: (i) cellular factors involved in mediating the effects of an 
activated  hormone-receptor  complex;  (ii)  cellular  uptake  of  substances  required  for  hormone 
synthesis; (iii) enzymes involved in hormone synthesis or metabolism/clearance;  (iv) secretion of 
hormones from endocrine tissues; (v) binding of hormones to transport or sequestration proteins in 
blood plasma or within cells; and (vi) neurological function or neuro-endocrine signalling involved in 
regulation of endocrine function.  
                                                       
8  See http://www.epa.gov/endo/pubs/edspoverview/whatare.htm  Identification/Characterisation of EDs: scientific criteria and test methods 
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It follows from the EFSA definition of an EAS that any substance exhibiting endocrine activity, i.e. 
the ability to interact with one or more elements of an endocrine system, falls into the category of 
„endocrine active substances‟. It should be pointed out that, by definition, natural hormones (e.g. 
estradiol-17 , testosterone) and synthetic analogue hormones (e.g. 17 -ethinylestradiol, trenbolone) 
are EASs, though not all EASs are natural hormones or hormone analogues. Moreover, the scope of 
the definition of the endocrine system determines the variety of substances that may be identified as 
EASs; this variety is contingent on our increasing understanding of the endocrine system. 
 
Physiological modulation via the endocrine system 
By „physiological modulation‟ which is mentioned in the terms of reference, the Scientific Committee 
understands  „physiological  modulation  via  the  endocrine  system‟;  the  terminology  „endocrine 
modulation‟ is therefore used throughout the rest of this document. 
As noted in the Final Report on the State of the Art Assessment of Endocrine Disrupters (SAAED) the 
compensatory  feedback  mechanisms  that  typify  endocrine  systems  provide  homeostatic  capacity, 
which is adaptive (Kortenkamp et al., 2011). Exposure to exogenous substances that exhibit endocrine 
activity (i.e. EASs) may stimulate modulation in these feedback systems. If this modulation and its 
effects are temporary and within the homeostatic capacity of the endocrine system of the exposed 
organism,  the  effect  of  the  substance  might  be  considered  endocrine  modulation  and  hence  non-
adverse (see below).  
 
Endocrine disruption and endocrine disruptor 
The  SAAED  points  out  that  regulation  of  chemicals  on  grounds  of  their  toxicological  properties 
“cannot  proceed  without  finding  scientifically  sound  definitions  of  the  effects  in  question  (here: 
endocrine disruption” (Kortenkamp et al., 2011). Consequently, there have been several widely cited 
attempts at defining an ED.  
In 1996, the US EPA proposed the following definition of an ED during a workshop (Kavlock et al., 
1996): 
 
 “An  ED  is  an  exogenous  agent  that  interferes  with  the  synthesis,  secretion,  transport, 
binding, action or elimination of natural hormones in the body, which are responsible for the 
maintenance of homeostasis, reproduction, development and/or behaviour.”  
 
Whilst the US EPA was the first agency to define endocrine disruption as a mode of action, this 
definition is ambiguous in not differentiating adequately between compensatory/homeostatic changes 
(i.e. endocrine  modulation  as  discussed  above)  and those that  lead to  adverse  health  effects  (see 
discussion on adversity below).  
The Weybridge definition (EC, 1997) of an endocrine disruptor makes explicit reference to adversity: 
 
“An ED is an exogenous substance that causes adverse health effects in an intact organism, 
or its progeny, secondary to changes in endocrine function.” 
 
as does the WHO/IPCS definition (WHO/IPCS, 2002): 
 
“An endocrine disrupter is an exogenous substance or mixture that alters function(s) of the 
endocrine system and consequently causes adverse health effects in an intact organism, or its 
progeny, or (sub)populations.” 
 
The WHO/IPCS definition departs from the Weybridge definition in two main respects: 1) use of 
„consequent‟  in  place  of  „secondary‟,  which  has  been  interpreted  as  placing  a  great  onus  on Identification/Characterisation of EDs: scientific criteria and test methods 
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demonstrating cause-effect linkage between endocrine activity and an adverse health effect; 2) adding 
(sub)populations, which may be seen to make the definition more directly applicable to ecotoxicology 
(see below). A survey presented in the SAAED Final report showed that most EU Member States 
acknowledge  the  WHO/IPCS  definition,  and  this  definition  is  extensively  discussed  in  SAAED 
(Kortenkamp et al., 2011). 
Recently,  the  Endocrine  Society  published  a  statement  of  principles  on  endocrine  disruptors  and 
public health protection (Zoeller et al., 2012), in which another definition of an ED has been proposed: 
 
“An ED is an exogenous chemical, or mixture of chemicals, that interferes with any aspect of 
hormone action.” 
 
This definition is a simplification of the definition developed by the US EPA (Kavlock et al., 1996). 
Zoeller et al. (2012) emphasise that while it is critical for hazard identification to be able to capture the 
sensitivity of human and wildlife to chemicals that pose a potential risk, the ability of a chemical to 
interfere with hormone action (i.e. the hazard), is of itself a reliable predictor for adverse outcomes. In 
their view, uncertainty in the relation between the endocrine activity and the manifestation of an 
adverse consequence relate to the dose, duration and timing of exposure (Zoeller et al., 2012). The 
above-mentioned areas of uncertainty would normally be addressed in a risk assessment that considers 
both hazard  and  exposure.  The  Scientific  Committee  stresses that a  positive signal for  endocrine 
activity obtained from in vitro or in vivo testing does not automatically imply that an adverse effect 
will be observed in an intact organism. As such, the SC cannot agree with the above views, as the 
Zoeller et al. statement implies that an ED is equivalent to an EAS as defined by EFSA. The SC 
however  concurs  with  the  suggestion  from  the  authors  that  the  uncertainties  associated  with  the 
hazard-based approach for the management of an ED should be addressed using a risk assessment 
approach, i.e. considering both hazard as determined in vivo and exposure (see section 5).  
In the OECD Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for 
Endocrine Disruption (OECD, 2012a), an operational definition of a „possible endocrine disruptor‟ is 
provided: 
 
“to mean a chemical that is able to alter the functioning of the endocrine system but for which 
information about possible adverse consequences of that alteration in an intact organism is 
uncertain.” 
 
This  term  and  its  definition  were  intentionally  chosen  to  be  distinct  from  „potential  endocrine 
disruptor‟,  so  it  could  be  unambiguously  applied  to  chemicals  being  tested  in  the  Conceptual 
Framework  (OECD,  2012a)  for  purposes  of  confirmation  or  elaboration  of  suspected  endocrine 
activity (i.e. resolving hazard identification and hazard characterisation). 
WHO/IPCS (WHO/IPCS, 2002) defines a „potential endocrine disruptor‟ as follows: 
 
“A  potential  endocrine  disruptor  is  an  exogenous  substance  or  mixture  that  possesses 
properties that might be expected to lead to endocrine disruption in an intact organism, or its 
progeny, or (sub)populations.” 
 
Presumably those properties represent the innate ability of the substance (e.g. as might be identified 
from in vitro evidence) to interact with elements of the endocrine system of an exposed organism, and 
a „potential endocrine disruptor‟ could therefore be considered equivalent to an EAS. It follows that a 
potential endocrine disruptor is a substance for which uncertainty exists about the realisation of the 
adverse effect in an intact organism (i.e. in vivo).  
The SC considers that the meaning of possible/potential ED overlaps with the definition of an EAS, as 
suggested previously by EFSA (EFSA, 2010). For these terminologies, EAS is used in this opinion.  Identification/Characterisation of EDs: scientific criteria and test methods 
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Adversity 
The US EPA definition (Kavlock et al., 1996) and the simplified version proposed by the Endocrine 
Society, define an ED in relation to mode of action alone, which is comparable to the definition of an 
EAS (as discussed above). In contrast, Weybridge and WHO/IPCS define EDs in terms of both mode 
of action and adversity of the effect.  
An adverse effect has been defined by WHO/IPCS (2009) as follows: 
 
“Change in the morphology, physiology, growth, development, reproduction, or, life span of 
an organism, system, or (sub)population that results in an impairment of functional capacity, 
an  impairment  of  the  capacity  to  compensate  for  additional  stress,  or  an  increase  in 
susceptibility to other influences.” 
 
The later part of this definition “an impairment of the capacity to compensate for additional stress, or 
an increase in susceptibility to other influences” is context- dependent, i.e. there is a reduced capacity 
of  a  specific  population  sample  of  organisms;  As  such,  these  organisms  are  responding 
physiologically to their environment: the testing laboratory, micro/mesocosm, or the wild. Therefore, 
by this definition, adversity cannot be presumed or established from the hazard alone. This is echoed 
in the National Research Council of the US National Academies (NRC) report on toxicity testing in 
the 21
st century (NRC, 2007), prepared for the US EPA, which states: 
 
“The consequences of a biologic perturbation depend on its magnitude, which is related to 
the  dose,  the  timing  and  duration  of  the  perturbation,  and  the  susceptibility  of  the  host. 
Accordingly,  at  low  doses,  many  biologic  systems  may  function  normally  within  their 
homeostatic limits. At somewhat higher doses, clear biologic responses occur. They may be 
successfully handled by adaptation, although some susceptible people may respond. More 
intense or persistent perturbations may overwhelm the capacity of the system to adapt and 
lead to tissue injury and possible adverse health effects.” 
 
Whether or not adversity results from exposure of the intact organism or (sub)population to an EAS 
(as a hazard) is determined by the nature (strength) of the relationship between the hazard and the 
biological response (effect), the state of the organism/(sub)population (the other stresses it faces) and 
the intensity of the exposure to the hazard. Some of this information can be gathered through hazard 
characterisation. 
As noted above with respect to definitions, the WHO/IPCS definition departs from the Weybridge 
definition  in  adding  „(sub)populations‟,  which  may  be  seen  to  make  the  definition  more  directly 
applicable to environmental hazard and risk assessment of chemicals. For the environment, adversity 
is seen in the context of the presumed protection goal, generally considered to be population stability 
(i.e. effects on individuals may be acceptable if they are not expected to have implications for the 
population). It should be noted that the difference in level of biological organisation at which the 
adversity (population) and endocrine mode of action (individual) are determined, presents something 
of  a  challenge  in  applying  definitions  of  endocrine  disruption  for  regulatory  purposes  in  the 
ecotoxicological context. An EAS should therefore only be identified as an environmental ED if it can 
be demonstrated or plausibly argued, that a wildlife
9 population is likely to be affected. Evidence that 
can be used for this includes laboratory or field data on such endpoints as growth, development and 
reproductive success, which in population models or other predictive methods lead to an extrapolation 
of biologically significant effects on population size or stability.  
                                                       
9 The term „wildlife‟ as used herein, covers non-target species only and does not cover wildlife intended to be controlled by 
the application of regulated products (i.e. target species). It is also noted that whilst the considerations in this opinion do 
not specifically address other animal populations (e.g. farmed animals or companion animals), the same principles could 
be applied to these groups of animals, taking account of potentially additional specific protection goals. Identification/Characterisation of EDs: scientific criteria and test methods 
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  Conclusion on the definitions that will be used by EFSA 
The EFSA Scientific Committee concludes that the WHO/IPCS (2002) definition of an ED (which is 
the same definition as the one used by the EC in the background provided to the terms of reference) 
and the WHO/IPCS (2009) definition of an adverse effect should be endorsed as working definitions 
in this opinion.  
It should be noted that in line with protection goals embedded in EU legislation, adverse effects are 
addressed at the level of the individual(s) for human health and at the level of the (sub)population for 
wildlife. 
An EAS is a substance that has the ability to interact directly or indirectly with the endocrine system, 
and subsequently results in an effect on the endocrine system, target organs and tissues;  there is 
however uncertainty as to whether it is likely to produce adverse effects measured on apical endpoints 
in vivo. In some cases, EASs may only produce biological changes that lie within an organism‟s 
homeostatic capacity, or be detoxified by metabolism, and would therefore not be expected to cause 
adverse effects in the intact organism. In other cases, EASs may perturb homeostatic systems and thus 
cause adverse health effects at the level of the whole organism. The latter types of  EASs can be 
termed EDs. 
 
3.  Criteria for identifying endocrine disruptors 
 
This section addresses the first and second parts of the agreed terms of reference: 1) what scientific 
criteria  should  be  used  to  identify  EDs  and  2)  what  is  an  adverse  effect  and  how  can  it  be 
distinguished from endocrine modulation.  
Following the decision of the EFSA Scientific Committee to use the WHO/IPCS definition of ED (see 
section 2) as a working definition for this opinion, an ED is defined by three criteria: i) the presence of 
an adverse effect in an intact organism or (sub)population; ii) the presence of an endocrine activity; 
and iii) a plausible or demonstrated causal relationship between the endocrine activity and the adverse 
effect.  
This chapter will only focus on issues that are specific to endocrine disruption. As such, the SC 
underlines  that  the  question  of  the  difference  between  physiological  modulation  (e.g.  endocrine 
modulation) and adversity is not unique to EDs and should therefore be addressed in a broader context 
(see section on recommendations). 
 
3.1.  Adversity and criteria to distinguish endocrine disruption from endocrine modulation 
 
As  described  in  section  2,  the  SC  decided  to  use  the  definition  for  adverse  effect  produced  by 
WHO/IPCS in 2009:  
“Change in the morphology, physiology, growth, development, reproduction, or, life span of 
an organism, system, or (sub)population that results in an impairment of functional capacity, 
an  impairment  of  the  capacity  to  compensate  for  additional  stress,  or  an  increase  in 
susceptibility to other influences.” 
 Identification/Characterisation of EDs: scientific criteria and test methods 
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This is a generic definition of adversity, which is not specific to the endocrine system.  
The definition of an ED agreed upon for this opinion (see section 2) implies that the adverse effect 
should be observed in an intact organism (e.g. not in in vitro systems, or castrated or ovariectomised 
test animals). In relation to the environment, the SC reiterates that the focus of any ecotoxicological 
hazard assessment is the protection of non-target populations. Therefore, it is important to establish 
that the adverse effects observed in experimental test animals are relevant to populations. Particular 
attention should hence be given to the adverse consequences on reproduction, growth/development, 
disease incidence and survival in one or more environmental species as these are the effects most 
likely to impact on population recruitment and stability. 
As noted in SAAED, the compensatory feedback mechanisms that typify endocrine systems provide 
homeostatic capacity against various endocrine perturbations. Exposure to exogenous substances that 
exhibit endocrine activity may stimulate modulation in these feedback systems. If this modulation is 
temporary and/or within the homeostatic capacity of the endocrine system of the exposed organism, 
the effect of the substance might be considered „endocrine modulation‟. Alternatively, if the body is 
unable  to  compensate  for  the  induced  changes  within  its  limits  of  homeostasis  (e.g.  for  some 
endocrine  modalities/axes/pathways  during  critical  periods  of  development  or  at  high  doses),  the 
threshold of adversity is crossed, and the observed changes are to be considered as adverse. It should 
be noted that a transient endocrine modulation, which is simply adaptive in the adult organism, can 
result in permanent adverse changes in the developing organism, as the system responsible for the 
normal endocrine homeostasis of the latter may not be fully developed yet (WHO, 2012).  
Overall, therefore, endocrine effects become adverse either by elicitation of a sub- (or supra-) normal 
response or persistence in a physiological state that is intended to be transitory. The SC notes that 
interpretation of endocrine disrupting effects should also consider nutritional status, as the latter may 
influence the former. This is well-known for thyroid disruption, where the effect strongly depends on 
the iodine status of the individual. 
The SC is in agreement with Kortenkamp et al. (2011) that, since points have not been defined where 
„threshold of adversity‟ is crossed, it is difficult to propose specific criteria to differentiate between 
effects that represent an endocrine modulation and adverse effects on the endocrine system. Expert 
judgement will therefore be required to assess on a case-by-case basis the toxicological relevance of 
such  changes.  In  general,  transient,  inconsistent  and  minor  fluctuations  at  the  biochemical  and 
molecular  level  may  be  considered  adaptive  (i.e.  non-adverse),  whilst  sustained,  consistent  and 
permanent  changes  at  the  cell-,  organ-  or  organism-level,  resulting  in  pathology  or  functional 
impairment in vivo, as well as altered timing of development, may be considered adverse. 
The point at which endocrine modulation becomes an adverse effect cannot be determined on the basis 
of  an  absolute  response  value,  but  on  the  basis  of  a  relative  response  (compared  to  the 
control/background response). The SC is therefore of the opinion that, as adversity is a prerequisite for 
identifying  a  substance  as  an  ED,  it  is  necessary  to  determine  a  biological  threshold  between 
endocrine modulation and adverse effect. For the time being, it is difficult to propose generic criteria 
to determine when this biological threshold is crossed. This is therefore likely to be done on a case-by-
case basis through expert judgement. 
For most toxic processes, it is generally assumed that there is a threshold of exposure below which no 
biologically significant effect will be induced (Dybing et al., 2002; WHO/IPCS, 2009). The existence 
of dose thresholds cannot be proven or ruled out by experimental approaches, because all methods for 
measuring  effects  have  their  limits  of  detection  which  will  obscure  thresholds,  if  they  exist 
(Kortenkamp et al., 2011). However, the presence of homeostatic and cytoprotective mechanisms, and 
the redundancy of cellular targets, mean that a certain degree of interaction of the substance with the 
critical sites or their occupancy must be reached in order to elicit a toxicologically relevant effect 
(Dybing et al., 2002). Below this critical (threshold) level of interaction, homeostatic mechanisms 
would be able to counteract any perturbation produced by xenobiotic exposure, and no structural or Identification/Characterisation of EDs: scientific criteria and test methods 
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functional  changes  would  be  observed.  In  certain  developmental  stages,  homeostatic  capacity  is 
limited and this will affect the sensitivity of the organism. 
 
Specificity - Endocrine effects secondary to non-endocrine related toxicity  
Adverse effects occurring in the presence of marked toxicity tend to represent the unspecific and 
generalised response of the body to the chemical insult (e.g. arising from the saturation of kinetic 
processes,  through  overwhelming  of  defence/repair  mechanisms  or  through  elicitation  of  stress 
responses). In the presence of generalised toxicity, it is most likely that the endocrine system will also 
be  affected,  especially  considering  that  one  of  the  main  functions  of  the  endocrine  system  is 
maintenance of homeostasis in response to different stimuli/stressors. The SC therefore concludes that 
endocrine-related adverse effects secondary to marked toxicity caused by a non-endocrine mode of 
action should not be considered as an endocrine-mediated mode of action.  
 
3.2.  Endocrine activity 
 
As noted in section 2, „endocrine activity‟ implies the inherent ability of a substance to interact or 
interfere  with  one  or  more  components  of  an  endocrine  system  and  „endocrine  active  substance‟ 
indicates a substance that is able to interfere with the endocrine system, but does not necessarily lead 
to adverse effects. Therefore, the Scientific Committee considers endocrine activity as a collection of 
modes of action, potentially leading to adverse outcomes, rather than as a (eco)toxicological hazard in 
itself. 
Endocrine activity information could be obtained from  existing information, read-across, in silico 
tools, in vitro and in vivo screening assays (Levels 1, 2 and 3) of the current OECD Conceptual 
Framework
10 (OECD, 2012a) or from other mechanistic investigations.  These mechanistic studies 
should be evaluated on their merits on a case-by-case basis.  
 
3.3.  Causal relationship between endocrine activity and adversity 
 
In  order  to  conclude  that  a  substance  is  an  ED  there  must  be  a  reasonable  evidence  base  for  a 
biologically plausible causal relationship between the induced endocrine perturbation/activity and the 
adverse effects seen in intact organism studies. The SC underlines that there should be no difference 
between the level of evidence needed to demonstrate the endocrine activity/mode of action and the 
level of evidence needed to demonstrate the adverse effect. 
As for any other (eco)toxicological hazard, endocrine-mediated adverse effects may be identified in 
standard  toxicological  tests  that  are  routinely  performed  to  fulfil  the  requirements  of  various 
regulatory programmes. In particular, endocrine-mediated toxicity may be detected in repeated-dose, 
reproductive and developmental toxicity, and carcinogenicity studies, although supplementary and 
more focussed studies, such as mechanistic studies investigating the potential for endocrine activity, 
may be necessary to decide whether a causal relationship between the observed adverse effects and an 
endocrine  activity  is  biologically  plausible.  The  SC  is  aware  that  recent  reports  (EEA,  2012; 
WHO/UNEP, 2013) question the adequacy of these tests, with respect to combined exposures of EASs 
(see further section 4.7.2.2).  
                                                       
10 See:   
http://www.oecd.org/env/chemicalsafetyandbiosafety/testingofchemicals/oecdconceptualframeworkforthetestingandassess
mentofendocrinedisruptingchemicals.htm  Identification/Characterisation of EDs: scientific criteria and test methods 
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Demonstration of all the key events of an endocrine mode of action leading to the adverse outcome is 
not necessary, as this requires a very high burden of proof. However, it is important that there is 
logical and plausible reasoning to explain any (potential) causal relationship between the observed 
endocrine activity and the endocrine-mediated adverse effects. This concept of „plausibility‟ implies 
expert judgement. A minimum set of criteria was described by Bradford Hill (Bradford Hill, 1965) to 
provide adequate evidence of a causal relationship between an incidence and a consequence (e.g. 
exposure  and  ill  health),  including  biological  plausibility,  consistency  of  findings,  specificity, 
predictivity, coherence, concordance of dose response relationships and temporal associations  and 
characterisation of uncertainties.  
The SC considers that a test does not necessarily need to be standardised in order to demonstrate either 
the endocrine activity or the adverse effect. Any data whose robustness has been demonstrated is 
acceptable for the hazard assessment. This assessment of the individual data for robustness needs to 
include  a  judgment  on:  1)  The  validity  of  the  method  or  model  used  (i.e.  Is  the  method/model 
sufficiently predictive?); 2) The adequacy of the individual pieces of information, composed of the 
elements reliability (i.e. Was the method/model applied correctly?); and 3) Its relevance (i.e. Was the 
method/model appropriate for the intended purpose?). 
Weight-of-evidence 
All the available information on adversity and endocrine activity (in silico, in vitro and in vivo data 
including  observational  studies)  should  be  considered  together,  by  adopting  a  weight-of-evidence 
approach. Guidance on how to consider weight-of-evidence has been provided by WHO (e.g. Boobis 
et al., 2006; Boobis et al., 2008) and SCENIHR (2012). Evidence for adversity and endocrine activity 
should therefore be evaluated in parallel and not in sequence.  
In relation to human health, the default assumption of any adverse effect seen in toxicity studies is that 
the effect is relevant to humans. This assumption can be rebutted with sound scientific data showing 
non-relevance.  It  is  proposed  that  a  structured  framework,  e.g.  the  WHO/IPCS  human  relevance 
framework  (e.g.  Boobis  et  al.,  2008),  is  used  to  analyse  the  available  evidence  and  biological 
plausibility to facilitate a robust and transparent conclusion.  
As discussed in a previous opinion of the Scientific Committee (EFSA Scientific Committee, 2011), 
“Absence of Evidence is not Evidence of Absence”. It follows that it is not possible to prove the 
absence of any effect (including endocrine-related effects) and therefore, a negative test would not 
allow the exclusion of endocrine activity. The various types of above-described data should therefore 
be considered as part of a weight-of-evidence approach to conclude about whether a substance is an 
ED. The SC underlines the need for a testing strategy (see section 4.8) to generate appropriate data. 
 
4.  Availability  and  appropriateness  of  test  methods  for  identifying  and  characterising 
effects mediated by endocrine active substances 
 
This section addresses the third part of the agreed terms of reference: are existing toxicity testing 
methods appropriately covering the effects of endocrine active substances? This section therefore 
reviews available methods that can help to identify an endocrine activity (both human health and the 
environment are considered). This is termed mechanistic information.  
Furthermore, since the definition of an ED endorsed by the SC includes the criterion of an adverse 
effect, this section also reviews available methods that can help to identify and characterise endocrine-
mediated adverse effects. Various endocrine-sensitive endpoints are generally included in standard Identification/Characterisation of EDs: scientific criteria and test methods 
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toxicity tests. These tests for apical endpoints are designed to identify and characterise the in vivo 
adverse effects that may be endocrine-related. 
Utilising the OECD revised Conceptual Framework (CF) (OECD, 2012a) as the starting point for 
assessing the adequacy of the available (internationally) standardised / validated
11 test methods for the 
identification  and  characterisation  of  effects   mediated  by  EASs  as  well  as  the  analyses  and 
recommendations from SAAED (Kortenkamp et al., 2011), this section addresses the current human 
health and environmental test methods available from the OECD and US EPA websites
12, and related 
guidance focusing particularly on validated tests, test guidelines (TGs) and the relevant test projects in 
the OECD work plan (see also Appendix C).  
During this stock-taking process, potential gaps in the current testing suite of internationally validated 
methods and sufficiently standardised protocols close to validat ion were reported. It is outside the 
scope of this section to consider test methods that were not internationally standardised for regulatory 
toxicity testing but used predominantly for academic research purposes.  
 
4.1.  Background to OECD guidance on test methods for endocrine active substances 
 
In 1998, the OECD initiated a high-priority programme to revise existing and to develop new TGs for 
the screening and testing of EDs. Since then, a number of potential assays have been developed into 
TGs and others are in development. The screens and tests are summarised within the OECD revised 
CF for Testing and Assessment of Endocrine Disrupters (OECD, 2012a). The CF schematically lists 
and provides a guide to the OECD TGs and standardised test methods available, under development or 
proposed that can be used to evaluate chemicals for endocrine disruption. Substantial guidance on the 
use and interpretation of the tests and on the identification of potential information gaps is provided in 
OECD Guidance Document (GD) 150. 
All the validated TGs have been approved by all OECD Member Countries (i.e. they are consensus 
documents).  The  SC  therefore  acknowledges  the  relevance  and  utility  of  the  test  methods  and 
appreciates the ongoing validation review work and TG development to address further endocrine 
relevant endpoints. 
For the development of the following sections, the SC also considered the relevant OECD Detailed 
Review Papers (DRP) such as DRP No 178 (OECD, 2012b) on novel methods and endpoints for 
evaluating endocrine disruptors, DRP No 97 (OECD, 2008) on metabolism for endocrine disruptor 
tests, DRP No 57 (OECD, 2006) on the Thyroid Hormone Disruption Assays, and DRP No 135 
(OECD, 2010) on Environmental Endocrine Disruptor Screening: the Use of Oestrogen and Androgen 
Receptor Binding and Transactivation Assays in Fish. The SC also appreciates that the OECD ED-
related expert working groups and validation management groups are currently developing many of 
the  recommendations  contained  within  these  DRPs,  and  that  this  information  is  not  yet  publicly 
available, as it has not been finalised. 
In 2009, hosted by Denmark, the OECD held a workshop on “OECD Countries‟ Activities Regarding 
Testing, Assessment and Management of Endocrine Disrupters”. This workshop recommended further 
work for OECD, in particular: 
                                                       
11 „Internationally standardised‟ means that these assays have been validated and approved for test guidelines (TGs) use by 
the OECD and the mutual acceptance of data (MAD) principle applies. „Validation‟ refers to the formal process through 
which assays are shown to dependably work as intended and thus produce reliable results that can be compared across 
studies and laboratories (Hartung et al., 2004; OECD, 2005a). Whilst lack of validation does not necessarily mean an assay 
is invalid, it does mean results from the assay could be considered unreliable by regulatory agencies, depending on a 
number of other factors, such as inter-laboratory reproducibility. 
12   http://www.oecd-ilibrary.org/content/package/chem_guide_pkg-en; http://www.ehso.com/testmethodsdl.php  Identification/Characterisation of EDs: scientific criteria and test methods 
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(i)  The  development  of  a  guidance  document  for  the  assessment  of  endocrine  disruptors  (now 
published as OECD GD 150), and  
(ii)  The  revision  of  the  2002  Conceptual  Framework  for  Testing  and  Assessment  of  Endocrine 
Disrupters: 
The  GD  on  Standardized  Test  Guidelines  for  Evaluating  Chemicals  for  Endocrine 
Disruption, GD 150 (OECD, 2012a), produced by the Endocrine Disrupters Testing and 
Assessment Task Force Advisory Group (EDTA-AG) was co-authored by a large group 
of international experts and endorsed by OECD member countries. It provides guidance 
on how tools from lower levels of the CF can be used to determine which higher level 
tests are needed for a specific chemical, to increase evidence that it is or is not an ED. The 
EDTA-AG  selected  three  chemical  case  studies  to  take  through  the  revised  CF  to 
demonstrate the value of data interpretation pathways (OECD, 2012c).  
The  revised  CF is contained  within  GD  150, and the  guidance  on  data interpretation 
covers  27  of  the  assays  listed  in  the  CF,  including  in  vitro,  mammalian  and  non-
mammalian methods. Methods currently in (pre)validation are addressed in an annex. The 
GD is intended to be a living document which will be updated periodically in the light of 
experience, and as new assays are validated and developed into approved TGs. 
(iii) The development of a DRP on endpoints not included in existing test guidelines (see OECD 
information on OECD Work Related to Endocrine Disrupters (2012)), which is now published:  
OECD Detailed Review Paper No 178. The State of the Science on Novel In vitro and In 
vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors 
(OECD, 2012b).  
 
Introduction to the OECD revised Conceptual Framework 
The information contained within the CF addresses the complexity and comprehensive relevance of 
information  available  in  five  ascending  Levels:  from  Level  1  (existing  information  and  non-test 
information, which should guide the initial needs for testing and assessment), to Level 2 (selected in 
vitro endocrine mechanistic/mode of action test methods), to in vivo selective endocrine mechanistic 
screening  methods  in  Level  3,  in  vivo  apical  tests  (for  adverse  effects)  which  include  endocrine 
relevant endpoints in Level 4, and more comprehensive data over more extensive parts of the life 
cycle in Level 5. 
The mechanistic studies in Levels 2 and 3 of the CF can identify endocrine activity as a prerequisite 
for a substance to be considered an EAS, but individually are often insufficient for ED identification. 
The output from Level 2 and 3 tests can be utilised for subsequent prioritisation for further testing, 
using the methods with apical endpoints (e.g. those of Levels 4 and 5). The latter identify the adverse 
effect that is a prerequisite for an EAS to be regarded an ED. The GD is based on the need to evaluate 
data  on  EDs  using  a  weight-of-evidence  (WoE)  approach,  priority  setting  and  adverse  outcome 
pathway (AOP) approach (NRC, 2007; Ankley et al., 2010; OECD, 2012e). In principle, no single 
assay is likely to provide all the information needed to decide whether a substance is an ED (according 
to the WHO/IPCS definition endorsed by the SC) because of the need to provide both mechanistic 
information showing how the substance interacts with the endocrine system, and apical information 
describing the adverse effects this interaction may cause. The results from a combination of tests 
increase the WoE and further elucidate the AOP. As detailed in the OECD CF (OECD, 2012a), it is 
possible to enter and exit the CF at all Levels, depending upon the nature of the existing information, 
and the regulatory needs for testing and assessment. The assessment of each substance should be made Identification/Characterisation of EDs: scientific criteria and test methods 
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on a case-by-case basis, again, taking into account all the available information. There may be some 
occasional instances, whereby a pattern of responses characterised by a spectrum of adverse effects in 
vivo clearly known to be caused by an established endocrine activity (as identified from existing 
(Level 1) information) may be present. For example, male rats exposed to anti-androgenic substances 
may exhibit a range of symptoms such as non-descended testis or external genitalia malformations 
(Foster, 2005). In such cases, the adverse effects could be regarded as being diagnostic of endocrine 
disruption, and endocrine activity could be inferred rather than being demonstrated.  
See Appendix C for an extract of the CF list and sections 4.4, 4.5 and 4.6 for further details on the 
tests contained within each Level of the CF for mammals, aquatic organisms and birds. For each of 
these tests, the corresponding test guideline presents and discusses both the advantages and limitations 
of the test and can be consulted directly. 
 
4.2.  OECD revised Conceptual Framework Level 1: existing data and non-test information 
 
The OECD GD (OECD, 2012a) states that “It is important to emphasise that before conducting any 
assessment of data from an endocrine disruption screen or test, all existing information on the test 
chemical  should  be  collated”.  Therefore  Level  1  of  the  CF  consists  of:  Physical  &  chemical 
properties, e.g., Molecular Weight reactivity; volatility, biodegradability; all available information, 
including  epidemiological  and  field  studies;  (eco)toxicological  data  from  standardised  or  non-
standardised  tests;  read-across;  chemical  categories;  (Quantitative)  Structure Activity  Relationship 
((Q)SARs) and other in silico predictions; and Absorption, Distribution, Metabolism and Excretion 
(ADME) model predictions.  
 
4.2.1.  Considerations  for  the  use  of  epidemiological,  field  and  experimental 
animal information when characterising the hazards for humans or wildlife 
of exposure to endocrine active substances 
 
There are important considerations that first need to be taken into account when both designing and 
interpreting epidemiological studies to assess plausible causal relationships in relation to EASs. These 
include the following confounding factors: 1) environmental EASs are numerous and ubiquitous, 2) 
humans are generally exposed to low levels and to multiple substances and, 3) other „environmental‟ 
conditions such as lifestyle factors, including nutritional status, may come into play. Precise estimates 
of the exposure (by using appropriate biomarkers, where available) to a particular EAS together with 
the identification of the related critical developmental stage(s) are major challenges in studies aimed at 
assessing the effects of EASs in humans. Furthermore, reproductive endpoints in humans may be 
characterised by a broad range of natural variability in a heterogenous population. Therefore, their 
assessment in epidemiological studies is challenging.  
For field data, in principle, there is no major difference between the evaluation of effects of EDs and 
non-EDs. However, in view of the need to be confident whether an adverse effect of an ED is likely to 
have consequences at the population level, the use of field data, if available, may be valuable. In the 
absence of such data, regulators must be confident of being able to extrapolate from laboratory data on 
endpoints  such  as  growth  and  reproduction  to  potential  effects  on  populations,  ideally  but  not 
necessarily through the use of population modelling. It is acknowledged that some effects, particularly 
those affecting individual behaviour, may not easily be apparent when observing at (sub)population 
level. Identification/Characterisation of EDs: scientific criteria and test methods 
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Animal studies have contributed considerably to our understanding of health disorders resulting from 
endocrine disruption in humans and wildlife, although many of these studies have been carried out 
with  high  exposure  levels  that  are  not  necessarily  relevant to humans  or  wildlife.  For regulatory 
purposes, whilst maintaining a sufficient number of doses to obtain a robust dose response curve, 
experiments with animals should also be made at exposure levels relevant for humans or wildlife. 
Considering the uncertainties surrounding the effects of EASs on human health or wildlife and the 
limitations of extrapolation from non-clinical data, it can be concluded that the conduct of the above 
types  of  studies,  in  spite  of  inherent  challenges  such  as  methodological  set-up,  quality  or 
dose/concentrations used, remains an essential component of the evaluation of possible effects of 
EASs in large populations. Further descriptions of these types of studies are provided in Appendix D, 
highlighting critical issues which characterise the conduct and most importantly the interpretation of 
such studies.  
 
4.2.2.  Computational toxicology and non-test methods for screening substances 
for endocrine activity 
 
4.2.2.1.  Background 
The  conventional  methods  of  testing  chemical toxicity  require  the  use  of animals.  The  Scientific 
Committee and the Panel on Plant Protection Products and their Residues recognised in previous 
opinions (EFSA, 2009b; EFSA Panel on Plant Protection Products and their Residues, 2012a), the 
importance of minimising the use of experimental animals during food/feed risk assessments, as well 
as screening substances for priority setting and subsequent testing. In this regard, computational (in 
silico) toxicology offers a non-animal test approach based upon biological and chemical properties, 
for rapid screening of chemicals against some toxicological endpoints related to endocrine activity. 
These tools belong to Level 1 of the OECD CF for ED testing. 
In silico and non-animal test method approaches include molecular modelling tools; structure activity 
relationships  (SAR) upon which physico-chemical read-across and chemical categories are based; 
predictive  statistical  models  such  as  (Quantitative)  Structure  Activity  relationships  ((Q)SARs); 
databases; and expert systems.  
These tools may be freely or commercially available; however, the focus of this section is on the 
freely available data and tools. Additional information on the commercially available tools (such as 
Topkat, Leadscope, Derek, Meteor, Hazard Expert) can be found in the reviews cited herein. It is 
important to note that the regulatory acceptance of these tools is currently very limited. However, the 
tools may be useful for screening purposes or when designing an integrated testing strategy. Extensive 
efforts are underway at European and international levels to improve the quality, reliability, use and 
integration of such tools.  
The following sections provide an overview of the different tools and their relative endpoint specific 
utility.  
 
4.2.2.2.  In silico 3-Dimensional Molecular Modelling Approaches  
In  silico  3-Dimensional  (3D)  molecular  modelling  tools  based  upon  the  receptor/enzyme-ligand 
docking simulation in protein crystal structures and/or homology modelling of receptors have been 
reliably  used  in  pharmacological  research  and  development  for  decades.  There  are  numerous 
published examples in the medicinal and pharmacological literature. Molecular dynamics are useful 
for  revealing  facets  of  activation  and  inactivation,  so  improving  mechanistic  understanding  and Identification/Characterisation of EDs: scientific criteria and test methods 
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predicting molecular ligand binding activity. These 3D computational tools can have a high level of 
accuracy, and in the last 10 years have been explored and applied in the fields of EASs chemical risk 
assessment (e.g. Jacobs et al., 2003; Jacobs, 2004; Akahori et al., 2005; D'Ursi et al., 2005; Vedani et 
al., 2012). 
 
4.2.2.3.  Chemical categories and read-across 
As defined by the OECD, „a chemical category is a group of chemicals whose physicochemical and 
human health and/or ecotoxicological properties and/or environmental fate properties are likely to be 
similar or follow a regular pattern, usually as a result of structural similarity‟ (OECD, 2007a, 2009a). 
In practice, endpoint information for one chemical (the source chemical) is used to predict the same 
endpoint for another chemical (the target chemical), which is considered to be „similar‟ in some way 
(usually on the basis of structural similarity or on the basis of the same mode or mechanisms of 
action). However, there are a number of limitations that should be kept in mind including the fact that 
molecules of similar structure sometimes have dissimilar biological activity (Van Drie, 2003).  
The  freely  available  OECD  (Q)SAR  Toolbox  (see  also  section  4.2.2.5)  provides  a  platform  for 
grouping chemicals that share structural and/or functional activity similarities, using a substantial set 
of high quality databases. The strategy for screening in the Toolbox involves grouping and searching 
the  available  databases  using  the  structure  alerts  from  the  target  substance,  e.g.  for  ER  binding 
potential (OECD, 2007a, 2009a). 
 
4.2.2.4.  Predictive (Q)SAR models 
SAR is an approach designed to discover relationships between chemical structure (or structural-
related properties) and biological activity (or target property) of studied compounds. (Q)SARs are 
algorithm–driven  models  based  on  a  (quantitative)  structure-activity  relationship.  They  provide 
mathematical descriptions of the biological activity of a group of chemical substances in terms of one 
or more of their physicochemical properties. The biological activity, including toxicity, can occur at 
the molecular level, the tissue, target organ, biological system and whole organism level. (Q)SARs 
can be local - in that the compounds used to derive the model are all closely related (i.e. are from a 
„narrow‟ applicability domain) either structurally, by mode of action, or both, - and these are usually 
more robust. However, they are not applicable to the wider chemical universe. Global (Q)SARs use a 
more structurally diverse chemical training set; so they are usually applicable to a wider „domain‟ but 
are generally less robust in their predictivity. The principles for the development of reliable and robust 
(Q)SAR models have been agreed by the OECD (OECD, 2004). In brief, the models need to be 
relevant to specific regulatory endpoints, to have been developed using a transparent methodology and 
an  unambiguous  algorithm,  and  tested  rigorously  for  robustness  and  predictivity  against  external 
datasets,  i.e.  those  not  used  in  modelling.  The  „applicability  domain‟  for  each  model  is  also 
determined and clearly defined.  
A fully tested (Q)SAR model generally yields reliable estimates of toxicity of untested chemicals 
(70% or higher accuracy) as long as they fall within the model‟s prediction domain. Thus, a (Q)SAR 
model will have a limited value for assessment of those chemicals that are outside its prediction space. 
Combining assessments from more than one (Q)SAR model with additional information from, e.g. 
structural alerts and read-across estimates from analogous molecules in a WoE approach can improve 
the utility of these tools and the reliability of the overall in silico assessment.  
The available (Q)SAR models relevant to EASs have been reviewed, amongst others by Benfenati et 
al. (2005), Lo Piparo and Worth (2010), and Castello and Worth (2011) and by external contracts Identification/Characterisation of EDs: scientific criteria and test methods 
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commissioned  to  assist  the  development  of  an  EFSA  opinion  on  the  toxicological  relevance  of 
pesticide metabolites (EFSA Panel on Plant Protection Products and their Residues, 2012a).  
Since the most widely studied mechanism of action for endocrine disruption has been ER binding, it is 
not surprising that the first robust EASs relevant (Q)SARs to emerge have been for that modality. The 
Danish National Food Institute has published environmental chemical relevant models on the ER, 
androgen receptor (AR) (Jensen et al., 2008; Vinggaard et al., 2008) and the Pregnane X Receptor 
(PXR) (Dybdahl et al., 2012). Combinations of 3D modelling tools with (Q)SARs such as 3D (Q)SAR 
models are also available for steroid hormone receptors such as the AR, glucocorticoid receptor (GR), 
PXR, peroxisome proliferator-activated receptor (PPAR) gamma, progesterone receptor, and thyroid 
receptors (TRs), and the cytosolic  aryl hydrocarbon receptor (AhR) (Jacobs, 2004; Vedani et al., 
2012). There are models published for other endocrine modalities, such as the retinoid X receptor and 
oestradiol sulfotransferase, but only a few have so far been validated or are sufficiently broad to be of 
general use. The large diversity of chemicals that might interfere with the endocrine system and the 
many potential molecular targets make the establishment of a single (Q)SAR for EASs an unrealistic 
goal (Jacobs et al., 2008; OECD, 2008). (Q)SAR models for the more complex endpoints, such as 
developmental and reproductive toxicity, are not considered reliable on their own (Maslankiewicz et 
al., 2005; Lo Piparo and Worth, 2010; JRC, 2011; Worth et al., 2011; EFSA Panel on Plant Protection 
Products  and  their  Residues,  2012a),  but  again  may  have  WoE  utility  if  used  appropriately  in 
combination with other in silico models and tools.  
 
4.2.2.5.  Databases and freely available software platforms 
Databases of EASs are available  and include the US FDA Endocrine Disruptor Knowledge Base 
(EDKB);  the  Endocrine  Active  Substances  Information  System  (EASIS);  the  US  EPA  Endocrine 
Disruptor  Screening  Program  (EDSP)  Universe  of  Chemicals.  In  the  EU,  the  Endocrine  Active 
Substances Information System (EASIS)
13 is under development to update the existing database of the 
EC‟s DG Environment. 
 
Freely available software platforms 
A  major  software  platform  that  is  useful  for  in  silico  screening  of  EASs  is  the  OECD  (Q)SAR 
Toolbox. This is a software application intended to fill gaps in (eco)toxicity data needed for assessing 
chemical  hazards;  it  incorporates  databases  on  physico-chemical  data  and  on  experimental 
(eco)toxicological  data,  a  range  of  (Q)SAR  models  of  varying  quality,  together  with  (Q)SAR 
modelling  tools  and  Expert  Systems.  It  incorporates  a  large  number  of  databases  for  various 
toxicological endpoints; however, to date the only endocrine-specific database in the Toolbox is the 
OASIS ER Binding Database that consists of 1460 diverse compounds with Relative ER Binding 
Affinity data, where the data generated is all relative to the positive control 17-beta-oestradiol.  
The (Q)SAR models contained in the Toolbox include the MultiCASE RBA (Q)SAR, which is based 
on a hierarchical statistical analysis of a training set composed of structures and ER binding data of 
313 chemicals. The training dataset comprises inactive, weak and powerful ER binders, and while 
they represent a variety of chemical classes, these were mainly pesticides and hormone analogues, and 
were not representative of industrial chemicals or regulated food ingredients. The output is a predicted 
percentage  relative  binding  affinity  to  the  ER  for  target  substances  that  fall  within  the  chemical 
applicability  domain  of the  model.  For  such limited  applicability  of the  domain, the accuracy  of 
prediction  has  been  reported  to  be  around  84%  (Klopman  and  Chakravarti,  2003).  In  his  paper 
evaluating the OECD (Q)SAR Application Toolbox for the profiling of ER binding affinities (Level 1 
of the OECD CF), Mombelli (2012) notes that the predictive performances of the ER-profiler are 
lower  than  that  obtainable  by  utilising  tests  from  Level  2  of  the  OECD  CF,  such  as  the  stably 
                                                       
13 http://ihcp.jrc.ec.europa.eu/our_activities/food-cons-prod/endocrine_disrupters/eas_database Identification/Characterisation of EDs: scientific criteria and test methods 
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transfected transcriptional activation assay (TA test) for detecting oestrogenic activity (TGs 455, 457). 
The author concludes however that, even though predictions are not as reliable as the TA test, ER-
profiler and more generally (Q)SAR models for binding affinities, can still provide a useful tool for 
grouping chemicals into categories and/or prioritizing chemicals for experimental testing. They can 
also play an important role as a first step of an integrated testing strategy for reproductive toxicity. For 
further discussion, see also the reviews by Benfenati et al. (2005), and Roncaglioni and Benfenati 
(2008). 
The recent conceptual construct of Adverse Outcome Pathways, linking a molecular initiating event 
with an apical adverse outcome that is relevant to a regulatory decision (Ankley et al., 2010; OECD, 
2012e) is being promoted by the OECD as a way to integrate existing knowledge from in vivo tests 
with the results of molecular screening and omics assays, computational predictive methods and other 
sources of information. Once completed and agreed, they will be included in the OECD (Q)SAR 
Toolbox,  and  OECD  member  countries  can  propose  and  initiate  work  on  such  AOPs,  including 
endocrine relevant AOPs.  
Another (Q)SAR model in the Toolbox is the Danish EPA‟s Relative ERBA (Q)SAR, which is based 
on ER binding in vitro. The results from this model are based on the (Q)SAR database developed by 
the Danish EPA to support regulatory assessment of chemicals, and comprises predictions by some 70 
models for around 166,000 organic chemicals for a wide range of endpoints.  
The Virtual Toxlab also provides a free platform- the OpenVirtual Toxlab (Vedani et al., 2012). 
 
4.2.2.6.  Expert systems based on computational models 
Expert systems are computational tools that combine the different  in silico approaches to predict 
bioactivity of a chemical substance from its structure, and the term is not to be confused with „expert 
judgement‟. A transparent and data rich regulatory example is that of the US EPA ER expert system. 
In 2009, the Federal Insecticide, Fungicide, and Rodenticide Act Scientific Advisory Panel (FIFRA 
SAP) of the US EPA externally reviewed the use of “An Effects Based Expert System to Predict 
oestrogen  Receptor  (ER)  Binding  Affinity  for  Food  Use  Inert  Ingredients  and  Antimicrobial 
Pesticides: Application in a Prioritisation Scheme for Endocrine Disruptor Screening” (U.S. EPA-
SAP,  2009a,  2009b).  This  expert  system  is  designed  to  support  prioritisation  of  chemicals  for 
screening and testing. A decision based SAR alert system based upon binding to the rainbow trout ER 
(rtER) was reviewed by the OECD (OECD, 2009b). This expert system is considered to have good 
concordance with the human and rat ERalpha. The rtER expert system has been incorporated in the 
OECD (Q)SAR Toolbox, which also contains the ER binding alert developed by OASIS.  
The US EPA is targeting over 10,000 chemicals in developing their Endocrine Disruptor Screening 
Program (EDSP) and the work plan for this project includes in silico approaches as a major priority 
(U.S. EPA-SAP, 2011). Guidelines based upon the OECD validation principles (OECD, 2004) have 
recently been drawn up for the validation of in silico methods for this purpose (U.S. EPA, 2012a, 
2012b).  The  FIFRA  SAP  is  being  convened  to  further  address  scientific  issues  associated  with 
prioritizing the EDSP chemicals using computational toxicology tools in early 2013, and the final 
report is due to be published by May 2013.  
Additional  tools  of  relevance  include  the  application  of  physiologically-based  pharmacokinetic 
(PBPK) modelling in chemical risk assessment (Andersen, 2003; Blaauboer, 2003; Bouvier d'Yvoire 
et al., 2007; Clewell and Clewell, 2008; Adler et al., 2011), and dose response modelling methods 
(e.g. Burman and Wiklund, 2011; Plan et al., 2012). However, current research activities do not seem 
to  be  optimally  directed  at  developing  computational  tool  alternatives  for  endocrine-related 
reproductive and developmental toxicity endpoints in relation to PBPK modelling (Punt et al., 2011). 
To date both modelling techniques have had far greater application in pharmaceutical research and Identification/Characterisation of EDs: scientific criteria and test methods 
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clinical development, than for chemical risk assessment, including screening substances for endocrine 
activity, but remain highly relevant and an important computational area for further development 
particularly for the integration of data produced from in vitro/in silico methods into a biologically 
meaningful framework and for the extrapolation to in vivo conditions (Adler et al., 2011). 
 
4.2.2.7.  Summary 
With the large diversity of chemicals that might interfere with the endocrine system and the many 
potential molecular targets, the establishment of a single (Q)SAR for EASs is an unrealistic goal. 
However, for receptor mediated interactions (e.g. ER, AR, PXR, PPAR, GR, AhR), application of in 
silico methods in sequential/ step-wise approaches (combining relevant and reliable expert systems or 
(Q)SAR models), can contribute to the WoE basis in the prediction of toxicity to endocrine relevant 
modalities. In silico methods are also useful tools for screening and prioritisation for further testing. 
When interrogating such computational tools, a high level of attention needs to be paid to chemistry 
and biological endpoint data quality and data cleaning considerations, appropriate selection and use of 
descriptors and statistics. The use of (Q)SAR models, expert systems, category formation tools, as 
well as the interpretation of the results, require expert knowledge, because each of these tools have 
their own level of reliability and chemical applicability domain limitations. Additionally, a number of 
limitations should be kept in mind including the fact that molecules of similar structure sometimes 
have dissimilar biological activity.  
Overall, for molecular initiating event endpoints, such as ER and AR binding and activation, the 
quality and reliability of the tools are relatively high. However, for in vivo tissue, target organ and 
whole animal endocrine toxicity, such as reproductive and developmental toxicity, these tools have 
been found to be of limited applicability and low reliability compared to in vitro and in vivo testing. 
With respect to future work, it is recommended to explore additional tools, such as the application of 
PBPK and dose response modelling methods for screening and evaluating substances for endocrine 
activity. 
 
4.3.  General overview of available test methods at CF Levels 2-5, according to endocrine 
modality and taxa  
 
The purpose of this section is to give a general overview of the availability of test methods from the 
OECD CF for the identification and characterisation of an EAS/ED. The information is presented 
according to endocrine modalities that are known to (or could) be sensitive to disruption. Further 
details on the test methods available for mammals, aquatic organisms and birds are given in sections 
4.4, 4.5 and 4.6 respectively. For some endocrine modalities and taxa, no mechanistic and/or apical 
assays  have  been  developed  yet  in  internationally  standardised  (validated)  test  methods.  This  is 
probably due to priority setting, as for instance, determined by the relevance for humans and the 
environment, or for instance the resources and needs in the OECD Member States to do this work. 
The  areas  for  further  development  that  have  been  identified  are  therefore  also  presented  in  the 
following paragraphs.  
Table 1 provides a list of selected endocrine modalities/axes/pathways. These are not exhaustive (DRP 
178, OECD, 2012b) and it is as yet unknown whether all of them  can be affected by endocrine 
disruption in reality. The table furthermore lists the main taxa on which in vivo testing is performed 
(or may be proposed to be performed), and also includes in vitro testing. Information is provided as to 
whether mechanistic (M) and/or apical (A) tests (either standardised at the international level, or soon Identification/Characterisation of EDs: scientific criteria and test methods 
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to  be  so)  are  available  for  each  of  these  taxa,  and  for  each  of  the  indicated  endocrine 
modalities/axes/pathways.  
Regarding the applicability of test methods across taxa, more is known about mammalian endocrine 
systems than about equivalent systems in other taxa, although it should be noted that many of these 
systems have been highly conserved during the evolution of the vertebrates. This means that in some 
cases, for example with the oestrogen receptor, there is a good species concordance. However, with 
other  receptors,  this  is  not  necessarily  so  and  moreover,  the  downstream  effects  of  hormonal 
modulation  vary  considerably  between  species.  The  level  of  available  knowledge  about  the 
endocrinology of the various taxa (including mammals) is therefore also indicated in Table 1.  
 
4.3.1.  Endocrine  modalities  known  to  be  sensitive  to  disruption  and  their 
corresponding test methods 
 
Most of the knowledge about endocrine disruption has been acquired for substances which interact 
with oestrogen, androgen, or thyroid hormone systems or affect steroidogenesis in vertebrates (the so-
called EATS modalities). Such substances may be able to interact with ligand binding sites (i.e. by 
mimicking the relevant endogenous agonist (where known)), or block hormone action (i.e. act as an 
antagonist), or interfere with the endogenous ligand (hormone) synthesis, transport or metabolism. Of 
these effects in vertebrates, the so-called „feminising‟ actions of oestrogens and their mimics are 
probably the most studied and best understood, having been described in all groups from fish to 
mammals. Some effects of endocrine disrupting substances on human health have also been described 
(e.g. diethylstilbestrol and glycyrrhizinic acid). In addition, there is reasonably good knowledge about 
substances  which  mimic  or  antagonise  the  ecdysteroids  and  juvenile  hormones  in  insects  and 
crustaceans, because a variety of target-specific insecticides have been explicitly designed to have this 
type  of  action  in  arthropods.  Furthermore,  it  is  known  that  organotin  compounds  can  cause 
masculinisation in female molluscs, probably by interfering with the retinoid signalling pathway, but 
possibly  also  by  interfering  with  steroidogenesis  (aromatase  inhibition).  Finally,  vertebrate  sex 
steroids are able to cause adverse effects in molluscs, although the mechanisms of action are also not 
fully understood. 
 
In vitro EA(T)S tests based on mammalian systems: 
The currently (or soon to be) available internationally standardised in vitro assays are only applicable 
for detecting oestrogen/androgen/steroidogenic activity (see Table 1). It should be noted that none of 
these assays have significant metabolic competence. This means that the metabolic pathways as seen 
in a whole animal and responsible for bioactivation or de-activation of parent molecules cannot be 
evaluated  with  the  current  in  vitro  assays.  However,  the  OECD  is  encouraging  metabolism 
components to be added to the available in vitro tests (Jacobs et al., 2008; OECD, 2008). 
For substances affecting the thyroid hormonal axis, whilst tests providing information on thyroid-
related apical endpoints and thyroid-related in vivo biomarkers are available, standardised in vitro 
mechanistic  screens are  still lacking. The  OECD  is  considering  this  as  an  area  for  further  work, 
especially  because  sufficiently  developed  tests  (e.g.  TR  binding  assay,  iodide  uptake,  thyroid 
peroxidase inhibition, Thyroid Hormone (TH) transport protein displacement) already exist (see DRP 
57, OECD, 2006). 
 
In vitro EA(T)S tests based on other vertebrate systems:  
These will be potentially covered in the future when additional test guidelines become available. This 
will not be soon, since they are not in the current OECD work plan (OECD, 2012d). However, there is Identification/Characterisation of EDs: scientific criteria and test methods 
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a DRP on Environmental Endocrine Disruptor Screening: the Use of Estrogen and Androgen Receptor 
Binding and Trans-activation Assays in Fish (see DRP 135, OECD, 2010). 
 
In vivo EATS tests with vertebrates:  
With respect to the standardised in vivo assays, most of the EATS modalities and their apical effects 
are detectable using a range of mechanistic and/or apical assays based on mammals, fish and (to a 
lesser extent) amphibians. There are no standardised assays for these modalities in reptiles, and only 
apical assays in birds. 
Thus, at present, there is still a need to complete validation of several mechanistic and apical in vivo 
tests based on fish, birds and amphibians with sensitivity to EATS modalities, although currently 
available  assays  nevertheless  allow  a  fairly  effective  oestrogen/androgen/steroidogenesis  hazard 
assessment using fish.  
 
In vivo tests with invertebrates:  
In invertebrates, no standardised mechanistic assays are available, although apical reproduction assays 
under development with molluscs have sensitivity to some vertebrate steroids which form part of the 
EATS  modalities,  and  equivalent  assays  with  insects  (and  probably  crustaceans)  are  sensitive  to 
ecdysteroids  and  juvenile  hormone  mimics.  None  of  these  apical  tests  is  able  to  provide  a  firm 
diagnosis of a specific endocrine activity linked to a given adverse effect. 
 
Summary of in vitro and in vivo (non-)validated EA(T)S tests with aquatic organisms and birds:  
Considering the standardised assays as a whole, a reasonably complete set of assays is only available 
for  assessing  both  the  mechanistic  and  apical  effects  of  substances  acting  by 
oestrogenic/androgenic/steroidogenic modalities in a single group: fish. In other words, as of now, 
ecotoxicity testing of EASs is only able to provide a fairly comprehensive assessment of hazards to 
fish alone, posed by this limited group of substances (although even in fish, there is currently no 
internationally validated lifecycle test that includes mechanistic endpoints). At present, there is only a 
validated mechanistic screen (with limited apical endpoints) for thyroid effects in frogs, and it is not 
possible to measure longer-term apical hazards in amphibians. 
Almost the entire focus of aquatic test method development for EASs to date has been on the EATS 
modalities in vertebrates. Within three years, it is expected that the validated aquatic in vivo testing 
suite for mechanistic and apical testing of EASs acting via the EATS modalities in vertebrate aquatic 
wildlife  will  be  largely  complete  for  regulatory  purposes  through  the  combined  use  of  fish  and 
amphibian  assays.  A  multi-generation  test  with  birds  is  also  expected  to  be  internationally 
standardised within the same timescale. However, there is little prospect at present of developing a 
lifecycle test with amphibians.  
 
4.3.2.  Non-EATS endocrine modalities not at present known to be sensitive to 
disruption and for which standardised test methods are not available 
 
Other endocrine modalities have been described in a DPR on The State of the Science on Novel in 
vitro and in vivo Screening and Test methods and Endpoints for Evaluating Endocrine Disruptors 
(DRP  178,  OECD,  2012b).  As  mentioned  in the  OECD  DRP  178,  it  is  possible  that  a range  of 
additional endocrine modalities in vertebrates (including Hypothalamus-pituitary-adrenocortical axis 
(HPA)  axis;  somatotropic  axis;  retinoid  pathway;  vitamin  D  pathway;  Peroxisome  Proliferator-
Activated  Receptor  (PPAR)  signalling  pathway;  pancreatic  signalling;  renal  signalling)  may  be 
susceptible  to  endocrine  disruption  (see  Table  1).  The  downstream  effects  of  disruption  of  these Identification/Characterisation of EDs: scientific criteria and test methods 
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endocrine  pathways  are  probably  detectable  in  some  standardised  apical  vertebrate  assays.  For 
example, evidence for impairment of functional capacity of the endocrine pancreas may be found in 
vertebrate  apical  studies  (degenerative  changes,  e.g.  concerning  the  islets  of  Langerhans  may  be 
detected by histopathological examination in the context of OECD TG 408, and changes in blood 
sugar  levels  would be covered  by  clinical  chemistry).  However,  as  yet  there  are  no standardised 
mechanistic assays which are able to identify these modes of action (for the taxa discussed above). 
However, as discussed in the DRP, endpoints with sensitivity to these modalities could be added to 
existing  in  vivo  vertebrate  apical  assays,  and  in  vitro  screens  could  also  be  developed  and/or 
standardised. 
Another area of lack of knowledge concerns interference with the many peptide hormone pathways in 
invertebrates. Again, the apical insect or crustacean reproduction and/or lifecycle assays may reveal 
some of the downstream effects of such interference, but standardised mechanistic assays for these 
modalities  are  not  available.  Furthermore,  many  other  invertebrate  phyla  (e.g.  echinoderms; 
nemertines) have not been the subject of any standardised test developments, apical or otherwise, 
although apical reproduction assays for annelids, mites and collembolans have been published by 
OECD. 
 
The Epigenome and endocrine disruption: Epigenetic modulations underlie critical developmental 
processes  and  contribute  to  determining  adult  phenotype.  Alterations  to  the  phenotype,  due  to 
exposure  to  environmental  insults during  sensitive  periods  of development,  are  mediated through 
alterations in epigenetic programming in affected tissues. The Annex to DRP 178 (OECD, 2012b) 
evaluates  the  potential  role  of  chemical-induced  epigenetic  modifications  to  endocrine  signalling 
pathways,  during  sensitive  windows  of  exposure,  as  a  mechanism  of  endocrine  disruption,  and 
examines the potential methods and assays for assessing such disruption in a screening and testing 
programme. It concludes that whilst it may be premature to initiate OECD test guideline activity, 
because of the rapid scientific development in this field, it is important to monitor progress.  
 
In vitro and in vivo (non-)validated non-EATS tests for mammals (human health)  
Some of the validated mammalian apical tests may also be sensitive to endocrine modalities other than 
the EATS modalities (e.g. involving other axes or signalling pathways), but validated in vitro and in 
vivo mechanistic screens for such other endocrine modalities have not been developed yet, although 
work is ongoing (OECD, 2012b). In the short-term, it has been suggested to enhance the available 
guideline mammalian toxicity studies with the addition of further apical endpoints sensitive to these 
other modalities (OECD, 2012b). 
 
In vitro and in vivo (non-)validated non-EATS tests for the environment 
Some  of  the  validated  apical  assays  using  fish  may  be  sensitive  to  other  vertebrate  endocrine 
modalities, although this remains to be demonstrated, and they do not provide mechanistic data. Also 
the validated arthropod apical assays are expected to be sensitive to ecdysteroid and juvenile hormone 
disruptors, but again provide no mechanistic information. However, several more assays (described in 
section 4.5.1) are expected to complete international validation in the next three years to overcome 
this need for non-EATS mechanistic assays. As with the assays that have already been validated, those 
still in validation are focused on one or more of the EATS modalities, although it is possible that the 
apical effects of some other known modalities will be detected by them, depending on whether they 
are vertebrate- or arthropod-based.  
 
Non-EATS modalities in aquatic vertebrates 
Many of these non-EATS modalities have been described in detail (OECD, 2012b), and non-validated 
mechanistic assays for some already exist, although most are in vitro rather than in vivo. Therefore, Identification/Characterisation of EDs: scientific criteria and test methods 
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the major gaps in the aquatic test guideline suite concerns in vivo mechanistic assays for the non-
EATS  modalities  in  vertebrates.  There  is  a  potential  need  to  develop  and/or  validate  a  suite  of 
mechanistic in vitro and/or in vivo assays for aquatic vertebrates, covering non-EATS modalities such 
as the corticosteroid axis, the somatotropic axis, vitamin D signalling, retinoid signalling and the 
PPAR pathway. Before such developments take place, however, research is required to decide which 
(if any) of these types of endocrine modalities can be damaged by chemical exposures of wildlife. If it 
is concluded that some of these modalities are disrupted in the real world, it may become necessary to 
investigate and possibly augment the responsiveness of some existing in vivo assays. 
 
Non-EATS modalities in aquatic invertebrates: 
Another major gap in the aquatic test guideline suite is the absence of in vivo mechanistic assays for 
all modalities in invertebrates. To some extent, this development is being held back by the poor 
knowledge  of  endocrinology  in  many  invertebrate  phyla.  Therefore,  basic  knowledge  about  the 
endocrine systems in several invertebrate phyla (e.g. molluscs) needs to be improved to permit the 
development of mechanistic in vitro and/or in vivo assays based on these taxa. Such mechanistic assay 
development is probably possible for arthropods at the present state of knowledge with respect to 
ecdysteroid and juvenile hormone disruptors. 
 
4.3.3.  Other general limitations in the available test suite 
 
Sensitive life stages – whole life cycle 
In relation to mammals, a limitation of the current suite of test methods available for the identification 
of EDs (and therefore an area for further developing it) is the lack of a single study involving exposure 
through the complete life cycle of a mammal, from conception to old age or a single study involving 
developmental exposure with follow-up into old age. 
 
Limitations of animal models 
It has also been suggested that a relevant weakness of current test methods is the limitation of some 
animal models in relation to certain human endocrine disorders in which EDs have been suggested to 
play  a  role,  such  as  some  mammary  gland  tumours  and  other  hormonal  cancers,  endometriosis, 
metabolic syndrome and reproductive senescence (Kortenkamp et al., 2011).  
The Scientific Committee notes that as the limitations described above are discussed in DRP 178 
(OECD, 2012b), their consideration is envisaged at the OECD level. 
 
Despite  the  fact  that the existing  internationally  standardised  assays  might  miss  some  endocrine-
sensitive  endpoints,  this  should  not  necessarily  lead  to  the  non-identification  of  EDs.  Given  the 
complexity of the endocrine system with its multiple signalling pathways and cross-talks, an ED is 
expected to produce a pleiotropic response with a range of effects, some of which are likely to be 
observed in an appropriate guideline study.  Identification/Characterisation of EDs: scientific criteria and test methods 
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Table 1:   Degree  of  knowledge  about  selected  endocrine  modalities/axes/pathways  and  availability  (now  and  in  the  near  future)  of  internationally 
standardised mechanistic (M) and apical (A) methods for identifying and/or characterising the effects of EASs. A? = non-validated, but probable apical 
sensitivity. n/a = not applicable. HPA = Hypothalamus – Pituitary – Adrenocortical axis; PPAR = Peroxisome Proliferator-Activated Receptor signalling 
pathway. For the endocrine systems covered on the right-hand side of the table as from HPA axis onwards, it is noted that their sensitivity to disruption by 
realistic exposures is largely unknown at present. Main source of information is the OECD (OECD, 2012a, 2012b, 2012f). 
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4.4.  Available internationally standardised test methods for mammals  
 
The OECD revised CF lists five in vitro (mammalian and non-mammalian) mechanistic screens at 
Level 2, two in vivo screens at Level 3, eleven in vivo tests at Level 4 and two in vivo tests at Level 5. 
The complete list of the CF is extracted and presented in Appendix C. 
The Level 2 in vitro mechanistic screens include validated (either by the OECD or US EPA) tests for 
oestrogen  receptor  (ER)-mediated,  androgen  receptor  (AR)-mediated  and  steroidogenesis  (S) 
interference-mediated modalities. These are the ER US EPA OPPTS 890.1250 (U.S. EPA, 2011a) and 
the AR US EPA OPPTS 890.1150 (U.S. EPA, 2011b) binding assays, the ER transactivation assay 
(OECD TG 455), the steroidogenesis assay (OECD TG 456) and the aromatase US EPA OPPTS 
890.1200 assay (U.S. EPA, 2011c). Level 2 also includes a test for ER agonists and antagonists 
(OECD  TG 457)  and  assays  for thyroid  hormone-mediated  modalities (TR  binding  assay,  iodide 
uptake,  thyroid  peroxidase  inhibition,  TH  transport  protein  displacement)  for  which  no  validated 
methods are yet available. A validated AR transactivation assay is also not available, but validation 
work is ongoing. 
The  Level  3  in  vivo  screening  assays  include  two  validated  tests,  one  sensitive  to  oestrogen 
agonists/antagonists (Uterotrophic assay in rodents, OECD TG 440) and one sensitive to androgen 
agonists/antagonists (Hershberger assay in rodents, OECD TG 441). 
The Level 4 in vivo tests are essentially guideline mammalian toxicity studies, which include apical 
endpoints  sensitive  to  endocrine  disruption.  Some  of  these  tests  may  also  include  additional 
biomarkers of endocrine activity (e.g. thyroid and sex steroid hormone levels). The Level 4 tests are: 
the enhanced 28-day study (OECD TG 407); the 90-day study (OECD TG 408); the one-generation 
reproduction toxicity study (OECD TG 415); the male pubertal assay (US EPA OPPTS 890.1500, 
(U.S. EPA, 2011d)); the female pubertal assay (US EPA OPPTS 890.1450, (U.S. EPA, 2011e)); the 
intact  adult  male  endocrine  screening  assay  (no  guideline  available);  the  prenatal  developmental 
toxicity study (OECD TG 414); the chronic toxicity and carcinogenicity studies (OECD TG 451-3); 
the  enhanced  reproductive  screening  test  (OECD  TG  421);  the  enhanced  combined  28-
day/reproductive  screening  assay  (OECD  TG  422);  and  the  developmental  neurotoxicity  study 
(OECD TG 426). These tests are predominantly responsive to one or more of the EATS modalities, 
but  may  be  also  sensitive  to  some  additional  endocrine  modalities  (e.g.  those  involving  the 
corticosteroid axis, somatotropic axis, vitamin D signalling, retinoid signalling, pancreatic system, or 
PPAR pathway – as described in DRP 178 (OECD, 2012b), or other endocrine glands/structures). For 
example,  in  the  repeated  dose  toxicity  studies  (OECD  TG  407,  408,  451-3),  histopathological 
investigations of the adrenal gland could provide data on endocrine relevant endpoints involving the 
corticosteroid  axis;  or  in  the  reproductive  toxicity  studies (OECD  TG  414,  415,  421,  422,  426), 
growth evaluation could provide information on apical endpoints involving the somatotropic axis and 
the retinoid signalling pathway.  
The  Level  5  in  vivo  tests  include  two  validated  reproductive  toxicity  studies,  the  extended  one-
generation study (OECD TG 443) and the two-generation study (OECD TG 416). These tests provide 
more comprehensive data on endocrine-relevant apical endpoints (predominantly  mediated by the 
EATS modalities but also by other endocrine modalities such as those involving the corticosteroid 
axis, somatotropic axis, vitamin D signalling, retinoid signalling, PPAR pathway or other endocrine 
glands/structures) over more extensive parts of the life cycle of the organism, although old age or 
senescence is generally not covered. 
Table 2 lists the in vivo mammalian toxicity screens and tests from Levels 3 to 5 of the OECD revised 
CF, showing their known or potential responsiveness to various endocrine modalities. Identification/Characterisation of EDs: scientific criteria and test methods 
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Table 2:   In vivo mammalian toxicity screens and tests listed in the OECD CF, showing their known or potential responsiveness to various (selected and 
not exhaustive) endocrine modalities/axes/pathways. For each test, its level of the CF is shown: those at Level 3 are suitable for identification of endocrine 
activity, while those at Levels 4 and 5 are more suitable for hazard identification and characterisation. M: screen providing some mechanistic information; A: 
screen or test providing some apical information; P: apical endpoints potentially responsive, but not yet fully evaluated.  
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Oestrogen  M    A  A  A    A    A  A  A  A  A  A  A 
Anti-estrogens  M    A  A  A    A    A  A  A  A  A  A  A 
Androgen  M  M  A  A  A  A    A  A  A  A  A  A  A  A 
Anti-androgen    M  A  A  A  A    A  A  A  A  A  A  A  A 
Thyroid    M  M/A  A  A  A  A  A  A  A  A  A  A  A  A 
Anti-thyroid    M  M/A  A  A  A  A  A  A  A  A  A  A  A  A 
Steroidogenesis      A  A  A  A  A  A  A  A  A  A  A  A  A 
HPA/Corticosteroid axis      P  P  P        P  P  P  P  P  P  P 
Somatotropic axis      P  P  P        P  P  P  P  P  P  P 
Vitamin D signalling      P  P  P        P  P  P  P  P  P  P 
Retinoid signalling      P  P  P        P  P  P  P  P  P  P 
PPAR pathway      P  P  P        P  P  P  P  P  P  P 
Other potential endocrine 
modalities not covered in 
OECD, 2012b 
    P  P  P        P  P  P  P  P  P  P 
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4.5.  Available internationally standardised test methods for aquatic organisms  
 
The CF lists five aquatic ecotoxicity tests at Level 3, twelve aquatic tests at Level 4, and seven aquatic 
tests at Level 5, although several of these are still in the early stages of validation. Table 3 lists the in 
vivo  aquatic  assays  with  some  sensitivity  to  EDs;  nine  have  been  nationally  or  internationally 
validated. Some of the validated assays are essentially mechanistic screens (OECD TG 230; OECD 
GD 140 (OECD, 2009c)), while others have both mechanistic and apical endpoints (OECD TG 229; 
OECD TG 231; OECD TG 234), and a third category just have apical endpoints at present (US EPA 
OPPTS 850.1500 (U.S. EPA, 2004), OECD TG 218/219; OECD TG 211; OECD TG 233). 
The assays giving some mechanistic information all use vertebrates (fish or amphibians), and are 
responsive to one or more of (anti-)oestrogens, (anti-)androgen, (anti-)thyroid, or steroidogenesis-
disrupting (EATS) modalities. On the other hand, additional potential modalities (involving inter alia 
the corticosteroid axis; somatotropic axis; vitamin D signalling; retinoid signalling; or PPAR pathway 
(see DRP 178, OECD, 2012b) may be expected to affect endpoints such as growth, reproduction and 
development in the US EPA OPPTS 850.1500 fish lifecycle toxicity test (U.S. EPA, 2004). However, 
this assay would not at present give information about mechanisms, and it has not been validated with 
these modalities in mind. Furthermore, it is not yet known whether the effects of these modalities 
occur at realistic levels of exposure, so test developments in this area may be premature. Finally, it is 
probable that the Daphnia reproduction and chironomid lifecycle assays are sensitive to arthropod-
specific EDs, but again they do not provide mechanistic data. 
Detailed guidance on the interpretation of results from many of the aquatic assays is given in the 
OECD Fish Toxicity Framework (OECD, 2012g) (see also Appendix C for a short introduction). 
The nine aquatic ecotoxicity assays with expected sensitivity to some EDs but with no assigned 
numbers in Table 3 are still in development and/or validation at OECD. One of these is a mechanistic 
screen for thyroid-acting substances in frogs, the Xenopus Embryo Thyroid Signalling Assay, which 
uses transgenic X. laevis larvae and gives diagnostic results in three days (much more quickly than 
OECD TG 231). Another amphibian method currently being validated, the Larval Amphibian Growth 
and Development Assay which exposes X. laevis from the larval stage to sexual maturity, is expected 
to  provide  mechanistic  and  apical  information  about  EATS  modalities,  but  does  not  include 
reproduction as an endpoint so cannot be considered a full lifecycle test.  
There  are  also  two  higher-tier  fish  tests  in  validation.  The  first  is  the  Fish  Reproduction  Partial 
Lifecycle Test which is essentially an OECD TG 229 followed by TG 234, thus exposing fish (several 
possible  species  including  Pimephales  promelas  and  Danio  rerio)  from  reproduction  in  the  F0 
generation through to sexual differentiation of the F1 generation. The second is the Medaka Multi-
Generation  Test  (MMGT)  which  exposes  Oryzias  latipes  from  reproduction  of  the  F0  fish  to 
reproductive maturity in the F2 generation. Both tests include some mechanistic as well as apical 
endpoints. One focus of the validation programme is to establish whether the MMGT provides any 
greater sensitivity to certain EDs than single lifecycle tests. If not, a version of the US EPA OPPTS 
850.1500 fish lifecycle toxicity test (U.S. EPA, 2004), with added mechanistic endpoints may be 
sufficient to provide the high tier information required at Level 5 of the CF. 
Several  apical  invertebrate  assays  are  being  validated  by  OECD.  These  include  Partial  and  Full 
Lifecycle  Tests  with  gastropod  molluscs  (Potamopyrgus  antipodarum  and  Lymnaea  stagnalis),  a 
Copepod Reproduction and Development Test with Amphiascus tenuiramis, a Mysid 2-Generation 
Test with Americamysis bahia, and a Daphnia magna Multigeneration Test. It is expected that the 
molluscs  will show  sensitivity  to  some  vertebrate  EATS  modalities  as  well  as  to  others  such  as 
disruptors of retinoid signalling (e.g. organotins), while the arthropods are expected to be sensitive 
inter alia to ecdysteroid and juvenile hormone disruptors. Identification/Characterisation of EDs: scientific criteria and test methods 
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Table 3:   Aquatic in vivo ecotoxicity screens and tests listed in the OECD CF, showing their known or potential responsiveness to various (selected and not 
exhaustive) endocrine modalities/axes/pathways. For each test, its Level of the CF is shown: those at Level 3 are suitable for identification of endocrine 
activity, while those at Levels 4 and 5 are more suitable for hazard identification and characterisation. M: screen providing some mechanistic information; A: 
screen or test providing some apical information; P: apical endpoints potentially responsive, but not yet fully evaluated.  
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Corticosteroid axis  
            P  P  P  P                 
Somatotropic axis               P  P  P  P                 
Vitamin D               P  P  P  P                 
Retinoid signalling               P  P  P  P  P            P   
PPAR pathway               P  P  P  P                 
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4.6.  Available internationally standardised test methods for birds 
 
Whilst effects upon predatory birds, particularly eggshell thinning provided early sentinel warnings of 
the endocrine disrupting effects of some pesticides over 50 years ago, at present there are no finalised, 
internationally  standardised  and  agreed  test  methods  specifically  for  assessing  the  hazards  of 
endocrine disrupting substances to birds. Test guideline work is under development (OECD, 2005b).  
The Avian Two Generation Test with the Japanese quail Coturnix japonica runs for 21 weeks, from 4 
weeks old F0 reproducing adults to 2 weeks old F2 chicks, and hence encompasses more than one 
complete generation. It is therefore expected to be responsive to most substances with EATS activities. 
This test is included in the OECD Work plan 2012. Some of the endpoints affected by EATS in this 
test are also included in an apical test (TG 206).  
OECD TG 206 is designed primarily as an apical test for chemicals with suspected reproductive 
toxicity, but it is not a lifecycle test as it only runs from the stage of pre-laying adults to 14 days old 
offspring. Furthermore, only the adults are exposed to the test substance (via food), and any effects on 
sexual development would not be detectable. The endpoints are all apical measures of development, 
growth  or  reproduction.  Key  endpoints  which  might  be  affected  by  EDs  include  egg  production, 
viability and hatchability.  
Detailed information for testing of birds is also given in the DRP on the avian two-generation toxicity 
test (OECD, 2007b).  
Regarding the interpretation of results from the above tests, detailed guidance is given in GD150 
(OECD,  2012a)  and  a  table  with  interpretation  results  is  presented  in  Appendix  C.  Briefly,  the 
outcome of the above two tests in combination with other in vivo and in vitro information provides a 
tool for assessing whether a compound is a potential endocrine active substance or not.  
 
4.7.  Discussion  on  the  appropriateness  of  available  internationally  standardised  test 
methods 
 
4.7.1.  Considerations specific to endocrine activity and disruption 
 
The appropriateness of test methods regarding the coverage of modalities and taxa is reviewed in the 
section above (4.3). In conclusion, considerable strides have been made by the OECD in the last 
decade  to  develop/standardise  in  vitro  and  in  vivo  mechanistic  and  in  vivo  apical  assays  with 
sensitivity to EDs. A reasonably complete suite of standardised assays (for endocrine activity and for 
endocrine hazard identification and/or characterisation) is only available (or will soon be available) for 
the  EATS  modalities  relevant  for  mammals  and  fish,  with  fewer  tests  available  for  birds  and 
amphibians. While downstream effects of disruption of some non-EATS pathways/modalities may be 
detectable in some standardised apical vertebrate assays, it is important to recognise that standardised 
mechanistic assays for non-EATS modalities relevant to mammals, fish and other vertebrates are not 
or not yet available. For invertebrates relevant mechanistic assays are conspicuous by their absence 
from the OECD testing suite, mainly due to poor understanding of invertebrate endocrinology. Finally, 
a range of major taxa such as reptiles and echinoderms have not yet been considered by OECD for any 
endocrine assay development. It is unknown at present whether it will be possible to read-across to 
untested groups from tests with other taxa.  Identification/Characterisation of EDs: scientific criteria and test methods 
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4.7.2.  Considerations not unique to endocrine activity and disruption 
 
Other  considerations  of  appropriateness  relate  to  more  general  aspects  while  testing  effects  of 
substances (i.e. not exclusively for testing potential endocrine activity/disruption) and are discussed 
below. 
 
4.7.2.1.  Critical windows of susceptibility 
 
This section discusses whether or not available test methods cover appropriately exposure during the 
critical  windows  of  susceptibility  to  EASs.  It  is  noted  that  this  issue  of  critical  windows  of 
susceptibility is relevant for all developmental toxicants and not only for EASs. 
Hormones, among other factors, are important for the correct development of organs and tissues to 
take place. Disruption at critical points during such development can result in irreversible changes of 
the organ/tissue.  
In mammals, critical periods of development have been identified at conception, during pregnancy, 
infancy, childhood and puberty. For a comprehensive review of endocrine mediated effects and the 
timing of exposure in mammals including humans see Annex I of SAAED (Kortenkamp et al., 2011) 
and the recent WHO report on possible developmental early effects of endocrine disruptors on child 
health (WHO, 2012). 
Also in other vertebrates such as fish, disturbances at critical periods of development can result in 
dysfunction and/or disease across the entire lifespan.  
In wildlife, there are a number of examples of exposure during critical windows of susceptibility 
which can lead to irreversible effects. For example, permanent changes in fish sex ratios are induced 
following early-life stage exposure to some androgen, oestrogen and steroidogenesis disruptors. Thus, 
exposure of zebrafish embryos and fry to some oestrogens (e.g. 17alpha-ethinylestradiol) can lead to 
an  increase  in  females  in  the  phenotypic  sex  ratio  when  the  fish  start  to  differentiate  sexually 
(Andersen et al., 2003). A second example concerns male sticklebacks exposed to an oestrogen as 
juveniles.  Even  though  their  phenotypic  sex  remains  unaltered  and  despite  them  being  reared  to 
adulthood in clean water, their sexual behaviour is affected and they make fewer nests and rear fewer 
eggs than normal males (Maunder et al., 2007). 
It is widely accepted that, in relation to potential effects from exposure during critical periods of 
susceptibility,  testing  in  vivo  is required. This  is  to encompass  sufficiently  sensitive  endpoints  of 
toxicological relevance during the sensitive life stages that allow judgement of adversity. To avoid the 
possibility that relevant effects are overlooked, the administration of test compounds needs to address 
recognised periods of sensitivity and endpoint assessment has to cover all life stages. In the OECD CF 
for testing and assessment of endocrine disrupting substances, some Level 4 and 5 tests do cover 
critical periods of development in utero and in later life stages. On the other hand, fish lifecycle and 
multi-generation  tests  cover  all  relevant  windows  of  exposure  and  can  be  expected  to  reveal  the 
longer-term effects of even short-term exposures at all stages of the lifecycle. 
However, several recent review reports concluded that current mammalian tests do not cover certain 
endpoints that might be induced by exposure during fetal or pubertal development but emerge later in 
life like certain cancers (breast, prostate, testis, ovarian and endometrial) and effects on reproductive 
senescence (EFSA, 2010; Kortenkamp et al., 2011; EEA, 2012; OECD, 2012b). See also section 4.3.3. Identification/Characterisation of EDs: scientific criteria and test methods 
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4.7.2.2.  Combined exposure to multiple substances 
 
In the assessment of combined exposure toxicity involving several substances affecting a common 
target, the concept of dose addition may be applied to predict the toxicological outcome, assuming that 
all of the substances to which exposure occurs might contribute to the common effect, depending on 
their individual potency and their individual concentrations.  
The Scientific Committee recognises that exposure to more than one EASs (e.g. from a mixture or 
from  several  sources  at  approximately  the  same  time)  could  occur  in  such  a  way  that  combined 
toxicity could arise. EDs can work together to produce additive effects, even when combined at low 
doses that individually do not produce observable effects, “making accurate risk assessment difficult 
or impossible” for this type of substances (WHO/UNEP, 2013). 
The SC recognises that information on interactions at the receptor level may be obtained from in vitro 
studies. However, because of differences in toxicokinetic properties of the various substances, it is not 
enough to predict the nature of the combined effects from in vitro studies, when an intact organism 
would be exposed to any combination of substances from the same category (with a likely similar 
mechanism contributing to the specified mode of action).  
The SC notes that the current tests are being developed to address single substances. It acknowledges 
that it is necessary to first develop the tests for single substances with adequate dose response data for 
reference  substances  (first  for  EATS  and  then  for  other  modalities),  before  addressing  combined 
exposure to multiple substances. 
The  SC  notes  that  these  considerations  are  not  unique  to  EASs,  but  are  equally  applicable  to 
substances  with  other  mechanisms  or  modes  of  action.  Considering  the  complexity  of  combined 
exposure to multiple substances, this aspect of hazard and risk assessment of  EASs could not be 
further  addressed  here.  For  further  information  on  this  issue,  see  the  following  existing  or  soon 
available publications: 
-  the opinion of the EC Scientific Committees (SCCS, SCHER, SCENIHR) on Toxicity and 
Assessment of Chemical Mixtures (SCHER/SCENIHR/SCCS, 2011),  
-  the EC State of the Art Report on Mixture Toxicity (Kortenkamp et al., 2009),  
-  the opinion of the EFSA Scientific Panel on Plant Protection products and their Residues (PPR 
Panel)  to  evaluate  the  suitability  of  existing  methodologies  and,  if  appropriate,  the 
identification of new approaches to assess cumulative and synergistic risks from pesticides to 
human health (EFSA, 2008), 
-  the opinion of the PPR Panel on risk assessment for a selected group of pesticides from the 
triazole  group  to  test  possible  methodologies  to  assess  cumulative  effects  from  exposure 
through  food  from  these  pesticides  on  human  health  (EFSA  Panel  on  Plant  Protection 
Products and their Residues, 2009),  
-  chapter 6 of the EFSA Scientific Opinion on the science behind the development of a risk 
assessment of Plant Protection Products on bees (Apis mellifera, Bombus spp. and solitary 
bees), which discusses how to take account of cumulative and synergistic effects (EFSA Panel 
on Plant Protection Products and their Residues, 2012b, and references therein), 
-  an  EFSA  Scientific  Report  reviewing  the  terminology,  methodologies  and  frameworks 
developed by national and international agencies for the human risk assessment of combined 
exposure to multiple chemicals. The publication of this report is expected later in 2013.  
-  an EFSA PPR Panel Scientific Opinion on the identification of pesticides to be included in 
cumulative assessment groups on the basis of their toxicological profile. The publication of 
this opinion is expected later in 2013. Identification/Characterisation of EDs: scientific criteria and test methods 
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4.7.2.3.  Low-dose effects and non-monotonic dose response curves 
 
Conventional in vivo toxicity testing in regulatory toxicology and ecotoxicology, e.g. in chronic, sub-
chronic or reproductive / developmental studies, involves a high dose and a few lower doses (usually 
two to four) that cover about a 50- to 100- fold range. The high dose has to be near the maximum 
tolerated dose, i.e. a dose that causes some sublethal effect in the organism (e.g. loss of body weight in 
mammals) to reveal the full toxic potential of the substance. With pesticide dossiers, for example, the 
current practice is normally to select the lowest dose at a level expected not to result in adverse effects. 
The conventional hazard characterisation approach for threshold effects considers that no detectable 
adverse effects will occur below this No-Observed-Adverse-Effect-Level (NOAEL) / No-Observed-
Effect
14-Concentration  (NOEC)  and based on that paradigm, these cut -off  levels can be used as 
Reference Points (also called Points of Departure) for derivation of health-based guidance values in 
human or ecotoxicological risk assessments.  
In the scientific literature on  EASs or EDs, an extensive discussion is  taking place on two aspects 
related to the shape of the dose response curve, which could challenge this paradigm:  
-  The issue of possible effects at low doses (meant as doses or concentrations below those 
which are considered to be no-effect levels, or levels of exposure which are (far) below the 
current health-based guidance value (e.g. Tolerable Daily Intake (TDI) or Acceptable Daily 
Intake (ADI))) has been subject to discussion for more than a decade (Melnick et al., 2002; 
EFSA, 2010).  
-  For EASs it has been proposed that monotonic dose response curves cannot be assumed, but 
rather, that for such substances non-monotonic dose responses should be anticipated. Such 
non-monotonic dose response curves (NMDRCs) can be characterised by a change in slope 
direction along the dose interval studied, contrary to conventional dose responses, which show 
a consistent increase in adversity along the dose range (Vandenberg et al., 2012).  
 
While  most  reported  low  dose  and  NMDRCs  findings  have  been  observed  with  rodents  and  are 
therefore connected to human health, studies in molluscs and fish suggest that these findings can also 
be relevant for environmental organisms (e.g. Jobling et al., 2004). 
The term low-dose effects is not synonymous with or equivalent to NMDRC. Many authors use the 
terms low-dose effects and NMDRCs interchangeably, which creates considerable confusion.  
It has been postulated that conventional in vivo testing is inadequate for the identification of low-dose 
effects or NMDRCs displayed by some EDs and for the characterisation of the shape of the dose 
response curve in the low-dose range, as monotonicity is normally assumed, and doses much lower 
than the traditional NOAEL/NOEC are usually not investigated (Vandenberg et al., 2012). Since the 
effects of low doses cannot be predicted by the effects observed at high doses, the authors recommend 
to use a wider range of doses, extending into the low-dose range, when testing substances for possible 
endocrine disrupting properties.  
In contrast, other authors have contested whether low-dose effects and NMDRCs do exist. This subject 
has been the topic of intense debate, mainly due to issues relating to reproducibility. Already in 2000, 
the issue of low-dose effects was addressed in a review by US-NTP (U.S. NTP, 2001; Melnick et al., 
2002),  in  which  it  was  pointed  out  that  these  findings  could  not  be  replicated  and  that  their 
                                                       
14 The NOEC in ecotoxicological studies is usually defined by the absence of adverse effects in the same way as the NOAEL 
in mammalian studies. Identification/Characterisation of EDs: scientific criteria and test methods 
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toxicological relevance had not been determined (EFSA, 2010). A few examples of reports/reviews 
casting doubts on the relevance of NMDRCs (Kitchin and Drane, 2005; Mushak, 2007; Chapin et al., 
2008; Mayo and Spanos, 2008) were cited in the EFSA report (2010). Thus, it should be considered 
that assessment of reproducibility of findings that might indicate low-dose effects or NMDRCs, is 
important  to  rule  out  spurious  results.  In  a  response  to  the  paper  by  Vandenberg  et  al.  (2012), 
Rhomberg  and  Goodman  (2012)  argued  that  Vandenberg  et  al.  have  based  their  arguments  on 
examples  which  have  been  questioned  by  other  scientists  and  do  not  provide  sound  evidence  to 
substantiate their views.  
During the June 2012 EFSA Scientific Colloquium on low dose responses in toxicology and risk 
assessment (EFSA, 2012), discussion was conducted on the question of whether there was sufficient 
scientific  evidence  for  the  existence  of  low-dose  effects  and  NMDRCs.  These  findings  were 
considered  plausible  and  reliable  by  some  of  the  participants  at  the  Colloquium,  however,  no 
consensus
15 on this was reached amongst the experts participating in the colloquium discussions. It 
was stated that the quality and robustness of data for studies reporting NMDRCs should be assessed, 
as for any other studies. During the EFSA Colloquium, it was further suggested to undertake a critical 
examination of the existing literature to explore the reliability of the low-dose effects and NMDRCs 
findings, and to assess how they  may impact on current hazard and risk assessment approaches and 
testing strategies (EFSA, 2012).  
The US National Institute for Environmental Health Sciences/NIH and the Joint Research Centre's 
Institute for Health and Consumer Protection organised a low dose effects and non -monotonic dose 
responses  for  endocrine active  chemicals  workshop  in  Berlin  on  11 -13  September  2012. This 
workshop sought to examine the evidence for low dose effects and non -monotonic dose responses in 
relation to endocrine active chemicals, with the goal of establishing whether the  current observations 
are  sufficient  to  re -examine  the  ways  in  which  chemicals  are  tested  for  endocrine  disrupting 
properties, and how risks to human health may be managed. Most of the participants were in 
agreement that non-monotonic dose responses do occur and may be expected at some dose ranges for 
some substances, but the extent to which they might occur at so-called „low doses‟ was considered to 
be a separate issue. There was a suggestion that a definition of „low dose‟ would be helpful, as it is 
currently used with different meanings in different contexts, and that there was also a need to carry out 
a  practical  assessment  of  the  type  of  effects  that  may  be  considered  adverse,  in  the  context  of 
endocrine disruption.  
Most recently, low-dose effects and NMDRCs have been considered in the WHO/UNEP State of the 
Science of Endocrine Disrupting Chemicals – 2012 report (WHO/UNEP, 2013).  
“The „low dose‟ hypothesis posits that exogenous chemicals that interact with hormone action 
can do so in a manner that is quite specific such that traditional toxicological endpoints are 
not  sufficient  to  preclude  adverse  outcome,  and  they  do  so  with  dose  responses  that  are 
nonlinear and potentially non-monotonic (Vandenberg et al., 2012).” 
 
In relation to NMDRCs, a main message of the WHO/UNEP report is that  
“EDs  produce  nonlinear dose responses  both  in  vitro  and  in  vivo; these  non  linear  dose 
responses can be quite complex and often include non-monotonic dose responses. They can be 
due to a variety of mechanisms; because endogenous hormone levels fluctuate, no threshold 
can be assumed.” 
 
Thus on balance, reviewing the recent colloquia, workshop and WHO/UNEP expert report, the debate 
is evolving in the scientific community as to the existence and/or relevance of low-dose effects and 
NMDRCs in (eco)toxicology in relation to endocrine disruption or other endpoints/modes of action, 
but still lacks consensus. More work needs to be conducted to agree the definitions of the respective 
                                                       
15 It should be noted that the objective of EFSA Scientific Colloquia is to air views in areas for which the scientific thinking 
is not yet concluded.  Identification/Characterisation of EDs: scientific criteria and test methods 
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terms, and in practical terms to consider whether or how it could impact upon risk assessment (i.e. 
assessment of dose response relationships for adverse effects) and testing strategies. 
Therefore, the Scientific Committee cannot conclude whether the current test methods are adequate to 
fully define dose response relationships. However, the available information is equally insufficient to 
conclude that current dose response analysis in regulatory (eco)toxicology should be modified on a 
routine basis. Nevertheless, on a case-by-case basis, if triggered by unusual findings, an extended dose 
response analysis could be performed in a second tier. 
The SC further notes that, as low-dose effects and NMDRCs are not unique to endocrine activity, 
these subjects merit a follow-up in a broader context.  
 
4.8.  Testing strategies  
 
As mentioned in section 4.1, in principle no single test allows by itself a conclusion that a substance is 
an  ED;  all  the  available  information  (in  silico,  in  vitro  and  in  vivo  data,  including  observational 
studies) should be considered. There is therefore a need for further development of testing strategies to 
generate adequate data for the identification and assessment of endocrine disrupting properties. An 
example of a test strategy for fish developed at an OECD workshop in 2010, which makes use of some 
of the tests that are discussed in sections 4.2.2 and 4.5, is described below.  
The  approach  described  in  the  OECD  Fish  Toxicity  Testing  Framework  (OECD,  2012g)  (see 
Appendix C for details and a decision tree) provides an outline strategy for collecting all the data 
needed  to  perform  a  risk  characterisation.  It  forms  a  sound  basis  for  developing  an  EU-wide 
ecotoxicity testing strategy for substances, which includes full consideration of both endocrine-related 
and other toxicity. At the present stage of test validation and development, it should however be noted 
that it will only be possible to design testing strategies sensitive to EDs with EATS modes of action. 
Schemes  sensitive  to  other  possible  modes  of  action  cannot  be  implemented  until  the  ecological 
importance of such modalities has been evaluated, and suitable in vitro and in vivo screening assays 
have been validated. Furthermore, it is apparent that the generic fish testing strategy is data-intensive 
and might not be applicable to substances for which few data are likely to be available. 
 
5.  Elements of hazard characterisation of endocrine disruptors 
 
A hazard-based approach is included in EU regulation on the assessment of certain substances (e.g. 
active  substances  in  plant  protection  products),  for  possible  endocrine  disruptive  properties  (see 
section 1.2). Section 3 discusses the criteria for the identification of a substance as an ED. As hazard 
identification is only the first step of hazard assessment, with hazard characterisation being the next, 
the SC examined whether there is a scientific basis to consider critical effect, severity, (ir)reversibility 
and potency, for the characterisation of EDs.  
The  REACH  Regulation  (see  Appendix  B)  provides  that  substances  with  endocrine  disrupting 
properties  can  be  identified  as  “substances  of  very  high  concern  (SVHCs)”  and  included  in  the 
Candidate List of Chemicals , and may subsequently be made subject to the authorisation requirement 
of the Regulation. Identification of  EDs as SVHCs  under REACH Article 57(f) requires that the 
substance has endocrine disrupting properties and that there is scientific evidence of probable serious 
effects to human health or the environment, which gives rise to an equivalent level of concern to the 
level of concern of other substances listed in Article 57(a-e) (i.e. Carcinogenic, Mutagenic or toxic for 
Reproduction  (CMR)  Category  1A  and  1B,  Persistent,  Bioaccumulative  and  Toxic  (PBT),  very 
Persistent and very Bioaccumulative (vPvB)). Identification/Characterisation of EDs: scientific criteria and test methods 
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5.1.  Critical effect 
 
Hazard identification usually reveals a range of qualitatively different adverse effects of a substance, 
representing different toxic endpoints such as body weight decrements or organ toxicity, e.g. liver 
toxicity  or  neurotoxicity.  These  adverse  effects  are  elicited  in  most  cases  at  different  dose  or 
concentration levels. During risk assessment, the hazard characterisation step (e.g. establishment of a 
health-/ecotoxicology-based guidance value) consists of a dose/concentration–response assessment to 
identify at which dose/concentration adverse effects occur, taking into account uncertainties. The first 
adverse effect, or its known precursor key event, that occurs in the most sensitive species as the dose 
rate  or  concentration  of  an  agent  (e.g.  a  substance)  increases  is  called  the  „critical  effect‟. 
Dose/concentration-response modelling may be needed to determine which effect results in the lowest 
reference point, i.e. which is the critical effect. The SC is of the opinion that hazard characterisation 
should be based on the effect leading to the lowest health/ecotoxicology-based guidance value.  
ECETOC (2011) proposed to use the concept of „critical effect‟ in identifying a chemical as an ED for 
regulatory purposes with the rationale that, if the endocrine-mediated adverse effects occur within a 
range  up  to  10  times  higher  than  the  critical  effect,  the  substance  is  then  considered  as  an  ED. 
However, the SC disagrees with the idea that a substance can be identified as an ED only when the 
endocrine-mediated adverse effects occur within a certain range of the critical effect. According to the 
agreed  definition  and  criteria  for  EDs,  all  substances  with  the  ability  to  cause  adverse  effects 
consequent to an endocrine mode of action are to be regarded as EDs, independently from critical 
effect considerations. The proposal by ECETOC goes beyond the hazard identification of EDs and 
falls at the interface between science, policy and risk management, and hence outside the remit of 
EFSA.  
 
5.2.  Severity / (ir)reversibility / potency 
 
Severity and (ir)reversibility 
Severity may describe the magnitude of an adverse effect and/or the qualitative nature of the effect, 
and thus may be associated with the typical manifestations of certain endpoints (e.g. developmental 
effects or cancer).  
(Ir)reversibility considerations may contribute to judgment of severity, although an effect may be 
regarded  as  being  severe  without  being  irreversible.  Reversibility  implies  that  recovery  of  the 
individual  or  population  may  occur  after  cessation  of  exposure  to  the  toxic  substance.  The  SC 
considers that to inform whether exposure to a substance represents a toxicological risk
16, severity and 
(ir)reversibility should be evaluated in relation to degree and timing of exposure. 
Potency 
Potency in general terms can be seen as a descriptor for the relationship between the biological or 
biochemical effect elicited by a chemical substance and the dose or concentration necessary to achieve 
this effect. Potency is therefore a measure of a substance‟s activity or strength to produce the effect, 
and  is  part  of  the  dose  response  considerations  in  the  hazard  characterisation  of  a  substance  as 
described  above.  Potency  is  usually  considered  in  a  context,  e.g.  in  comparison  of  substances 
                                                       
16 The problem formulation discussion between the risk assessor and the risk manager aims at defining the parameters within 
which risk is assessed; this includes among other the identification of protection goals and the definition of adverse effects. 
The risk assessor will then be able to characterise the toxicological risk of a given substance and its level of concern in 
relation to the pre-agreed protection goals.  Identification/Characterisation of EDs: scientific criteria and test methods 
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displaying the same effect. Relative potency of an ED which for example mimics a hormone should 
also be considered in comparison to that of the natural endogenous hormones.  
Potency  values established  in  single  in vitro  assays may  differ  from  the  dose-effect relationships 
observed in the intact animal. In accordance with the criteria for defining an ED, which link alteration 
of functions of the endocrine system to the adverse effects in the intact organism, potency in the 
present opinion therefore refers to potency associated with in vivo adverse effects. 
Potency for a particular endpoint in vivo may depend not only on the degree of exposure (the dose), 
but also on the duration and timing of exposure. Thus, for the establishment of potency values for 
EDs,  critical  periods  of  development  (studies  covering  different  life  stages)  and  the  duration  of 
exposure should be taken into account. The SC is of the opinion that, to assess whether or not a 
(predefined) level of concern is reached for an ED, potency should not be used alone but should take 
account of actual or predicted exposure.  
It is the opinion of the SC that, if regulation of identified EDs is to be based on a level of concern, 
whether or not this level of concern is reached, can only be determined by risk assessment. This 
should take actual or predicted exposure into account, and consider the whole body of evidence in a 
combined manner to characterise the risk. 
Whether hazard characterisation criteria alone, or risk assessment should be used for defining the level 
of concern for identified EDs for further regulatory measures is beyond the scope of this opinion and 
is a risk management decision. 
 
CONCLUSIONS  
 
Definition of endocrine disruptor and adverse effect 
 
  The Scientific Committee (SC) defined an endocrine active substance (EAS) as: 
 
“any chemical that can interact directly or indirectly with the endocrine system, and 
subsequently result in an effect on the endocrine system, target organs and tissues.” 
(EFSA, 2010). 
 
  It  should  be  pointed  out  that  the  range  of  substances  that  may  be  identified  as  EASs  is 
contingent on our increasing understanding of the endocrine system. 
 
  The SC concludes that the WHO/IPCS 2002 definition of endocrine disruptor (ED) and the 
WHO/IPCS 2009 definition of adverse effect should be adopted as a basis for the criteria for 
the identification of EDs: 
 
-  “An endocrine disrupter is an exogenous substance or mixture that alters function(s) 
of the endocrine system and consequently causes adverse health effects in an intact 
organism, or its progeny, or (sub)populations.” (WHO/IPCS, 2002). 
 
-  “An adverse effects is a change in the morphology, physiology, growth, development, 
reproduction, or, life span of an organism, system, or (sub)population that results in 
an impairment of functional capacity, an impairment of the capacity to compensate 
for  additional  stress,  or  an  increase  in  susceptibility  to  other  influences.” 
(WHO/IPCS, 2009). Identification/Characterisation of EDs: scientific criteria and test methods 
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Criteria for identifying endocrine disruptors 
 
  An ED is defined by three criteria i) the presence of an adverse effect in an intact organism or 
a  (sub)population;  ii)  the  presence  of  an  endocrine  activity;  and  iii)  a  plausible  causal 
relationship between the endocrine activity and the adverse effect.  
 
-  Assessment of adversity is not unique to endocrine-related adverse effects. Scientific 
criteria for assessment of adversity have not been generally defined. In general, but 
not  always,  transient,  inconsistent  and  minor  fluctuations  at  the  biochemical  and 
molecular level may be considered adaptive, i.e. non-adverse. Changes at the cell-, 
organ-,  organism-,  or  (sub)  population  level  resulting  in  pathology  or  functional 
impairment in vivo, as well as altered timing of development,  may be considered 
adverse.  It  is  therefore  difficult  to  propose  ED-specific  criteria  for  adversity  and 
expert  judgement  is  therefore  required  to  assess  on  a  case-by-case  basis  the 
(eco)toxicological  relevance  of  such  changes  and  when  the  biological  threshold 
between endocrine modulation and adverse effect has been crossed.  
 
-  Endocrine-related effects observed secondary to marked toxicity caused by a non-
endocrine  mode  of  action,  should  not  be  considered  specific,  genuine  endocrine 
disrupting effects.  
 
-  Endocrine activity  information  could be  obtained from  existing  information, read-
across, in silico tools, in vitro and in vivo screening assays (Levels 1, 2 and 3) of the 
current OECD Conceptual Framework (CF) or from other mechanistic investigations. 
These  mechanistic  studies  should  be  evaluated  on  their  merits  on  a  weight-of-
evidence basis.  
 
-  A prerequisite for an EAS to be regarded as an ED is the need to identify the adverse 
effect. For this, test methods with apical endpoints (Levels 4 and 5 of the CF) can be 
used together with existing information, read-across and other in vivo (eco)toxicity 
tests that provide information on apical endpoints. 
 
-  There  must  be  a  reasonable  evidence  base  for  a  biologically  plausible  causal 
relationship between the induced endocrine activity and the adverse effect(s) seen in 
an intact organism, or its progeny, or (sub)population. Evidence for this relationship 
should be obtained from the OECD CF or from other investigations and assessed on a 
weight-of-evidence (WoE) basis. 
 
Availability  and  appropriateness  of  test  methods  for  identifying  and  characterising  effects 
mediated by endocrine active substances 
 
Test methods for both mammalian and non-mammalian endocrine modalities, most of which have 
been developed and subsequently (internationally) standardised (and validated) in the framework of 
OECD programmes, were considered with respect to appropriateness. Methods used predominantly 
for academic research purposes were not specifically considered.  
 
  Computational  toxicology  and  non-test  methods:  Application  of  in  silico  methods  in 
sequential/step  wise  approaches,  combining  relevant  and  reliable  expert  systems  and/or 
(Quantitative) Structure Activity Relationship models, can contribute on a WoE basis to the 
prediction of endocrine activity. Overall, for molecular initiating event endpoints, such as Identification/Characterisation of EDs: scientific criteria and test methods 
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oestrogen receptor (ER) and androgen receptor (AR) binding and activation, the quality and 
reliability of the tools are relatively high. However, for the prediction of endocrine related 
toxicity in vivo, such as reproductive and developmental toxicity, these tools have been found 
to be of limited applicability and low reliability. 
 
  In vitro oestrogen, androgen, thyroid or steroidogenesis (EATS) tests: The currently (or soon 
to be) available internationally standardised in vitro assays based on mammalian systems are 
only applicable for detecting oestrogen, androgen, or steroidogenic activity. For substances 
affecting  the  thyroid  hormonal  axis,  whilst  tests  providing  information  on  thyroid-related 
apical endpoints and thyroid-related in vivo biomarkers are available, in vitro mechanistic 
screens relevant to the thyroid are still lacking. Work is ongoing at OECD level on thyroid. In 
vitro EA(T)S tests based on other vertebrate systems will be potentially covered in the future 
when additional test guidelines become available. 
 
  In vivo EATS tests for vertebrates: With respect to the standardised mechanistic and/or apical 
in  vivo  assays,  most  of  the  EATS  modalities  and  their  expected  apical  effects  are  only 
detectable in mammalian and fish (and to a lesser extent amphibian) assays. There are no 
standardised assays for these modalities for reptiles, and only apical assays for birds. 
 
  Non-EATS tests for vertebrates: Some of the standardised mammalian apical tests may also be 
sensitive to other than EATS modalities (e.g. involving other axes or signalling pathways), but 
internationally standardised in vitro and in vivo mechanistic screens for these modalities have 
not been developed yet, although work is ongoing. Regarding the environment, some of the 
fish apical assays standardised for oestrogen, androgen or steroidogenic modalities may be 
sensitive to other vertebrate endocrine modalities.  
 
  EATS and non-EATS tests for invertebrates: Standardised arthropod apical assays are sensitive 
to  ecdysteroid  and  juvenile  hormone  disruptors,  but  provide  no  mechanistic  information. 
There are no standardised mechanistic assays for any modalities in invertebrates, although 
apical  reproduction  assays  under  development  with  molluscs  have  sensitivity  to  some 
vertebrate steroids. None of these apical tests is able to provide a firm diagnosis of a specific 
endocrine activity linked to a given adverse effect. 
 
In  principle,  no  single  assay  is  likely  to  provide  all  the  information  needed  to  decide  whether  a 
substance is an ED because of the need to provide both mechanistic information showing how the 
substance interacts with the endocrine system, and apical information describing the adverse effects 
this interaction may cause.  
 
Appropriateness of available internationally standardised test methods  
 
Taken together, but bearing in mind the recommendations made below, a reasonably complete suite of 
standardised assays (for testing the effects of EASs) is available (or will soon be available) for the 
EATS modalities relevant for mammals and fish, with fewer tests available for birds and amphibians. 
While downstream effects of disruption of some non-EATS pathways/modalities may be detectable in 
some standardised apical vertebrate assays, it is important to recognise that standardised mechanistic 
assays for non-EATS modalities relevant to mammals, fish and other vertebrates are not yet available. 
For invertebrates relevant mechanistic assays are conspicuous by their absence from the OECD testing 
suite, mainly due to poor understanding of invertebrate endocrinology. Finally, a range of major taxa, 
e.g. reptiles or echinoderms have not yet been considered by  the OECD for any endocrine assay 
development. It is unknown at present whether it will be possible to read-across to untested groups 
from tests with other taxa. Identification/Characterisation of EDs: scientific criteria and test methods 
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The SC discussed briefly the following aspects related to the testing of substances. The Committee 
notes that these considerations are not unique to EASs, but are equally applicable to substances with 
other mechanisms of action. 
 
  Critical windows of susceptibility: To assess potential effects from exposure during critical 
windows of susceptibility, testing in vivo is required to encompass sensitive life stages. The 
SC  noted  that  some  tests  in  the  OECD  CF  do  cover  exposure  during  critical  periods  of 
development in utero. However, current mammalian tests may not cover effects that might be 
induced by exposure during fetal or pubertal development, but may emerge during later life 
stages. Fish lifecycle tests cover all relevant windows of exposure and can be expected to 
reveal the longer-term effects of developmental exposures at all stages of the lifecycle. 
 
  Combined exposure to multiple substances: The SC recognises that exposure to multiple EASs 
may occur in such a way that combined toxicity could arise. The issue of mixture toxicity 
resulting from combined exposure to multiple substances will be addressed by EFSA in a 
separate activity. 
 
  Low-dose effects and non-monotonic dose response curves (NMDRCs): The SC notes the lack 
of consensus in the scientific community as to the existence and/or relevance of low-dose 
effects  and  NMDRCs  in  (eco)toxicology  in  relation  to  endocrine  disruption,  or  other 
endpoints/modes of actions. 
 
Elements for hazard characterisation of endocrine disruptors  
 
The SC examined in section 5 whether there is a scientific basis to include aspects considered during 
hazard characterisation, such as critical effect, severity, (ir)reversibility and potency in defining the 
level of concern for identified EDs.  
 
  Critical effect: The SC is of the opinion that hazard characterisation (e.g. establishment of a 
health/ecotoxicology-based  guidance  value)  should  be  based  on  the  effect  leading  to  the 
lowest health/ecotoxicology-based guidance value, irrespective of the mode of action. Such a 
health/ecotoxicology-based  guidance  value  would  also  protect  against  endocrine-mediated 
effects occurring at higher doses. 
 
  Severity, (ir)reversibility and potency: The SC considers that to inform on a level of concern 
for EASs, severity, (ir)reversibility and potency should be evaluated in relation to degree, 
timing and duration of exposure. Levels of concern are not determined exclusively by risk 
assessment but also by protection goals set by the risk management. 
 
In conclusion, endocrine disruptors, of natural or synthetic origin, can be identified according to three 
criteria: endocrine activity, adversity of effects and a plausible link between endocrine activity and 
adverse  effect. The  SC  considers that  a reasonably  complete  suite  of  assays  is  (or  will  soon  be) 
available to identify and characterise the important hazards of EATS substances in mammals and fish, 
with fewer tests available for birds and amphibians. Furthermore, these evaluation methods should, in 
principle, be fit for the purpose of establishing safe doses/concentrations of EDs if (1) certain aspects 
(e.g. follow up of exposure at critical windows of susceptibility to later life stages) are addressed and 
(2) used with all available information in a WoE approach. It should also be noted that standardised 
mechanistic assays for non-EATS modalities relevant to mammals, fish and other vertebrates are not 
yet available. For invertebrates, relevant mechanistic assays are lacking from the OECD testing suite. 
Finally, a range of major taxa e.g. reptiles or echinoderms, have not yet been considered by OECD for 
any endocrine assay development. 
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Furthermore, to inform on risk and level of concern for the purpose of risk management decisions it is 
the opinion of the SC that risk assessment (taking into account hazard and exposure data/predictions) 
makes best use of available information. EDs can therefore be treated like most other substances of 
concern for human health and the environment, i.e. be subject to risk assessment and not only to 
hazard assessment. 
 
RECOMMENDATIONS 
 
Recommendations specific to endocrine active substances 
 
  The following areas were identified as requiring further development regarding test methods: 
 
-  Additional tools, such as the application of  physiologically based pharmacokinetic 
and dose response modelling  should be further considered as possible  methods to 
contribute to the screening / evaluation of substances for endocrine activity under 
Level 1 of the OECD CF. 
-  Whilst the suite of standardised assays for testing the effects of EASs is reasonably 
comprehensive for the EATS modalities relevant for mammals and fish,  there are 
fewer tests available for birds and amphibians or other taxa.  
-  In relation to mammals, there is a lack of a single study involving exposure through 
the  complete  life  cycle,  from  conception  to  old  age  or  a  single  study  involving 
developmental exposure with follow-up into old age. 
-  Improvement of predictive models in relation to certain human endocrine disorders in 
which EDs have been suggested to play a role.  
 
  While  downstream  effects  of  disruption  of  some  non-EATS  pathways/modalities  may  be 
detectable in some standardised apical vertebrate assays, mechanistic assays for non-EATS 
modalities relevant to mammals, fish and other vertebrates are not or not yet available. Given 
the costs involved for the development of new standardised test methods, further information 
on the relevance of possible endocrine disruption of non-EATS modalities in real life (humans 
and  the  environment)  is  needed  to  prioritise  future  test  development.  Further  research  is 
therefore  needed  on  whether  exposures  to  substances,  which  could  affect  non-EATS 
modalities, are associated with adverse effects in humans or in the environment. 
 
  The SC also underlined the need for further development of testing strategies to generate 
adequate data for the identification and assessment of endocrine disrupting properties. An 
example has been developed in outline for fish species by the OECD. 
 
 
General recommendations, not unique to endocrine active substances 
 
Although mentioned in the context of EDs, the SC recommends as a follow up activity to clarify the 
following issues in broader context and in further detail:  
 
  Biological thresholds and criteria for adversity vs. physiological modulation / homeostatic 
responses, 
 
  Combined exposure to multiple substances, 
 
  Non-monotonic dose response curves. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    48 
REFERENCES  
Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau 
A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, 
Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, 
Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, 
Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, 
Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tahti 
H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A and Zaldivar JM, 2011. Alternative 
(non-animal) methods for cosmetics testing: current status and future prospects-2010. Archives of 
Toxicology, 85, 367-485. 
Akahori Y, Nakai M, Yakabe Y, Takatsuki M, Mizutani M, Matsuo M and Shimohigashi Y, 2005. 
Two-step models to predict binding affinity of chemicals to the human estrogen receptor alpha by 
three-dimensional quantitative structure-activity relationships (3D-QSARs) using receptor-ligand 
docking simulation. SAR and QSAR in Environmental Research, 16, 323-337. 
Allen Y, Scott AP, Matthiessen P, Haworth S, Thain JE and Feist S, 1999. Survey of estrogenic 
activity in United Kingdom estuarine and coastal waters and its effects on gonadal development of 
the flounder Platichthys flesus. Environmental Toxicology and Chemistry, 18, 1791-1800. 
Andersen L, Holbech H, Gessbo A, Norrgren L and Petersen G, 2003. Effects of exposure to 17 alpha-
ethinylestradiol during early development on sexual differentiation and induction of vitellogenin in 
zebrafish (Danio rerio). Comparative Biochemistry and Physiology, 134, 365-374. 
Andersen  ME,  2003.  Toxicokinetic  modeling  and  its  applications  in  chemical  risk  assessment. 
Toxicology Letters, 138, 9-27. 
Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, 
Russom CL, Schmieder PK, Serrrano JA, Tietge JE and Villeneuve DL, 2010. Adverse outcome 
pathways:  a  conceptual  framework  to  support  ecotoxicology  research  and  risk  assessment. 
Environmental Toxicology and Chemistry, 29, 730-741. 
Bars R, Broeckaert F, Fegert I, Gross M, Hallmark N, Kedwards T, Lewis D, O'Hagan S, Panter GH, 
Weltje L, Weyers A, Wheeler JR and Galay-Burgos M, 2011. Science based guidance for the 
assessment  of  endocrine  disrupting  properties  of  chemicals.  Regulatory  Toxicology  and 
Pharmacology, 59, 37-46. 
Benfenati E, Roncaglioni A, Boriani E, Porcelli C, Spreafico M and Lo Piparo E, 2005. Validation of 
selected, non-commercial (Q)SAR models for Estrogen Receptor and Androgen Receptor binding. 
Final  report  of  JRC  contract  CCR.IHCP.C430414.X0.  96  pp.  Available  from: 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/information-sources/qsar-document-
area/Final_report_Mario_Negri.pdf. 
Bern HA, Mills KT, Hatch DL, Ostrander PL and Iguchi T, 1992. Altered mammary responsiveness to 
estradiol and progesterone in mice exposed neonatally to diethylstilbestrol. Cancer Letters, 63, 117-
124. 
Blaauboer BJ, 2003. Biokinetic and toxicodynamic modelling and its role in toxicological research 
and risk assessment. Alternatives to laboratory animals : ATLA, 31, 277-281. 
Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D and Farland W, 
2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Critical 
Reviews in Toxicology, 36, 781-792. 
Boobis AR, Doe JE, Heinrich-Hirsch B, Meek M, Munn S, Ruchirawat M, Schlatter J, Seed J and 
Vickers C, 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for 
humans. Critical Reviews in Toxicology, 38, 87-96. 
Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C, Coecke S, Freidig A, 
Gundert-Remy U, Hartung T, Jacobs MN, Lave T, Leahy DE, Lennernas H, Loizou GD, Meek B, Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    49 
Pease C, Rowland M, Spendiff M, Yang J and Zeilmaker M, 2007. Physiologically-based Kinetic 
Modelling  (PBK  Modelling):  meeting  the  3Rs  agenda.  The  report  and  recommendations  of 
ECVAM Workshop 63. Alternatives to Laboratory Animals, 35, 661-671. 
Bradford Hill A, 1965. The Environment and Disease: Association or Causation? Proceedings of the 
Royal Society of Medicine, 58, 295-300. 
Burman CF and Wiklund SJ, 2011. Modelling and simulation in the pharmaceutical industry - some 
reflections. Pharmaceutical Statistics, 10, 508-516. 
Castello P and Worth A, 2011. Information sources and databases on Endocrine Active Substances. 
JRC Technical Notes CT 31854. 28 pp. Available from: http://ihcp.jrc.ec.europa.eu/our_activities/food-
cons-prod/endocrine_disrupters/eas_database/info-sources-databases-endocrine-active-substances. 
Chapin RE, Adams J, Boekelheide K, Gray LE, Hayward SW, Lees PS, McIntyre BS, Portier KM, 
Schnorr TM, Selevan SG, Vandenbergh JG and Woskie SR, 2008. NTP-CERHR expert panel 
report on the reproductive and developmental toxicity of bisphenol A. Birth defects research. Part 
B, Developmental and Reproductive Toxicology, 83, 157-395. 
CHEM Trust 2011a. CHEM Trust‟s Contribution to the Ongoing Debate on Criteria for EDCs. 38 pp. 
Available  from: 
http://www.chemtrust.org.uk/documents/CHEM%20Trust%20Position%20on%20EDC%20Criteri
a%20-%20Sept11.pdf. 
CHEM Trust 2011b. A CHEM Trust and HEAL Briefing: Challenges and solutions in the regulation 
of  chemicals  with  endocrine  disrupting  properties.  8  pp.  Available  from: 
http://www.chemtrust.org.uk/documents/Criteria%20Briefing%20CT&HEAL%20FINAL.pdf. 
Clewell  RA  and  Clewell  HJ,  3rd,  2008.  Development  and  specification  of  physiologically  based 
pharmacokinetic models for use in risk assessment. Regulatory toxicology and pharmacology : 
RTP, 50, 129-143. 
Colborn  T  and  Corlie  C,  1992.  Advances  in  Modern  Environmental  Toxicology,  Volume  XXI, 
Chemically-induced  alterations  in  sexual  and  functional  development:  The  wildlife/human 
connection. Princeton Scientific Publishing Co. Inc., New Jersey, USA, 403 pp. 
D'Ursi P, Salvi E, Fossa P, Milanesi L and Rovida E, 2005. Modelling the interaction of steroid 
receptors with endocrine disrupting chemicals. BMC Bioinformatics, 6 Suppl 4, S10. 
Dybdahl  M,  Nikolov  NG,  Wedebye  EB, Jonsdottir SO  and  Niemela JR,  2012.  QSAR  model  for 
human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations 
with genotoxicity, endocrine disruption and teratogenicity. Toxicology and Applied Pharmacology, 
262, 301-309. 
Dybing E, Doe J, Groten J, Kleiner J, O'Brien J, Renwick AG, Schlatter J, Steinberg P, Tritscher A, 
Walker  R  and  Younes  M,  2002.  Hazard  characterisation  of  chemicals  in  food  and  diet.  dose 
response, mechanisms and extrapolation issues. Food and Chemical Toxicology, 40, 237-282. 
EC  (European  Commission),  1997.  Proceedings  of  the  European  Workshop  on  the  Impact  of 
Endocrine  Disrupters  on  Human  Health  and  Wildlife.  Weybridge,  UK.  58  pp.  Available  from 
http://ec.europa.eu/environment/chemicals/pdf/workshop_report.pdf. 
EC  (European  Commission),  1999.  Community  Strategy  for  Endocrine  Disrupters  -  a  range  of 
substances suspected of interfering with the hormone systems of humans and wildlife. Available 
from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:1999:0706:FIN:EN:PDF. 
EC (European Commission), 2000. First report on the harmonisation of risk assessment procedures - 
Part 1 : The Report of the Scientific Steering Committee's Working Group on Harmonisation of 
Risk Assessment Procedures in the Scientific Committees advising the European Commission in 
the area of human and environmental health. Part 2 : Appendices. 26-27 October 2000. Scientific 
Steering  Committee,  Health  and  Consumer  Safety  Directorate.  Available  from: 
http://ec.europa.eu/food/fs/sc/ssc/out82_en.html. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    50 
ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals), 2009. Guidance on 
Identifying Endocrine Disrupting Effects. Technical Report No 106, 133 pp. 
ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals), 2011. Risk Assessment 
of Endocrine Disrupting Chemicals. Workshop Report No 21, 32 pp. 
EEA  (European  Environment  Agency),  2012.  The  Impacts  of  Endocrine  Disrupters  on  Wildlife, 
People and their Environments – The Weybridge+15 (1996–2011) Report. Technical Report No 
2/2012. 116 pp. 
EFSA (European Food Safety Authority), 2008. Opinion of the Scientific Panel on Plant Protection 
products and their Residues to evaluate the suitability of existing methodologies and, if appropriate, 
the identification of new approaches to assess cumulative and synergistic risks from pesticides to 
human  health  with  a  view  to  set  MRLs  for  those  pesticides  in  the  frame  of  Regulation  (EC) 
396/2005. The EFSA Journal, 704, 1-84. 
EFSA  (European  Food  Safety  Authority),  2009a.  Guidance  of  the  Scientific  Committee  on 
Transparency in the Scientific Aspects of Risk Assessments carried out by EFSA. Part 2: General 
Principles. The EFSA Journal, 1051, 1-22. 
EFSA  (European  Food  Safety  Authority),  2009b.  Existing  approaches  incorporating  replacement, 
reduction and refinement of animal testing: applicability in food and feed risk assessment. The 
EFSA Journal, 1052, 1-77. 
EFSA (European Food Safety Authority), 2010. Scientific Report of the Endocrine Active Substances 
Task Force. EFSA Journal, 8(11):1932, 59 pp. 
EFSA  (European  Food  Safety  Authority),  2012.  EFSA  Scientific  Colloquium  XVII:  Low-dose-
response  in  toxicology  and  risk  assessment.  64  pp.  Available  from: 
http://www.efsa.europa.eu/en/supporting/doc/353e.pdf. 
EFSA Panel on Plant Protection Products and their Residues (PPR), 2009. Scientific Opinion on Risk 
Assessment  for  a  Selected  Group  of  Pesticides  from  the  Triazole  Group  to  Test  Possible 
Methodologies to Assess Cumulative Effects from Exposure through Food from these Pesticides on 
Human Health. EFSA Journal, 7(9):1167, 104 pp. 
EFSA Panel on Plant Protection Products and their Residues (PPR), 2012a. Scientific Opinion on 
Evaluation of the Toxicological Relevance of Pesticide Metabolites for Dietary Risk Assessment. 
EFSA Journal, 10(7):2799, 187 pp. 
EFSA Panel on Plant Protection Products and their Residues (PPR), 2012b. Scientific Opinion on the 
science behind the development of a risk assessment of Plant Protection Products on bees. (Apis 
mellifera, Bombus spp. and solitary bees). EFSA Journal, 10(5):2668, 275 pp. 
EFSA Scientific Committee, 2011. Statistical Significance and Biological Relevance. EFSA Journal, 
9(9):2372, 17 pp. 
Foster PM, 2005. Mode of action: impaired fetal leydig cell function - effects on male reproductive 
development produced by certain phthalate esters. Critical Reviews in Toxicology, 35, 713-719. 
Gehring  U,  Casas  M,  Brunekreef  B,  Bergstrom  A,  Bonde  JP,  Botton  J,  Chevrier  C,  Cordier  S, 
Heinrich J, Hohmann C, Keil T, Sunyer J, Tischer CG, Toft G, Wickman M, Vrijheid M and 
Nieuwenhuijsen M, 2013. Environmental exposure assessment in European birth cohorts: results 
from the ENRIECO project. Environmental Health, 12, 8. 
Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Hoffmann S, 
Roi AJ, Prieto P, Sabbioni E, Scott L, Worth A and Zuang V, 2004. A modular approach to the 
ECVAM principles on test validity. Alternatives to Laboratory Animals, 32, 467-472. 
Jacobs MN, 2004. In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology, 
205, 43-53. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    51 
Jacobs MN, Dickins M and Lewis DF, 2003. Homology modelling of the nuclear receptors: human 
oestrogen receptorbeta (hER ), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and 
the constitutive  androstane  receptor (CAR) ligand  binding  domains from  the  human  oestrogen 
receptor    (hER )  crystal  structure,  and  the  human  peroxisome  proliferator  activated  receptor 
alpha (PPAR ) ligand binding domain from the human PPAR  crystal structure. The Journal of 
Steroid Biochemistry and Molecular Biology, 84, 117-132. 
Jacobs  MN,  Janssens  W,  Bernauer  U,  Brandon  E,  Coecke  S,  Combes  R,  Edwards  P,  Freidig  A, 
Freyberger A, Kolanczyk R, Mc Ardle C, Mekenyan O, Schmieder P, Schrader T, Takeyoshi M 
and  van  der  Burg  B,  2008. The  use of  metabolising  systems  for  in  vitro testing  of  endocrine 
disruptors. Current Drug Metabolism, 9, 796-826. 
Jameson JL, 2010. Harrisson‟s Endocrinology, 2nd edition. Mc Graw-Hill, New York, USA, 560 pp. 
Japanese Ministry of the Environment 2005. MOE‟s Perspectives on endocrine disrupting effects of 
substances-ExTEND  2005.  36  pp.  Available  from: 
http://www.env.go.jp/en/chemi/ed/extend2005_full.pdf. 
Jensen GE, Niemela JR, Wedebye EB and Nikolov NG, 2008. QSAR models for reproductive toxicity 
and  endocrine  disruption  in  regulatory  use-a  preliminary  investigation.  SAR  and  QSAR  in 
Environmental Research, 19, 631-641. 
Jobling S, Casey D, Rogers-Gray T, Oehlmann J, Schulte-Oehlmann U, Pawlowski S, Baunbeck T, 
Turner AP and Tyler CR, 2004. Comparative responses of molluscs and fish to environmental 
estrogens and an estrogenic effluent. Aquatic Toxicology, 66, 207-222. 
JRC  (Joint  Research  Center),  2011.  Applicability  of  (Q)SAR  analysis  in  the  evaluation  of 
developmental  and  neurotoxicity  effects  for  the  assessment  of  the  toxicological  relevance  of 
metabolites and  degradates  of  pesticide active  substances for  dietary  risk  assessment.  External 
Scientific  Report.  EFSA  (European  Food  Safety  Authority).  Available  from: 
www.efsa.europa.eu/en/supporting/pub/169e.htm. 
Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster M, Mac 
MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T and Tilson HA, 
1996. Research needs for the risk assessment of health and environmental effects of endocrine 
disruptors: a report of the U.S. EPA-sponsored workshop. Environmental Health Perspectives, 104 
Suppl 4, 715-740. 
Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM and Flick RW, 2007. 
Collapse of a fish population after exposure to a synthetic estrogen. Proceedings of the National 
Academy of Sciences of the United States of America, 104, 8897-8901. 
Kitchin KT and Drane JW, 2005. A critique of the use of hormesis in risk assessment. Human & 
Experimental Toxicology, 24, 249-253. 
Klopman  G  and  Chakravarti  SK,  2003.  Structure–activity  relationship  study  of  a  diverse  set  of 
estrogen receptor ligands (I) using MultiCASE expert system. Chemosphere, 51, 445-459. 
Kortenkamp A, Backhaus T and Faust M, 2009. State of the Art Report on Mixture Toxicity. Final 
Report  of  EU  Project  Contract  070307/2007/485103/ETU/D.1.  391  pp.  Available  from: 
http://ec.europa.eu/environment/chemicals/pdf/report_Mixture%20toxicity.pdf. 
Kortenkamp A, Martin O, Faust M, Evans R, McKinlay R, Orton F and Rosivatz E, 2011. State-of-
the-Art  Assessment  of  Endocrine  Disrupters.  Final  Report  of  EU  Project  Contract 
070307/2009/550687/SER/D3.  135  pp.  Available  from: 
http://ec.europa.eu/environment/endocrine/documents/4_SOTA%20EDC%20Final%20Report%20V3%206
%20Feb%2012.pdf. 
Lo  Piparo  E  and  Worth  A,  2010.  Review  of  QSAR  Models  and  Software  Tools  for  Predicting 
Developmental and Reproductive Toxicity. JRC Scientific and Technical Reports EUR 24522 EN. 
32 pp. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    52 
Main KM, Skakkebaek NE, Virtanen HE and Toppari J, 2010. Genital anomalies in boys and the 
environment. Best practice & research. Clinical endocrinology & metabolism, 24, 279-289. 
Martina CA, Weiss B and Swan SH, 2012. Lifestyle behaviors associated with exposures to endocrine 
disruptors. Neurotoxicology, 33, 1427-1433. 
Maslankiewicz L, Hulzebos EM, Vermeire TG, Muller JJA and Piersma AH, 2005. Can chemical 
structure predict reproductive toxicity? RIVM Report No. 601200005, 76 pp. 
Matthiessen  P  and  Gibbs  PE,  1998.  Critical  appraisal  of  the  evidence  for  tributyltin  mediated 
endocrine disruption in mollusks. Environmental Toxicology and Chemistry, 17, 37-43. 
Maunder RJ, Matthiessen P, Sumpter JP and Pottinger TG, 2007. Impaired reproduction in three-
spined sticklebacks exposed to ethinyl estradiol as juveniles. Biology of Reproduction, 77, 999-
1006. 
Mayo  D  and  Spanos  A,  2008.  Risks  to  health  and  risks  to  science:  the  need  for  a  responsible 
"bioevidential" scrutiny. Human and Experimental Toxicology, 27, 621-625. 
Melnick R, Lucier G, Wolfe M, Hall R, Stancel G, Prins G, Gallo M, Reuhl K, Ho SM, Brown T, 
Moore J, Leakey J, Haseman J and Kohn M, 2002. Summary of the National Toxicology Program's 
report of the endocrine disruptors low-dose peer review. Environmental Health Perspectives, 110, 
427-431. 
Mombelli E, 2012. Evaluation of the OECD (Q)SAR Application Toolbox for the profiling of estrogen 
receptor binding affinities. SAR and QSAR in Environmental Research, 23, 37-57. 
Mushak P, 2007. Hormesis and its place in nonmonotonic dose-response relationships: some scientific 
reality checks. Environmental Health Perspectives, 115, 500-506. 
Newbold RR, Padilla-Banks E, Jefferson WN and Heindel JJ, 2008. Effects of endocrine disruptors on 
obesity. International Journal of Andrology, 31, 201-208. 
NRC  (National  Research  Council),  2007.  Toxicity  Testing  in  the  21st  Century:  A  Vision  and  a 
Strategy. The National Academies Press, Washington, D.C., USA. 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  1992.  OECD  Guideline  for 
Testing of Chemicals: Test No 210: Fish, Early-Life Stage Toxicity Test. 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  1998.  OECD  Guideline  for 
Testing of Chemicals: Test No 409: Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents. 
OECD (Organisation for Economic Co-operation and Development), 2004. OECD Principles for the 
Validation, for Regulatory Purposes, of (Quantitative) Structure-Activity Relationship Models. 2 
pp. Available from: http://www.oecd.org/env/ehs/risk-assessment/37849783.pdf. 
OECD (Organisation for Economic Co-operation and Development), 2005a. Series on Testing and 
Assessment: No 34: Guidance Document on the Validation and International Acceptance of New 
or Updated Test Methods for Hazard Assessment. ENV/JM/MONO(2005)14, 96 pp. 
OECD (Organisation for Economic Co-operation and Development), 2005b. OECD Guideline for 
Testing of Chemicals: proposal for a new test guideline, Avian Two-generation Toxicity Test in the 
Japanese  Quail.  Draft,  Available  from: 
http://www.epa.gov/endo/pubs/edmvac/2gen_guide_gd_draft1.pdf. 
OECD (Organisation for Economic Co-operation and Development), 2006. Series on Testing and 
Assessment: No 57: Detailed Review Paper: Thyroid Hormone Disruption Assays. 
OECD (Organisation for Economic Co-operation and Development), 2007a. Series on Testing and 
Assessment: No 80: Guidance on Grouping of Chemicals. ENV/JM/MONO(2007)28, 99 pp. 
OECD (Organisation for Economic Co-operation and Development), 2007b. OECD Guideline for 
Testing of Chemicals: Test No 74: Detailed Review Paper for Avian Two-generation Toxicity 
Testing. ENV/JM/MONO(2007)21, 167 pp. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    53 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  2008.  OECD  Guideline  for 
Testing of Chemicals: Test No 97: Detailed Review Paper on the Use of Metabolising Systems for 
In Vitro Testing of Endocrine Disruptors. ENV/JM/MONO(2008)24, 95 pp. 
OECD (Organisation for Economic Co-operation and Development), 2009a. Series on Testing and 
Assessment: No 102: The Guidance Document for Using the OECD (Q)SAR Application Toolbox 
to  Develop  Chemical  Categories  According  to  the  OECD  Guidance  on  Grouping  Chemicals. 
ENV/JM/MONO(2009)5, 118 pp. 
OECD (Organisation for Economic Co-operation and Development), 2009b. Series on Testing and 
Assessment: No 111: Report of the Expert Consultation to Evaluate an Estrogen Receptor Binding 
Affinity Model for Hazard Identification. ENV/JM/MONO(2009)33, 119 pp. 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  2009c.  OECD  Guidance 
Document No 140: The 21-Day Androgenised Female Stickleback Endocrine Screening Assay. 
OECD (Organisation for Economic Co-operation and Development), 2010. Series on Testing and 
Assessment: No 135: Detailed Review Paper on Environmental Endocrine Disruptor Screening: 
The  Use  of  Estrogen  and  Androgen  Receptor  Binding  and  Transactivation  Assays  in  Fish. 
ENV/JM/MONO(2010)34, 64 pp. 
OECD (Organisation for Economic Co-operation and Development), 2012a. Series on Testing and 
Assessment:  No  150:  Guidance  Document  on  Standardised  Test  Guidelines  for  Evaluating 
Chemicals for Endocrine Disruption. ENV/JM/MONO(2012)22, 524 pp. 
OECD (Organisation for Economic Co-operation and Development), 2012b. Series on Testing and 
Assessment: No 178: Detailed Review Paper on the State of the Science on Novel In vitro and In 
vivo  Screening  and  Testing  Methods  and  Endpoints  for  Evaluating  Endocrine  Disruptors. 
ENV/JM/MONO(2012)23, 213 pp. 
OECD (Organisation for Economic Co-operation and Development), 2012c. Series on Testing and 
Assessment:  No  181:  Guidance  Document  on  Standardised  Test  Guidelines  for  Evaluating 
Chemicals  for  Endocrine  Disruption:  Case  Studies  Using  Example  Chemicals. 
ENV/JM/MONO(2012)34, 316 pp. 
OECD (Organisation for Economic Co-operation and Development), 2012d. Work Plan for the Test 
Guidelines  Programme  (TGP).  24  pp.  Available  from: 
http://www.oecd.org/env/chemicalsafetyandbiosafety/testingofchemicals/August%20Work%20pla
n%20for%20the%20Test%20guidelines%20programme%20June%202013.pdf. 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  2012e.  Draft  Proposal  for  a 
template  and  guidance  on  developing  and  assessing  the  completeness  of  Adverse  Outcome 
Pathways. 17 pp. Available from: http://www.oecd.org/chemicalsafety/testing/49963554.pdf. 
OECD (Organisation for Economic Co-operation and Development), 2012f. Information on OECD 
Work  Related  to  Endocrine  Disrupters.  8  pp.  Available  from: 
http://www.oecd.org/chemicalsafety/testingofchemicals/50067203.pdf. 
OECD (Organisation for Economic Co-operation and Development), 2012g. Series on Testing and 
Assessment: No 171: Fish Toxicity Testing Framework. ENV/JM/MONO(2012)16, 174 pp. 
PAN Europe, 2011. PAN Europe position paper on criteria for endocrine disrupting pesticides. 8 pp. 
Available from: http://www.pan-europe.info/News/PR/110525.html. 
Plan EL, Maloney A, Mentre F, Karlsson MO and Bertrand J, 2012. Performance comparison of 
various  maximum  likelihood  nonlinear  mixed-effects  estimation  methods  for  dose-response 
models. The AAPS Journal, 14, 420-432. 
Punt A, Schiffelers MJ, Jean Horbach G, van de Sandt JJ, Groothuis GM, Rietjens IM and Blaauboer 
BJ,  2011.  Evaluation  of  research  activities  and  research  needs  to  increase  the  impact  and 
applicability of alternative testing strategies in risk assessment practice. Regulatory toxicology and 
pharmacology : RTP, 61, 105-114. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    54 
Rhomberg  LR  and  Goodman  JE,  2012.  Low-dose  effects  and  nonmonotonic  dose-responses  of 
endocrine  disrupting  chemicals:  has  the  case  been  made?  Regulatory  Toxicology  and 
Pharmacology, 64, 130-133. 
Roncaglioni A and Benfenati E, 2008. In silico-aided prediction of biological properties of chemicals: 
oestrogen receptor-mediated effects. Chemical Society Reviews, 37, 441-450. 
SCENIHR  (Scientific  Committee  on  Emerging  and  Newly  Identified  Health  Risks),  2012. 
Memorandum on the use of the scientific literature for human health risk assessment purposes – 
weighing  of  evidence  and  expression  of  uncertainty.  46  pp.  Available  from: 
http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_s_001.pdf. 
SCHER/SCENIHR/SCCS  (Scientific  Committee  on  Health  and  Environmental  Risks/Scientific 
Committee on Emerging and Newly Identified Health Risks/Scientific Committee on Consumer 
Safety),  2011.  Toxicity  and  Assessment  of  Chemical  Mixtures.  50  pp.  Available  from: 
http://ec.europa.eu/health/scientific_committees/environmental_risks/docs/scher_o_155.pdf. 
Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL 
and Sullivan S, 2005. Decrease in anogenital distance among male infants with prenatal phthalate 
exposure. Environmental Health Perspectives, 113, 1056-1061. 
Toppari J, 2008. Environmental endocrine disrupters. Sexual Development, 2, 260-267. 
U.S. EPA-SAP (U.S. Environmental Protection Agency-FIFRA Scientific Advisory Panel), 2009a. An 
Effects-based Expert System to Predict Estrogen Receptor Binding Affinity for Food Use Inert 
Ingredients and Antimicrobial Pesticides: Application in a Prioritization Scheme for Endocrine 
Disruptor Screening, Meeting Minutes. EPA-HQ-OPP-2009-0322, 70 pp. 
U.S. EPA-SAP (U.S. Environmental Protection Agency-FIFRA Scientific Advisory Panel), 2009b. An 
Effects-based Expert System to Predict Estrogen Receptor Binding Affinity for Food Use Inert 
Ingredients and Antimicrobial Pesticides: Application in a Prioritization Scheme for Endocrine 
Disruptor  Screening,  Meeting  Materials.  Available  from: 
http://www.regulations.gov/#!docketDetail;D=EPA-HQ-OPP-2009-0322. 
U.S.  EPA-SAP  (U.S.  Environmental  Protection  Agency-FIFRA  Scientific  Advisory  Panel),  2011. 
Integrated  Approaches  to  Testing  and  Assessment  Strategies:  Use  of  New  Computational  and 
Molecular Tools. FIFRA SAP. Final FIFRA SAP IATA Meeting Report May 2011. EPA-HQ-
OPP-2011-0284-0054, 81 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2004. Ecological Effects Test Guidelines OPPTS 
850.1500 Fish Life Cycle Toxicity. 
U.S. EPA (U.S. Environmental Protection Agency), 2011a. Standard Evaluation Procedure OCSPP 
890.1250: Estrogen Receptor Binding Assay Using Rat Uterine Cytosol (ER-RUC). 12 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2011b. Standard Evaluation Procedure OCSPP 
890.1150: Androgen Receptor Binding Assay (Rat Ventral Prostate Cytosol). 12 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2011c. Standard Evaluation Procedure OCSPP 
890.1200: Aromatase Assay (Human Recombinant). 11 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2011d. Standard Evaluation Procedure OCSPP 
890.1500: Pubertal Development and Thyroid Function in Intact Juvenile/Peripubertal Male Rats 
Assay. 19 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2011e. Standard Evaluation Procedure OCSPP 
890.1450: Pubertal Development and Thyroid Function in Intact Juvenile/Peripubertal Female Rats 
Assay. 19 pp. 
U.S. EPA (U.S. Environmental Protection Agency), 2012a. Endocrine Disruptor Screening Program: 
Universe of Chemicals and General Validation Principles. November 2012. 17 pp. Available from: 
http://www.epa.gov/endo/pubs/edsp_chemical_universe_and_general_validations_white_paper_11_12.pdf. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    55 
U.S. EPA (U.S. Environmental Protection Agency), 2012b. Endocrine Disruptor Screening Program: 
Universe  of  Chemicals.  November  2012.  177  pp.  Available  from: 
http://www.epa.gov/endo/pubs/edsp_chemical_universe_list_11_12.pdf. 
U.S.  FDA  (U.S.  Food  and  Drug  Administration),  online.  Endocrine  Disruptor  Knowledge  Base 
(EDKB).  Available  from: 
http://www.fda.gov/scienceresearch/bioinformaticstools/endocrinedisruptorknowledgebase/default.htm. 
U.S. NTP (U.S. National Toxicology Programme), 2001. National Toxicology Program's Report of the 
Endocrine  Disruptors  Low-Dose  Peer  Review.  Available  from  http://ntp-
server.niehs.nih.gov/htdocs/liason/LowDoseWebPage.html. 
Van  Drie JH,  2003.  Pharmacophore  Discovery.  In:  Computational Medicinal  Chemistry  for  Drug 
Discovery. Eds Bultnick P, De Winter H, Langenaeker W, Tollenare JP. CRC Press, New York, 
USA, 1196 pp. 
Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Jr., Lee DH, Shioda T, Soto AM, vom 
Saal  FS, Welshons  WV, Zoeller  RT  and Myers JP,  2012.  Hormones  and endocrine-disrupting 
chemicals: low-dose effects and nonmonotonic dose responses. Endocrine Reviews, 33, 378-455. 
Vedani A, Dobler M and Smiesko M, 2012. VirtualToxLab  - a platform for estimating the toxic 
potential of drugs, chemicals and natural products. Toxicology and Applied Pharmacology, 261, 
142-153. 
Vinggaard  AM,  Niemela J,  Wedebye  EB and Jensen  GE,  2008.  Screening  of  397 chemicals and 
development  of  a  quantitative  structure-activity  relationship  model  for  androgen  receptor 
antagonism. Chemical Research in Toxicology, 21, 813-823. 
Vrijheid M, Casas M, Bergstrom A, Carmichael A, Cordier S, Eggesbo M, Eller E, Fantini MP, 
Fernandez MF, Fernandez-Somoano A, Gehring U, Grazuleviciene R, Hohmann C, Karvonen AM, 
Keil T, Kogevinas M, Koppen G, Kramer U, Kuehni CE, Magnus P, Majewska R, Andersen AM, 
Patelarou E, Petersen MS, Pierik FH, Polanska K, Porta D, Richiardi L, Santos AC, Slama R, Sram 
RJ, Thijs C, Tischer C, Toft G, Trnovec T, Vandentorren S, Vrijkotte TG, Wilhelm M, Wright J 
and  Nieuwenhuijsen  M,  2012.  European  birth  cohorts  for  environmental  health  research. 
Environmental Health Perspectives, 120, 29-37. 
WHO  (World  Health  Organization),  2012.  Endocrine  disrupters  and  child  health:  Possible 
developmental  early  effects  of  endocrine  disrupters  on  child  health.  84  pp.  Available  from: 
http://www.who.int/ceh/publications/endocrine_disrupters_child/en/index.html. 
WHO/IPCS (World Health Organization/International Programme on Chemical Safety), 2002. Global 
Assessment of the State-of-the-science of Endocrine Disruptors. WHO/PCS/EDC/02.2, 180 pp. 
WHO/IPCS  (World  Health  Organization/International  Programme  on  Chemical  Safety),  2009. 
Principles and Methods for the Risk Assessment of Chemicals in Food. Environmental Health 
Criteria  240.  689  pp.  Available  from: 
http://www.who.int/foodsafety/chem/principles/en/index1.html. 
WHO/UNEP (World Health Organization/United Nations Environment Programme), 2013. State of 
the  Science  of  Endocrine  Disrupting  Chemicals  -  2012.  296  pp.  Available  from: 
http://www.who.int/mediacentre/news/releases/2013/hormone_disrupting_20130219/en/index.html 
Worth A, Fuart-Gatnik M, Lapenna S and Serafimova R, 2011. Applicability of QSAR analysis in the 
evaluation  of  developmental  and  neurotoxicity  effects  for  the  assessment  of  the  toxicological 
relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. 
EFSA  External  Scientific  Report.  EFSA  (European  Food  Safety  Authority).174  pp.  Available 
from: http://www.efsa.europa.eu/de/supporting/doc/169e.pdf. 
Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff TJ and Vom Saal 
FS, 2012. Endocrine-disrupting chemicals and public health protection: a statement of principles 
from The Endocrine Society. Endocrinology, 153, 4097-4110. Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    56 
 
APPENDICES  
A.  OVERVIEW OF CURRENT STATE, RECENT REPORTS AND ACTIVITIES 
The  EFSA  Technical  Report  on  Endocrine  Active  Substances  (EASs)  (EFSA,  2010)  provides  an 
overview of European and international activities on EASs until 2010. This section aims at updating 
the reader on developments that occurred between 2010 and 2013. 
 
A.1   European Commission (EC)
17 
In March 1999, the Scientific Committee for Toxicity, Ecotoxicity and the Environment issued a 
report on „Human and Wildlife Health Effects of Endocrine Disrupting Chemicals, with Emphasis on 
Wildlife and on Ecotoxicology Test Methods‟ (EC, 1999). The report identified a „potential global 
problem‟ for wildlife.  
Against this background, a „Community Strategy for Endocrine Disrupters‟ was adopted by the EC in 
December 1999 (EC, 1999)
18. The objectives were to identify the problem of endocrine disruption, its 
causes and consequences and to identify appropriate policy action on the basis of the precautionary 
principle in order to respond quickly and effectively to the problem, thereby alleviating public 
concern. Four key elements were identified:  
-  the need for further research, 
-  the need for international co-ordination, 
-  the need for communication to the public, 
-  the need for policy action. 
 
On this basis a set of appropriate short, medium and long term actions was recommended, among 
which the establishment of a priority list of substances for further evaluation of their role in endocrine 
disruption and the development of international cooperation on this issue.  
 
Need for further research 
Since the start of the 4
th Framework Programme (FP) in 1994, through FP5, FP6 and the ongoing 
FP7
19, the EC funds research on endocrine disruption. Up to now more than 80 projects were launched 
focusing on endocrine disruptors (EDs) identification, risk assessment, education and information on 
chemicals as contaminants in the food cha in
20. Annex 1 – section 9.1 of the State of the Art of the 
Assessment of Endocrine Disruptors (SAAED) (Kortenkamp et al., 2011) provides a recent review of 
EU projects with potential relevance to the following criteria: 
-  Assay development / validation 
-  New insights in mechanisms of EDs 
-  Comparison and correlation of assays 
-  Identification of new chemicals with endocrine activity 
-  Data relevant to exposure assessment 
-  Data on the occurrence of conditions in humans 
-  Field studies of effects in wildlife 
-  Cross cutting issues 
 
                                                       
17   The text for section A1 has been taken from relevant EC webpages 
18 See http://ec.europa.eu/environment/endocrine/strategy/index_en.htm. 
19 http://cordis.europa.eu/fp7/home_en.html  
20 http://ec.europa.eu/research/endocrine/index_en.html Identification/Characterisation of EDs: scientific criteria and test methods 
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Need for international coordination 
The EC participated in the OECD working group of the National Co-ordinators for the Test Guidelines 
Programme (WNT) and also in its subsidiary body the Endocrine Disruptors Testing and Assessment 
Advisory  Group  (EDTA  AG).  This  activity  resulted  in  the  publication  of  the  OECD  guidance 
document on standardised test guidelines for evaluating chemicals for endocrine disruption (OECD, 
2012a). 
Some ten years ago the EC provided financial contribution to the publication of a comprehensive 
report on Global Assessment of the State-of-the-Science of Endocrine Disruptors, which was published 
in 2002 by the  IPCS (WHO/IPCS, 2002). Recently, the United Nations Environment Programme 
(WHO/UNEP) and WHO have published a 10-year update of this report and the EC has been involved 
(WHO/UNEP, 2013). 
 
Need for policy action 
In  2009,  a  study  on  the  State  of  the  Art  of  the  Assessment  of  Endocrine  Disruptors  has  been 
commissioned by the Directorate-General for the Environment to provide a basis for: 
i)  the development of scientific criteria for the identification of EDs, and 
ii)  the review and possible revision of the Community Strategy on EDs. 
 
The  study  was  finalised  by  the  contractor  at  the  end  of  January  2012  and  the  resulting  report 
(Kortenkamp et al., 2011) published on DG Environment‟s website.  
The report summarises advances in the state of the science since 2002 and maps out ways of dealing 
with endocrine disruptors in important pieces of EU chemicals regulation, such as the Plant Protection 
Product  Regulation  (EC)  No  1107/2009,  the  Biocides  Regulation  (EC)  No  528/2012  and  the 
Chemicals  Regulation  (EC)  No  1907/2006.  The  report  comes  to  a  number  of  conclusions  and 
recommendations for the assessment of EDs: 
-  The  definition  for  endocrine  disrupting  chemicals  developed  by  WHO/IPCS  is  generally 
accepted  as  being  applicable  to  both  human  health  and  ecotoxicological  hazard  and  risk 
assessment. 
-  Internationally agreed and validated test methods (OECD) for the identification of EDs are 
generally regarded as useful, but it is acknowledged that they capture only a limited range of 
the  known  spectrum  of  endocrine  disrupting  effects.  Considerable  gaps  exist  for  the 
identification of chemicals that can affect wildlife taxa. 
-  For a wide range of endocrine disrupting effects, agreed and validated test methods do not 
exist. This introduces considerable uncertainties, with the likelihood of overlooking harmful 
effects  in  humans  and  wildlife.  Until  better  tests  become  available,  hazard  and  risk 
identification has to rely also on epidemiological approaches. 
-  The information and testing requirements laid down in important pieces of EU chemicals 
regulation do not capture the range of endocrine disrupting effects that can be measured with 
internationally  agreed  and  validated  test  methods.  Testing  with  the  most  sensitive  and 
appropriate methods currently available and with exposure regimens that cover periods of 
heightened susceptibility during critical life stages is not conducted. 
-  An overview of proposals for regulating EDs by EU Member States and other organisations 
revealed  some  commonalities  and  areas  of  agreement.  However,  controversy  remains 
regarding the proposals to deal with EDs on the basis of potency-based cut-off values derived 
from the CLP Regulation (EC) No 1272/2008. 
-  Defining EDs for regulatory purposes will have to rely on criteria for adversity and endocrine-
related modes of action. A decision tree approach is developed that proceeds in a step-wise 
manner by excluding substances that neither produce adverse effects, nor show endocrine-
related modes of action. In the absence of appropriate evidence, relevance should be assumed 
by default. Identification/Characterisation of EDs: scientific criteria and test methods 
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-  The  final  regulatory  decision  rests  on  a  consideration  of  the  toxicological  profile  of  the 
substances in a weight-of-evidence (WoE) approach that still has to be developed. This WoE 
approach  will  have  to  consider  potency  together  with  other  factors  such  as  severity  and 
specificity of effect and irreversibility. Rigid potency-based cut-off values as decisive decision 
criteria are not recommended.  
-  Procedures that incentivise the provision of data in the case of data gaps are suggested. There 
are  still  enormous  knowledge  gaps  that  need  to  be  addressed  through  research  and 
development projects.  
 
On 11 and 12 June 2012, the EC organised a conference on "Endocrine Disruptors: Current challenges 
in science and policy"; the presentations and discussions covered the effects of EDs on human health 
and the environment, the risks, the identification of EDs and policy objectives.  
The outcome of the conference as well as the above-mentioned Kortenkamp et al. report will feed into 
the review of the European Commission's current strategy on endocrine disruptors. It will also provide 
input to the Commission's upcoming proposal for criteria for the identification of substances with 
endocrine disrupting properties (planned for end of 2013). 
To fulfil these tasks, the EC DG Environment established an ad-hoc advisory group of Member States 
and  Commission  Services  and  Agencies  (autumn  2010)  and  an  expert  sub-group  on  endocrine 
disruptors (November 2011). The ad-hoc advisory group is used for: 
-  information exchange on EDs 
-  bringing science on EDs and chemical‟s policy together 
-  discussing horizontal aspects of regulation on EDs 
-  providing orientation to the Commission on development and implementation of EU policy in 
this field 
The Expert sub-group is consulted to: 
-  exchange information on detailed technical and scientific issues on EDs  
-  support the ad-hoc group in technical and scientific issues  
The subgroup will produce a report providing definition and clarifications of basic terms related to 
EDs, proposing factors for the identification, characterisation and categorisation of EDs, discussing 
WoE considerations to categorise a substance as an ED, and suggesting a scheme for the evaluation of 
EDs for regulatory purposes. The report was not yet finalised at the time this opinion was adopted. 
 
A.2   European Environment Agency (EEA) 
In the 1996 Weybridge meeting on EDs (EC, 1997), the problem of EDs was first comprehensively 
discussed  by  both  European  and  United  States  regulatory  authorities.  Much  focus  was  placed  on 
oestrogenic compounds, and especially on receptor-mediated effects. 
Since then, substantial EU funds (i.e. over EUR 150 million spent until 2011 have been allocated to 
research into endocrine disruptors and their effects, and the WHO and the OECD have addressed the 
problem in many ways. Scientific progress over the last decade has expanded the scope considerably: 
it includes EDs that affect other hormone systems, e.g. the thyroid; EDs with new modes of action, 
e.g. inhibitors of endogenous hormone production or metabolism; and target tissues for EDs other than 
those in the reproductive system, such as the brain and cardiovascular system. The Weybridge+10 
workshop organised by the Academy of Finland, the EC DG Research and EEA in 2006 aimed to 
evaluate the impacts of this extensive research and to determine future goals in the areas of human and 
wildlife health effects, mechanisms of biological actions and models, exposures, risks, and policy 
options. 
The  Weybridge+15  (1996-2011)  report  (EEA,  2012)  reviewed  key  conclusions,  challenges  and 
recommendations that have been drawn from the research over the last 15 years (and discussed in the 
plenary session at the Weybridge+10 meeting). It concludes, among other, that endocrine disruption is 
a real phenomenon likely affecting both human and wildlife populations globally, but a much better Identification/Characterisation of EDs: scientific criteria and test methods 
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understanding of the role of chemicals as causal factors of a wider range of endocrine diseases and 
disorders  is  needed.  Screening  tests  and  technologies  (e.g.  „omics‟)  to  detect/predict  endocrine 
disruptive mode of action exist but there are still inadequacies in some areas. More knowledge on 
what types of EDs are most likely to be affecting humans and wildlife (which are most prevalent and 
potent?)  is  needed.  Considerable evidence  suggests  that  low-dose  effects  of EDs  often  cannot  be 
predicted from high-dose testing. These 'low-dose effects' of EDs have come under intense scrutiny as 
they oppose traditional toxicology paradigms. The different possible meanings of the term 'low dose' 
can cause confusion. Non-monotonic dose–response curves for EDs, including 'U-shaped' or 'inverted-
U-shaped' curves have been described, thus calling into question the appropriateness of assuming 
monotonicity as a basis for chemical risk assessments of EDs. 
 
A.3   European Parliament (EP) 
The  EP  Policy  Department  on  Economic  and  Scientific  Policy  dealing  with  Environment,  Public 
Health and Food Safety organised a workshop on „Endocrine Disruptors and Impact on Health‟ in 
Brussels on 18 September 2012. The workshop was organised in the context of the self-initiative taken 
by the ENVI Committee to better understand the impacts of EDs on health and to provide input into 
the ongoing policy discussions at EU-level. The outcome of the workshop, as well as the above-
mentioned previous work made on the ED issue by the EC and other EU bodies were then considered 
to prepare a draft report that includes a motion for an EP Resolution on the protection of public health 
from  endocrine  disruptors
21.  The latter calls on the Co mmission to submit as soon as possible 
proposals for comprehensive criteria together with testing and information requirements for chemicals 
on the commercial market, and for EU legislation to make clear what is regarded as a substance with 
endocrine-disrupting properties; it advocates considering the introduction of „endocrine disruptor‟ as a 
regulatory hazard class, and calls on the Commission to ensure that the criteria for identifying EDs are 
applied horizontally to all current and future legislation, and that appropriate testing requirements for 
the identification of substances with endocrine-disrupting properties are introduced in all relevant EU 
legislation. This draft report was adopted by the ENVI Committee on 23 January 2013 with a series of 
amendments  (more  than  150  amendments  were  tabled).  The  ENVI  report  notably  calls  for  fast 
measures to protect vulnerable groups such as children, young people and pregnant women. 
A  final  debate  on  the  basis  of  the  ENVI  report  took  place  in  plenary  session  of  the  European 
Parliament on 12 March 2013. The report was adopted on 14 March 2013. 
 
A.4   European Food Safety Authority (EFSA) 
Scientific report of the Endocrine Active Substances Task Force 
An EFSA technical report developed by a cross-EFSA task force was published on 30 November 2010 
to clarify the state-of-play on EASs and to make recommendations for scientific and communication 
issues (EFSA, 2010). Discussions within the Scientific Committee and the EFSA Advisory Forum had 
called for the development of a common approach within EFSA towards EASs. Both specific issues 
and new regulations made it necessary to follow up on developments with the EU bodies, Member 
States, and internationally, in order to avoid diverging assessment approaches and the duplication of 
work. The proposed actions for EFSA are to contribute to the work in progress under the auspices of 
the EC. The development of a generally accepted risk assessment methodology was identified as a 
challenge due to the complexity of the issues involved. Here, the task force recommends that EFSA 
continues  its  activities  aimed  at  developing  harmonised  methodologies  for  risk  assessment  of 
combined exposures to EASs in food. EFSA should continue to build a dialogue to develop a common 
strategy  with  the  EC,  other  EU  bodies,  Member  States‟  Competent  Authorities,  international 
organisations  and  partners,  as  well  as  external  experts  and  stakeholders  on  the  before  mentioned 
issues. EFSA should also work with the experts in its Advisory Group on Risk Communications in 
conjunction  with  the  communication  experts  from  Member  States,  and  continues  to  monitor  and 
                                                       
21 Available at: http://www.europarl.europa.eu/meetdocs/2009_2014/documents/envi/pr/912/912390/912390en.pdf  Identification/Characterisation of EDs: scientific criteria and test methods 
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analyse  media  and  stakeholder  developments,  in  order  to  define  a  strategy  for  communications 
addressing both the collective group and specific EASs. 
 
Colloquium on low dose responses 
EFSA held its 17
th Scientific Colloquium on low dose response in toxicology and risk assessment on 
14 June 2012 in Parma, where Scientists debated low-dose hypothesis. 
Over two days, 100 scientific international experts exchanged views and debated the possible health 
effects  of  low  levels  of  certain  chemicals  (the  „low-dose  hypothesis‟)  and  the  current  and  future 
challenges these pose for food and feed risk assessment. The Colloquium attracted risk assessors, risk 
managers, scientists and stakeholders from 21 countries, including 12 EU Member States, 4 candidate 
countries,  Japan,  Norway,  Russia,  Switzerland  and  the  United  States.  Prominent  toxicologists, 
endocrinologists and biochemists from academia, industry and public health authorities took part, 
including  representatives  of  several  European  National  Competent  Authorities,  the  European 
Commission, the Joint Research Centre (JRC), the Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR), the European Chemicals Agency (ECHA) and the U.S. Food and 
Drug Administration (U.S. FDA). 
The Colloquium came at a potentially critical juncture in a scientific debate that has been gaining 
prominence since the 1990s: increasing numbers of studies address effects of chemical substances at 
low doses, mainly those substances referred to as EASs or EDs. According to the low-dose hypothesis, 
these substances may cause adverse effects at low doses but not necessarily at all higher doses. They 
do  not  therefore  follow  the  classical  (or  „monotonic‟)  dose  response  curve,  showing  a  greater 
likelihood of an adverse effect at higher doses. Rather they may show a different kind of dose response 
curve, e.g. a U-shaped curve with responses both at low- and high-dose levels but not in intermediate 
ranges. Such a dose response curve is termed a non-monotonic dose response curve (NMDRC). Such 
findings challenge current concepts in chemical risk assessment. 
As  yet  no  scientific  consensus  has  been  reached  as  to  the  validity  of  the  low-dose  hypothesis. 
Recently, it has been claimed that a large number of new studies provide further support for this 
hypothesis. The relevance of these findings and the way they could impact on assessment of the 
possible risks of chemicals in food and feed were the main topic of this event. 
Following an introductory session where speakers summarised the current debate, participants were 
divided into four discussion groups each focusing on a specific key issue: the nature of an effect and 
the assessment of adversity; dose response relationships; the evidence for NMDRCs; the challenges 
for risk assessment. Related aspects were covered during the course of the debates, including effects of 
EASs, testing methods and strategies, and modelling techniques for predicting biological responses. 
The objective of EFSA‟s scientific colloquia is to bring together international experts from different 
sectors  for  an  open  scientific  debate  on  key  issues;  they  are  organised  so  as  to  provide  ample 
opportunity for the exchange of views. 
Presentations given and summary report of the colloquium are available at EFSA‟s website
22 . 
 
A.5  US NIEHS/NIH and EC Joint Research Centre IHCP 
In Berlin on 11-13 September 2012, the US National Institute for Environmental Health Sciences/NIH 
and the Joint Research Centre's Institute for Health and Consumer Protection organised a workshop on 
low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice 
                                                       
22 http://www.efsa.europa.eu/en/events/event/120614.htm Identification/Characterisation of EDs: scientific criteria and test methods 
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workshop. This workshop followed up on the EU Conference on Endocrine Disruptors organised by 
the European Commission, Directorate-General for Environment in close collaboration with the JRC-
IHCP in June 2012. 
This workshop sought to lay out the evidence for low dose effects and non-monotonic dose responses 
in  relation  to  endocrine  active  chemicals,  with  the  goal  of  establishing  whether  the  current 
observations  are  sufficient  to  re-examine  the  ways  in  which  chemicals  are  tested  for  endocrine 
disrupting properties and how risk to human health may be managed.  
Most of the participants were in agreement that non-monotonic dose responses do occur and may be 
expected at some dose ranges for some substances, but the extent to which they might occur at so-
called „low doses‟ was considered to be a separate issue. There was a suggestion that a definition of 
„low dose‟ would be helpful, as it is currently used with different meanings in different contexts, and 
that there was also a need to carry out a practical assessment of the type of effects that may be 
considered  adverse,  in  the  context  of  endocrine  disruption.  How  current  test guidelines  might  be 
augmented and evaluated with respect to detecting low-dose effects or non-monotonic dose responses 
was also discussed. 
Some  recommendations  included  developing  guidance  on  minimum  information  requirements  for 
publishing studies investigating endocrine disrupting activity, finding mechanisms for sharing raw 
data  from  experimental  studies,  and  creating  a  knowledge  base  for  compiling  findings  of  non-
monotonic dose response relationships. 
A report on the workshop is under preparation. 
 
A.6  World Health Organization and United Nations Environment Programme 
On 19 February 2013, the United Nations Environment Programme (WHO/UNEP) and World Health 
Organization  (WHO)  published  a  review  of  the  „State  of  the  Science  of  Endocrine  Disrupting 
Chemicals – 2012‟ (WHO/UNEP, 2013). This report updates the IPCS „Global Assessment of the 
State-of-the-Science of Endocrine Disruptors‟ (WHO/IPCS, 2002) published just over 10 years ago. 
The new review describes the current global status of scientific knowledge on exposure to, and effects 
of EDs, and identifies key concerns.  
 
Three strands of evidence fuel concerns over EDs: 
-  The high incidence and the increasing trends of many endocrine-related disorders in humans, 
e.g. large proportions (up to 40%) of young men in some countries have low semen quality, 
which reduces their ability to father children. 
-  Observations of endocrine-related effects in wildlife populations that have been affected by 
endocrine disruption, with negative impacts on growth and reproduction.  
-  The  identification  of  chemicals  with  endocrine  disrupting  properties  linked  to  disease 
outcomes in laboratory studies. 
 
Close to 800 chemicals are known or suspected to be capable of interfering with hormone receptors 
(some are known to interact with multiple hormone receptors simultaneously), hormone synthesis or 
hormone conversion. Numerous laboratory studies support the idea that chemical exposures contribute 
to endocrine disorders in humans and wildlife. The authors consider that EDs may produce non-linear 
dose response curves both in vitro and in vivo, by a variety of mechanisms. 
The most sensitive window of exposure to EDs is during critical periods of humans and wildlife 
development, such as during early development. Developmental effects will occur at lower doses than 
are required for effects in adults, these effects will often be irreversible and may not become evident 
until later in life. Hence testing for endocrine disruption should encompass the developmental period 
and include life-long follow-up to assess latent effects. Identification/Characterisation of EDs: scientific criteria and test methods 
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Human and wildlife populations all over the world are exposed to multiple EDs at the same time. 
However,  only  a  small  fraction  of  these  chemicals  have  been  investigated  in  tests  capable  of 
identifying  overt  endocrine  effects  in  intact  organisms.  Significant  knowledge  gaps  exist  as  to 
associations between exposures to EDs and other endocrine diseases. This lack of data introduces 
significant uncertainties about the true extent of risks from chemicals that potentially could disrupt the 
endocrine system. Disease risk due to EDs may therefore be significantly underestimated. 
The authors of the report underline the need for better information on how and when EDs act to reduce 
exposures during development and prevent diseases from occurring. Endocrine disruption represents a 
special form of toxicity that should be taken into account when designing studies and interpreting 
results: 
-  The effects of the mixtures of chemicals to which humans and wildlife are exposed should be 
better understood 
-  The  characteristics  of  the  endocrine  system  that  is  being  disrupted  should  be  taken  into 
account.  Endocrine  disruption is  no  longer  limited to  oestrogenic,  androgenic  and thyroid 
pathways and a better understanding of the endocrine systems is therefore needed. 
-  Testing  protocols  should  cover  aspects  such  as  sensitive  windows  of  exposure  across  the 
lifespan, low dose effects and NMDRCs.  
 
Internationally agreed and validated test methods for the identification of EDs capture only a limited 
range  of  the  known  spectrum  of  endocrine  disrupting  effects.  This  increases  the  likelihood  that 
harmful  effects  in  humans  and  wildlife  are  being  overlooked.  The  authors  recommend  the 
development of WoE approaches to allow for effective consideration of information from all levels 
(from  in  vitro  mechanistic  data  to  human  epidemiological  data).  The  need  for  a  transparent 
methodology for evaluating the strength of evidence of associations between exposure to chemicals 
and adverse health outcomes is also stressed. 
The report underlines the need to reduce exposures to EDs. Government actions to reduce exposures, 
while  limited,  have  proven  to  be  effective  in  specific  cases  (e.g.  bans  and  restrictions  on  lead, 
chlorpyrifos,  tributyltin,  PCBs  and  some  other  POPs).  This  has  contributed  to  decreases  in  the 
frequency of disorders in humans and wildlife. 
Despite  substantial  advances  in  the  understanding  of  EDs  in  the  last  10  years,  uncertainties  and 
knowledge gaps still exist that are too important to ignore. The need for an integrated, coordinated 
international effort to define the role of EDs in current declines in human and wildlife health and in 
wildlife populations is repeated by the authors. 
 
A.7   EU Member States 
In May 2011, the Environmental Protection Agency of the Danish Ministry of the Environment issued 
a position paper regarding the establishment of criteria for EDs and options for regulation
23. The report 
provides a proposal for scientific criteria for the identification of substances with endocrine disrupting 
properties for humans and the environment. A number of issues relevant for the developm ent of 
criteria for EDs are discussed and include definition of ED, specificity and level of evidence. The 
criteria include 3 groups, i.e. ED (group 1), suspected ED (group 2a) and indicated ED (group 2b). The 
evidence relevant for the 3 groups is discusse d and described based on the OECD test methods 
including the OECD  CF.  Moreover,  some theoretical examples illustrate the use of the criteria. 
Furthermore, the regulatory use of these criteria in relation to REACH article 57(f) and the new  Plant 
Protection Products (PPP) Regulation is considered. It is proposed that EDs in group 1 should be 
identified as SVHC in REACH article 57/f) and as ED substances under PPP. For suspected and 
                                                       
23 Available at: 
http://www.mst.dk/English/Chemicals/endocrine_disruptors/danish_proposal_for_criteria_for_endocrine_disruptors_submitt
ed_to_the_EU/  Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    63 
indicated EDs (group 2a and 2b), further data may be necessary to evaluate whether the substances is 
an ED (group 1). 
In May 2011, the UK Health and Safety‟s Chemicals Regulation Directorate and the German Institute 
for Risk Assessment issued a position paper on the regulatory definition of an  ED in relation to 
potential threat to human health
24. The document proposes that an exogenous substance or mixture is 
regarded as an ED of very high regulatory concern if it alters function(s) of the endocrine system and 
consequently causes adverse effects in an intact organism, or its progeny,  or (sub)populations. In 
addition, i) the adverse effects should have been seen in one or more toxicity studies of acceptable 
quality, in which the substance was administered by a route relevant for human exposure, ii) a 
plausible  mode-of-action/mechanistic  link  between  the  toxic  effects  of  concern  and  endocrine 
disruption, iii) the effects seen in experimental animals should be of potential relevance to human 
health and iv) serious adverse effect(s)  in animal studies related to endocrine disruption should have 
been produced at a dose at or below the relevant guidance value for the application of Category 1 
„Specific Target Organ Toxicity-Repeated Exposure, STOT-RE‟ classification & labelling. 
In  March  2012,  the  French  Agency  for  Food,  Environmental  and  Occupational  Health  &  Safety 
(ANSES) published an opinion regarding a request from the French Directorate General for Food, 
Directorate  General  for  Health,  Directorate  General  for  Risk  Prevention,  Directorate  General  for 
Competition,  Consumer  Affairs  and  Fraud  Control,  and  the  Directorate  General  for  Labour  for 
scientific and technical support for the revising of the European strategy on endocrine disruptors
25. 
The document proposes to use the WHO/IPCS  (2002) definitions for endocrine/potential EDs. The 
ANSES‟s proposal for the scientific criteria for identifying an ED that are applicable to the REACH, 
Biocides  and  PPP  Regulations  is  based  on  that  of  the  Danish  Authorities  which  separates  the 
endocrine  disrupting  substances  into  two  categories,  confirmed  and  potential,  with  this  second 
category being further divided into two sub-categories. ANSES proposes adding to the Danish position 
a regulatory criterion from the joint proposal by the United Kingdom and German authorities: a limit 
applicable only to plant protection substances. Substances with harmful endocrine disrupting effects, 
observed in mammals at a dose lower than 10 mg/kg bw/day, should be placed in Category 1 and thus 
cannot be approved under the Regulation. This value, established to facilitate decision-making, is 
based on the Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances 
and mixtures (STOT-RE 1 effect). 
In May 2012, the Danish Centre on Endocrine Disrupters evaluated 22 substances from the „Substitute 
It Now‟ (SIN) List 2.0 identified by the Non-Governmental Organisation ChemSec as substances of 
very high concern
26. The substances were categorised on the basis of the Danish proposal for criteria 
for EDs (see above), and according to the criteria proposed in the abo ve-mentioned joint British-
German position paper that proposes the use of a potency cut -off criteria. The evaluation using the 
Danish criteria lead in most cases to the same conclusion as the SIN List evaluation, with 15 of the 22 
substances categorised as EDs (category 1). Six of the 7 remaining compounds were categorised as 
suspected EDs (category 2A). The use of the potency cut-of criteria leads to 4 of the 15 ED substances 
(category 1) being considered as substances of very high concern. 
In February 2013, the Swedish Chemicals Agency published a position paper on the possibility to 
determine threshold levels for EDs; the paper is based on a review of 15 publications on endocrine 
disruption. The authors concluded that an ED is identified if a plausible li nk between the endocrine 
mode of action and the adverse effect can be demonstrated, and that the current available standardised 
test methods are limited to EATS hormonal systems. 
                                                       
24 Available at:  
http://www.bfr.bund.de/cm/343/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human
_health.pdf  
25 Available at: http://www.anses.fr/Documents/DPR2012sa0033EN.pdf  
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The authors  of  the  paper considered  more  specifically  whether the  scope  of Article  60(3)  of  the 
REACH Regulation (Regulation (EC) No 1907/2006) should be extended to include EDs, and whether 
EDs should be considered like CMR substances for which it is not possible to determine a threshold. 
The performed literature review provided arguments both for and against assuming a threshold for 
EDs. The authors conclude that the decision to accept or not a non-threshold model has to be based on 
the endpoint under consideration and what is known about its mode or mechanism of action. “Hence, 
the  assumption  of  no  threshold  may  be  as  valid,  or  questionable,  for  EDs  as  for  genotoxic 
carcinogens”. The authors consider that it will not be possible to arrive at a robust, reliable and 
sufficiently protective threshold values for EDs in the near future, and therefore recommend that EDs 
are covered by Article 60(3) of the REACH Regulation. 
 
A.8  Stakeholders’ initiatives 
PAN Europe  
In its position paper on criteria for endocrine disrupting pesticides, published in May 2011 (PAN 
Europe, 2011), PAN Europe proposes that a substance should be considered as having endocrine 
disrupting properties when effects on the endocrine system are observed, including effects secondary 
to other toxic effects. A known mechanism of action is not necessary. In order to identify substances 
having endocrine disrupting properties, it is necessary to study all hormonal systems, perform low-
dose  testing,  consider  the  notion  of  exposure  window  and  therefore  administer  the  substance  to 
animals during their development. The notion of threshold should not be used for endocrine disrupting 
properties because of available examples of non-linear dose responses.  
Possible definitions EDs are not discussed, as there is only a need to identify criteria for endocrine 
disrupting properties. PAN Europe proposes that the approach should be based on the hazard and not 
on risk assessment.  
An in-depth review of the scientific literature should be undertaken for a hazard assessment of the 
studied substance, with preference to be given to data from independent organisations. Concerning 
testing  of  substances,  PAN  Europe  recommends  a  modern  study  protocol  to  be  developed  by 
independent scientists working on endocrine disruption.  
Regarding the interpretation of study results, the effects observed in animals should by default be 
considered relevant for humans. If there is doubt about the adverse effects of chemicals with endocrine 
disrupting properties, the precautionary principle must be used and the chemical withdrawn from the 
market until further studies are evaluated. 
CHEM Trust  
In September 2011, CHEM Trust provided a “Contribution to the Ongoing Debate on Criteria for 
endocrine disrupting compounds” (CHEM Trust, 2011a); the paper was developed with input from 
WWF European Policy Office. In April 2012, CHEM Trust and HEAL discussed in a joint briefing 
“Challenges and solutions in the regulation of chemicals with endocrine disrupting properties (CHEM 
Trust,  2011b).  The  following  principles  were  recommended  to  play  a  role  when  developing  an 
assessment and identification scheme for EDs:  
Concerning the definition of an ED, CHEM Trust notes that the WHO/IPCS  (WHO/IPCS, 2002) 
definition provides a useful scientific working definition but requires too high a bar of proof that a 
substance, by disruption of the endocrine system, „consequently causes adverse health effects‟. CHEM 
Trust underlines the difficulty to establish the mechanism of action and therefore favours the definition 
put forward by experts at the Danish Centre on Endocrine Disrupters which still requires adverse 
effects but removes the word „consequently‟.  Identification/Characterisation of EDs: scientific criteria and test methods 
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Based  on  the  above-suggested  definition,  criteria  for  the  identification  of  an  ED  should  address 
whether the chemical (i) has ED properties (exact knowledge about the mechanism of action of how 
the endocrine disrupting property is exerted should not be a prerequisite) and (ii) has the ability to 
cause  adverse  effects  (in  laboratory  test  systems).  Regarding  the  adversity  criteria,  CHEM  Trust 
underlines  that  regulations  refer  to  „probable  serious  effects‟  and  „may  cause  adverse  effects‟; 
therefore adverse effect should be reasonably predicted. A potency threshold should not be included in 
the criteria to identify chemicals with ED properties 
CHEM Trust underlines that testing requirements for chemicals should be improved, so that these are 
better orientated to identifying EDs. Given the limitations of current OECD test methods, non-OECD 
test methods should be given due weight in hazard assessment, and in vitro information should be used 
as supporting evidence to avoid unnecessary testing. 
CHEM Trust acknowledges other ED properties, such as potential non-linear dose response curves and 
low dose effects, including possible lack of thresholds.  
With  regard  to  risk  management  considerations,  CHEM  Trust  recommends  that  a  chemical  with 
endocrine  disrupting  properties  should  trigger  regulation  even  if  these  are  not  the  „lead‟  effect. 
Potency  thresholds  should  not  be  used  to  exclude  certain  chemicals  with  endocrine  disrupting 
properties from stricter regulation, as it would unfortunately result in the legislation not achieving its 
goal of protecting health. 
ECETOC  
The  ECETOC  position  on  criteria  for  evaluating  and  identifying  EDs  starts  with  the  Weybridge 
definition of an ED: 
“An ED is an exogenous substance that causes adverse health effects in an intact organism, or 
its progeny, secondary to changes in endocrine function”. (EC, 1997) 
However,  as  noted  by  Bars  et  al.  (2011),  definitions  from  WHO/IPCS  (2002),  EC  (1999),  and 
Japanese Ministry of Environment (2005) are equally relevant, in sharing a common element, that of 
adversity of the effect. The ECETOC approach for identification of EDs thereby holds as central the 
need to demonstrate both an endocrine-active mechanism of action of a chemical AND a significant 
effect  on  an  apical  endpoint  relevant  to  the  protection  goals  (ECETOC,  2009).  In  the  case  of 
ecotoxicity testing therefore, apical effects would need to be considered as population relevant e.g. 
affecting  survival  or  reproduction.  ECETOC  recommends  using  a  WoE  assessment  technique  to 
evaluate the range of (eco)toxicity data, including in vitro and in vivo targeted studies, supporting 
studies and multi-endpoint apical studies available. 
 
A testing strategy that combines whole organism regulatory tests, with information on mode of action 
is proposed. Tests are categorised as being either: 
-  in vitro screens targeted to a particular mode of action:  
  ER/AR  binding  assays,  ER  Stably  Transfected  Transcriptional  Activation  (STTA) 
assay, aromatase activity assay and H295R screen for steroidogenic activity 
-  mechanistically informative in vivo studies targeted to one or more modes of ED activity 
  mammal 
o  Uterotrophic (OECD TG 440) and Hershberger (OECD TG 441) assays 
  Ecotox 
o  fish 21d screening assay (OECD TG 230) 
o  fish short-term reproduction assay (OECD TG 229) 
o  Amphibian metamorphosis assay (OECD TG 231) 
-  definitive (apical) and supporting in vivo studies that incorporate multiple endpoints that can 
be indicative of adverse effects and can be used in wider risk assessment Identification/Characterisation of EDs: scientific criteria and test methods 
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  mammal: 
o  Pubertal male/female rat assays, US EPA, (U.S. EPA, 2011d, 2011e) 
o  enhanced 28d repeat dose oral toxicity study (OECD TG 407) 
o  sub chronic studies; OECD TG 408; TG 409, (OECD, 1998) 
o  pre-natal  development  toxicity  study  (OECD  TG  414), 
chronic/carcinogenicity studies (OECD TGs 451, 452, 453) 
o  single generation rodent study (OECD TG 415 and extended version) 
o  rodent 2-generation study (OECD TG 416) 
  Ecotox:  
o  Fish sexual development test (OECD TG 234) 
o  modified fish full cycle test; e.g. modification of US EPA OPPTS 850.1500, 
(U.S. EPA, 2004) 
o  Avian and amphibian partial or full life-cycle tests still in development 
 
A  decision  matrix  for  evaluating  outcomes  from  tests  in  these  categories  has  been  developed 
(ECETOC, 2009). This combines test outcomes from apical definitive/supporting tests (indicative of 
an  adverse  effect)  and  mechanistically  informative  in  vivo  or  in  vitro  assays.  Only  when  testing 
indicates both „adverse effects giving concern for endocrine toxicity‟ from apical/supporting studies 
and evidence of „endocrine activity giving concern for endocrine toxicity‟ are the data considered to 
provide „Sufficient evidence of ED as per the Weybridge definition‟. In the absence of convincing 
evidence for the endocrine mode of action, the default is to assume human relevance. A series of 
supplemental decision trees are provided for evaluating such data relevant to mammal studies for 
human health, and for wildlife species (fish and amphibians or birds and mammals). In cases where 
there is deemed to be sufficient evidence of ED as per Weybridge there is further consideration of the 
toxicity profile of the chemical to consider: 
-  Are the effects specific? (i.e. can the effects be attributed to indirect effects arising from 
systemic toxicity). The concept of lead toxicity vs. specificity of endocrine-mediated effects 
should be taken into account. The acceptable degree of separation between the lead effect and 
the endocrine-mediated effect should be assessed on a case-by-case basis; a factor of 10 was 
suggested; i.e. if the degree of separation is >10X the substance should not be considered as an 
ED of concern. If the degree of separation is <10X, then the substance should be considered as 
an ED of concern. For ecotoxicological assessment, a greater degree of separation between the 
lowest  lead  effect  and  the  endocrine-mediated  effect  would  be  required  for  the  aquatic 
environment than the terrestrial environment due to the higher diversity of species 
-  Is  the  ED  mechanism  of  action  relevant  to  human  health/environmental  species? 
(unless exposure is negligible, reflecting the caveat in section 3.8.2 of Regulation (EC) No 
1107/2009) 
-  What is the potency of ED? The concept of potency could serve to discriminate the substances 
of higher concern from those of lesser concern, although it is seen as a poor substitute for risk 
assessment. Substances with ED properties which are not caught by the potency assessment 
and possible cut-off criterion are still considered as EASs and should be subject to a standard 
risk assessment. ECETOC proposes the following criteria when considering ED relative to 
human health concerns: 1) dose/concentration 2) exposure duration (acknowledging that weak 
EDs may only manifest detectable effects after longer exposure durations 3) type and severity 
of endocrine effects 4) number of species affected (acknowledging potential for read-across 
between  species/ecotox-human  health  models).  For  evaluating  the  „potency‟  of  EDs  with 
regard to environmental effects, ECETOC proposes to consider the same criteria as for human 
health  concerns  with  the  addition  of  „specificity  of  endocrine  effects  in  relation  to  other 
taxonomic groups (e.g. comparing potency of ED activity in a fish with other non-ED effects 
in algae).  
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B.  OVERVIEW OF PROVISIONS FOR ENDOCRINE DISRUPTORS IN EUROPEAN LEGISLATION  
Regulation  (EC)  No  1907/2006  concerning  the  Registration,  Evaluation,  Authorisation  and 
Restriction of Chemicals (REACH) 
Substances  having  endocrine  disrupting  properties  may  be  identified  as  Substances of Very  High 
Concern (SVHC) and may subsequently be made subject to the authorisation procedure under the 
European Union REACH Regulation (EC) No 1907/2006. 
Substances may be identified as SVHC under Article 57 of the REACH Regulation if they have 
certain properties, i.e. substances meeting the criteria for classification as Carcinogenic, Mutagenic or 
Toxic for Reproduction (CMR), Category 1A or 1B in accordance with the CLP Regulation
27; PBT 
substances, vPvB substances as defined by Annex XIII of the REACH Regulation; and substances for 
which there is scientific evidence of probable serious effects to human  health or the environment 
which give rise to an equivalent level of concern to the aforementioned substances. These latter Art . 
57(f) substances may include  EDs  and shall be identified on a case -by-case basis. Authorisation 
requirements apply to SVHC that are included in Annex XIV of REACH. 
If the substance is initially identified as an SVHC and subsequently subjected to authorisation, then 
any manufacturer, importer or downstream user must not, after a certain date, place that substance on 
the market for a use, or use it itself without prior authorisation, unless the use has been exempted. 
There is no tonnage limit for the authorisation requirement. An authorisation may be granted if it has 
been shown that the risks arising from the use of the substance are  adequately controlled or there are 
no suitable alternative substances or technologies and the socio-economic benefits outweigh the risk(s) 
identified. 
The guidance document that was written for the competent authorities for the preparation of a dossier 
on the identification of SVHC will be revised in line with the outcome of the European Commission‟s 
upcoming proposal for criteria for the identification of substances with endocrine disrupting properties 
(the proposal is planned for end of 2013).  
 
Regulation  (EC)  No  1107/2009  concerning  the  placing  of  plant  protection  products  on  the 
market  
Substances regarded as having endocrine disrupting properties that may be harmful to humans or non-
target organisms, unless the exposure is negligible under the conditions of use, cannot be authorised 
pursuant to Regulation (EC) No 1107/2009. Article 4(7) indicates the conditions and situations that 
might justify an exemption and also the measures to mitigate the risks, while also informing the 
European Commission. Moreover, by no later than 14 December 2013, the Commission is required to 
present proposed measures concerning specific scientific criteria for the determination of endocrine 
disrupting properties (Annex II, Point 3.6.5 of Regulation (EC) No 1107/2009). 
However, pending the adoption of these criteria, substances that are or have to be classified, pursuant 
to the provisions of Regulation (EC) No 1272/2008 (CLP Reg.), as Carcinogenic Category 2 or Toxic 
for Reproduction Category 2, shall be considered as having endocrine disrupting properties. 
In addition, substances such as those that are or have to be classified, pursuant to the provisions of the 
CLP Regulation, as Toxic for Reproduction Category 2 and which have toxic effects on the endocrine 
organs may be considered as having such endocrine disrupting properties. 
 
Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal 
products 
Biocidal substances are not approved if they have endocrine disrupting properties. They are identified 
using the criteria described in Article 57 (f) of the REACH Regulation. This non-approval does not 
                                                       
27 Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures Identification/Characterisation of EDs: scientific criteria and test methods 
 
EFSA Journal 2013;11(3):3132    68 
apply if the risk to humans and the environment is negligible, if the substance is essential to combat a 
serious  health  risk,  or  if  such  non-approval  would  result  in  disproportionate  negative  impacts  on 
society relative to the risks to humans and the environment. 
Scientific criteria for the determination of endocrine disrupting properties must be adopted no later 
than 13 December 2013. In the meantime, endocrine disrupting substances are considered to be those 
substances  which,  under  the  provisions  of  Regulation  (EC)  No  1272/2008,  are  -  or  should  be  - 
classified as:  
-  carcinogenic category 2 and toxic for reproduction category 2; 
-  toxic for reproduction category 2 and which have toxic effects on the endocrine organs; 
-  or  substances  that  have  been  identified  as  having  endocrine  disrupting  properties  under 
Articles 57 (f) and 59 (1) of Regulation (EC) No 1907/2006. 
 
Regulation (EC) No 1223/2009 on cosmetic products 
Endocrine  disrupting  substances  are  currently  not  restricted  in  the  scope  of  Regulation  (EC) 
1223/2009 on cosmetic products. The Regulation should be reviewed with regard to substances with 
endocrine-disrupting  properties  when  Community  or  internationally  agreed  criteria  for  identifying 
substances with endocrine-disrupting properties are available, or at the latest on 11 January 2015. 
 
Directive  2000/60/EC  establishing  a  framework  for  Community  action  in  the  field  of  water 
policy 
The Water Framework Directive (WFD) sets environmental objectives of good chemical status for 
surface waters and for the prevention of pollution of groundwater.  
At the national level, Member States are required to identify chemical pollutants of relevance for each 
of the water bodies, to set quality standards for water, to establish emission control measures and to 
achieve these standards by 2015. An indicative list of the main pollutants is included in Annex VIII of 
the  Directive;  a  specific  category  includes  those  „substances  and  preparations,  or  the  breakdown 
products of such, which have proved to possess carcinogenic or mutagenic properties or properties 
which may affect steroidgenic, thyroid, reproduction or other endocrine-related functions in or via the 
aquatic environment‟ (Annex VIII – Group 4). 
At the Community level, the WFD sets out a strategy against pollution of surface waters by chemical 
pollutants (Article 16). This strategy includes the identification of substances of particular concern at 
Community level. A first list of 33 substances was adopted in 200128; of these 33 substances, 21 are 
candidate endocrine disrupting substances for which evidence of endocrine disruption or potential 
endocrine disruption was found in the BKH Consulting Engineers (Delft, The Nether lands) reports 
(2000-2003). This first list was replaced by Annex II of the   Directive on Environmental Quality 
Standards (Directive 2008/105/EC) (EQSD)
29, also known as the Priority Substances Directive. As 
required by the WFD and EQSD, the Commission subse quently reviewed the list and in 2012 it put 
forward a proposal for a Directive amending the WFD and the EQSD  as regards priority substances. 
This proposal
30 includes a revised (second) list of priority substances, and provisions to improve the 
functioning  of the legislation. Although no direct reference is made to ED properties of these 
substances, endocrine disruption could become an important criterion for sorting substances or groups 
of substances into this group. 
 
 
                                                       
28 Decision No 2455/2001/EC of the European Parliament and of the Council of 20 November 2001 establishing the list of 
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C.  OVERVIEW OF OECD GUIDANCE, TEST GUIDELINES AND ONGOING ACTIVITIES  
The OECD work on EASs is carried out by its working groups of the Environment Health and Safety 
Testing Assessment programme, as a special activity supervised by the EDTA6, and reporting to the 
WNT. Three further expert groups manage the work: the Validation Management Groups on mammals 
(VMG – Mamm), on ecotoxicology (VMG-eco) and on non-animal (VMG-NA) testing - 3Rs. The 
Endocrine  Disrupters  Testing  and  Assessment  Task  Force  (EDTA-TF)  was  created  in  2002,  and 
adopted  a  Conceptual  Framework  (CF)  for  Testing  and  Assessment  of  Endocrine  Disrupting 
Chemicals (i.e. a toolbox with screening and  test methods for oestrogen-, androgen- and thyroid-
mediated modes of action). An overview with „Information on OECD Work related to Endocrine 
disruptors‟ is given in OECD (2012f). 
 
C.1   The OECD Guidance Document of August 2012  
 
The  OECD  Guidance  Document  of  August  2012  is  a  non-binding  guidance  on  standardised  test 
guidelines for evaluating chemicals for endocrine disruption (OECD, 2012a) incorporating the revised 
CF for testing and assessment of endocrine disruptors, as the main output of the EDTA6. This revised 
CF lays out possible screens, tests and data sources for EATS EDs, organised into 5 Levels which 
range from Level 1 (desirable and non test information), through Level 2 (in vitro assays providing 
data about selected endocrine mechanism(s)/pathway(s)), Level 3 (in vivo assays providing data about 
selected  endocrine  mechanism(s)/pathway(s)),  Level  4  (in  vivo  assays  providing  data  on  adverse 
effects on endocrine relevant endpoints), to Level 5 (in vivo assays providing more comprehensive 
data on adverse effects on endocrine relevant endpoints over extensive parts of the lifecycle of the 
organisms). Levels 3-5 present mammalian and non-mammalian assays in two separate columns, and 
the assays comprise both existing OECD test guidelines (TGs) and TGs in development and validation 
at OECD. See extract from the guidance here below (i.e. from OECD GD 150, OECD, 2012a, pp. 385-
387). 
 
Testing strategies 
 
The CF attempts to address ED testing by working as a tool kit, rather than a sequential testing 
programme, and  by defining whether information that can be generated in a particular method is 
mechanistically  informative,  apical  (and  therefore  of  relevance  to  adversity),  or  both.  The  CF  is 
therefore not intended as a testing strategy and does not include evaluation of exposure.  
On the other hand, the OECD held an international expert workshop in 2010 which reviewed available 
and forthcoming OECD test guidelines for measuring toxicity to fish, and inter alia developed an 
integrated testing strategy that included the new fish tests sensitive to endocrine disrupting substances 
and at the same time minimised the use of fish in chemical testing programmes. After revision and 
endorsement by OECD member states, this strategy has now been published (OECD, 2012g). 
A summary of the proposed generic testing strategy is shown in Fig. 1. When using the flow chart, it is 
essential to read it in conjunction with the accompanying text in (OECD, 2012g), but the main points 
regarding EDs will be briefly described below. The underlying philosophy is to use a WoE approach 
when deciding how to proceed at certain points. The strategy starts with an intensive data-gathering 
and  problem  formulation  step,  including  the  evaluation  of  a  range  of  physico-chemical  and  fate 
information, toxicity predictions from (Q)SARs, read-across data from other chemicals and organisms Identification/Characterisation of EDs: scientific criteria and test methods 
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(including mammals), and consideration of any existing in vitro or in vivo toxicity data (including any 
relevant information on potential endocrine disruption). 
The user is required to consider whether any suspicions regarding endocrine disruption have been 
raised following the initial data gathering, read-across and in vitro screening. If no suspicions exist, 
one proceeds down the standard route of considering the need for a fish early life stage (ELS) test; 
OECD TG 210 (OECD, 1992) or similar. The alternative is for the user to consider various forms of 
EDs screening or testing, depending on the strength of existing data. Weak suspicions trigger in vivo 
fish  screening  using  OECD  TG  229  or  230,  while  moderate  suspicions  trigger  the  fish  sexual 
development  test  (FSDT  –  OECD  TG  234)  or  a  fish  partial  life  cycle  reproduction  test.  Strong 
suspicions of endocrine activity will generally result in a requirement for fish full life cycle (FFLC) 
testing or multi-generation (MG) testing. Any alerts about endocrine disruptive activity resulting from 
the in vivo screens, FSDT or partial life cycle reproduction tests will in turn trigger FFLC or MG 
testing. On the other hand, if the EDS-sensitive screens do not raise concerns, the user is then required 
to consider ELS testing, which may in turn lead on to FFLC testing in some circumstances. 
 
Interpretation of results 
 
In the OECD guidance document, scenarios are given that represent all the possibilities of positive or 
negative results in combination with the presence of existing data and how to interpret such scenarios. 
For each assay under consideration, the GD considered 16 hypothetical scenarios, ranging from very 
data-rich situations in which positive, negative or equivocal data are available from both existing in 
vitro and in vivo assays, to very data-poor examples where little or no existing data are available. Half 
the scenarios cover situations in which the assay in question has provided a positive result (i.e. it has 
indicated  that  the  substance  has  produced  a  significant  response),  and  half  cover  negative  assay 
responses. For those assays which provide both mechanistic and apical information (e.g. vitellogenin 
and fecundity data in TG 229), the scenarios are elaborated even further to distinguish between assays 
providing different combinations of these data categories. In all cases, the interpretational advice is 
based on a WoE assessment in the light of the existing data posited in the 16 scenarios. 
 
Example of guidance on interpretation of assay results for birds: 
 
Together with the results of existing in vitro and in vivo information (see information in section 4.2.3) 
and the results of the OECD TG 206 and the ATGT (see section 4.2.4) the potential hazards of 
endocrine disrupting substances to birds is summarised in the below Table 4 (extracted from OECD 
GD 150, OECD, 2012a).  
 
The GD also provides advice on a possible next testing step which could be taken if the user considers 
it necessary to lessen uncertainty about the test substance. It should, however, be noted that the GD 
was not intended to provide a comprehensive hazard testing scheme. 
The OECD is committed to update this guidance with further evaluation of screens and tests with 
sensitivity for EDSs, and the 3 case studies (OECD, 2012c) did not uncover any significant problems, 
although further studies with negative substances would be desirable.  
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Figure 1:   Generic  fish  testing  strategy.  Reproduced  with  permission  from  OECD  (2012g)  Fish 
Toxicity Testing Framework. Series on Testing and Assessment no. 171, ENV/JM/MONO(2012)16 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=ENV/JM/MONO%282012%2916&doclanguage=en. Identification/Characterisation of EDs: scientific criteria and test methods 
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Table 4:   Possible conclusion from results of the TG 206 or ATGT, in vitro and in vivo assays. 
Presence of positive (+), negative (-) or equivocal/absent (Eq/0) existing results.  
Scenario 
Results  Tentative conclusions 
in vitro 
mechanistic 
data 
in vivo 
effects of 
concern 
TG 206  ATGT  Based on TG 206  Based on ATGT 
A  +  +  +  +  Probably an ED  Strong evidence for adverse effects 
B  +  -  +  +  Probably an ED  Strong evidence for adverse effects 
C  +  Eq/0  +  +  Probably an ED  Strong evidence for adverse effects 
D  -  +  +  +  May be an ED  Strong to medium strong evidence 
E  -  -  +  +  Unlikely an ED  Strong to medium strong evidence 
F  -  Eq/0  +  +  Unlikely an ED  Strong to medium strong evidence 
G  Eq/0  +  +  +  May be an ED  Strong to medium strong evidence 
H  Eq/0  -  +  +  May be an ED  Strong to medium strong evidence 
I  Eq/0  Eq/0  +  +  May be an ED  Strong to medium strong evidence 
J  +  +  -  -  Probably not an ED in birds  Probably not an ED in birds 
K  +  -  -  -  Probably not an ED in birds  Probably not an ED in birds 
L  +  Eq/0  -  -  Probably not an ED in birds  Probably not an ED in birds 
M  -  +  -  -  Probably not an ED in birds  Probably not an ED in birds 
N  -  -  -  -  Probably not an ED in birds  Probably not an ED in birds 
O  -  Eq/0  -  -  Probably not an ED in birds  Probably not an ED in birds 
P  Eq/0  +  -  -  Probably not an ED in birds  Probably not an ED in birds 
Q  Eq/0  -  -  -  Probably not an ED in birds  Probably not an ED in birds 
R  Eq/0  Eq/0  -  -  Probably not an ED in birds  Probably not an ED in birds 
 
 
Extract of the CF list 
Conceptual Framework for Testing and Assessment of Endocrine Disrupters, reproduced with permission 
from  the  OECD  (2012a)  Guidance  document  on  standardised  test  guidelines  for  evaluating  chemicals  for 
endocrine  disruption.  Series  on  Testing  and  Assessment  no.  150,  ENV/JM/MONO(2012)22 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282012%2922&doclanguag
e=en (OECD, 2012a), pp. 385-387  
 
The Conceptual Framework lists the OECD TGs and standardized test methods available, under development or proposed 
that can be used to evaluate chemicals for endocrine disruption. The Conceptual Framework is intended to provide a guide to 
the tests available which can provide information for endocrine disruptors assessment but is not intended to be a testing 
strategy. Furthermore, this Conceptual Framework does not include evaluation of exposure, however this should be included 
when deciding whether further testing is needed. Further information regarding the use and interpretation of these tests is 
available in GD 150 (i.e. this GD). 
 
Mammalian and non mammalian Toxicology 
Level 1: Existing data and non-test information 
-  Physical & chemical properties, e.g., MW reactivity, volatility, biodegradability 
-  All available (eco)toxicological data from standardized or non-standardized tests. 
-  Read across, chemical categories, QSARs and other in silico predictions, and ADME model predictions 
Level  2:  In  vitro  assays  providing  data  about  selected  endocrine  mechanism(s)  /  pathways(s)  (Mammalian  and  non 
mammalian methods) 
-  Estrogen or androgen receptor binding affinity 
-  Estrogen receptor transactivation (OECD TG 455)
31 
-  Androgen or thyroid transactivation (If/when TGs are available) 
-  Steroidogenesis in vitro (OECD TG 456) 
-  MCF-7 cell proliferation assays (ER ant/agonist) 
-  Other assays as appropriate 
 
                                                       
31 OECD Test Guideline 457: „BG1Luc Estrogen Receptor Transactivation Test Method for Identifying Estrogen Receptor 
Agonists and Antagonists‟. New test guideline added in November 2012. Identification/Characterisation of EDs: scientific criteria and test methods 
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Level 3: In vivo assays providing data about selected endocrine mechanism(s) / pathway(s)1 
Mammalian Toxicology for Level 3 
-  Uterotrophic assay (OECD TG 440) 
-  Hershberger assay (OECD TG 441) 
Non-Mammalian Toxicology for Level 3 
-  Xenopus embryo thyroid signalling assay (When/if TG is available) 
-  Amphibian metamorphosis assay   
-  Fish reproductive screening assay (OECD TG 229) 
-  Fish screening assay (OECD TG 230) 
-  Androgenized female stickleback screen (GD 140)  
 
Level 4: In vivo assays providing data on adverse effects on endocrine relevant endpoints 2  
Mammalian Toxicology for Level 4 
-  Repeated dose 28-day study (OECD TG 407) 
-  Repeated dose 90-day study (OECD TG 408) 
-  1-generation reproduction toxicity study (OECD TG 415) 
-  Male pubertal assay (see GD 150 Chapter C4.3)
3 
-  Female pubertal assay (see GD 150 Chapter C4.4)
3 
-  Intact adult male endocrine screening assay (see GD 150 Chapter Annex 2.5) 
-  Prenatal developmental toxicity study (OECD TG 414) 
-  Chronic toxicity and carcinogenicity studies (OECD TG 451-3) 
-  Reproductive screening test (OECD TG 421 if enhanced) 
-  Combined 28-day/reproductive screening assay (OECD TG 422 if enhanced) 
-  Developmental neurotoxicity (OECD TG 426) 
Non-Mammalian Toxicology for Level 4 
-  Fish sexual development test (Draft OECD TG 234) 
-  Fish reproduction Partial Lifecycle Test (when/If TG is Available) 
-  Larval amphibian growth & development assay (when TG is available) 
-  Avian reproduction assay (OECD TG 206)  
-  Mollusc partial lifecycle assays (when TG is available)
4 
-  Chironomid toxicity test (TG 218-219)
4 
-  Daphnia reproduction test (with male induction) (OECD TG 211)
4 
-  Earthworm reproduction test (OECD TG 222, 2004)
4 
-  Enchytraeid reproduction test (OECD TG 220, 2004)
4 
-  Sediment water lumbriculus toxicity test using spiked sediment (OECD TG 225, 2007)
4  
-  Predatory mite reproduction test in soil (OECD TG 226, 2008)
4 
-  Collembolan reproduction test in soil (TG OECD 232, 2009) 
4 
 
Level 5: In vivo assays providing more comprehensive data on adverse effects on endocrine relevant endpoints over more 
extensive parts of the life cycle of the organism 2 
Mammalian Toxicology for Level 5 
-  Extended one-generation reproductive toxicity study (OECD TG 443)
5 
-  2-Generation reproduction toxicity study (OECD TG 416 most recent update) 
Non-Mammalian Toxicology for Level 5 
-  Fish lifecycle toxicity test (FLCTT) (when TG is available) 
-  Medaka multigeneration test (MMGT) (when TG is available) 
-  Avian 2 generation reproductive toxicity assay (when TG is available) 
-  Mysid lifecycle toxicity test (when TG is available)
4  
-  Copepod reproduction and development test (when TG is available)
4 
-  Sediment water chironomid life cycle toxicity test (OECD TG 233)
4 
-  Mollusc full lifecycle assays (when TG is available)
4 
-  Daphnia multigeneration assay (if TG is available) 
4 
 
1 Some assays may also provide some evidence of adverse effects. 
2 Effects can be sensitive to more than one mechanism and may be due to non-ED mechanisms. 
3 Depending on the guideline/protocol used, the fact that a substance may interact with a hormone system in these assays does not necessarily mean that when the 
substance is used it will cause adverse effects in humans or ecological systems. 
4 At present, the available invertebrate assays solely involve apical endpoints which are able to respond to some endocrine disruptors and some non- 
EDs. Those in Level 4 are partial lifecycle tests, while those in Level 5 are full- or multiple lifecycle tests. 
5 The new EOGRT study (OECD TG 443) is preferable for detecting endocrine disruption because it provides an evaluation of a number of endocrine 
endpoints in the juvenile and adult F1, which are not included in the 2-generation study (OECD TG 416) adopted in 2001 
Notes to the OECD Revised Conceptual Framework 
Note 1: Entering at all levels and exiting at all levels is possible and depends upon the nature of existing information and 
needs for testing and assessment. 
Note  2:  The  assessment  of  each  chemical  should  be  made  on  a  case-by-case  basis,  taking  into  account  all  available 
information. 
Note 3: The framework should not be considered as all inclusive at the present time. At levels 2, 3, 4 and 5 it includes assays 
that are either available or for which validation is under way. With respect to the latter, these are provisionally included. 
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C.2   Ongoing activities at OECD 
 
Extensive international OECD collaborative efforts have been conducted previously, to improve the 
endocrine relevance of tests contained within the OECD CF, at review, guidance and validation levels. 
Thus for example, in addition to the development of in vitro tests (oestrogen, androgen receptor and 
steroidogenesis) in Level 2 of the CF, and how metabolism could be better incorporated, TGs have 
also been examined for ways in which endocrine endpoint information could be better addressed and 
collected.  Examples  for  human  health  hazard  assessment  include  TG  407,  which  underwent  an 
additional validation exercise, after some additional endocrine mediated endpoints were added (such 
as weight of testes, adrenals, prostate, and histopathology of gonads accessory sex organs, uterus, 
adrenal, thyroid and vagina), and put into context with other toxicological effects. Parameters for 
which insufficient data were available, or only showed weak evidence of their ability to help in the 
detection of EDs in the validation exercise were proposed as optional endpoints (e.g. the ovary, uterus 
and thyroid weights and histopathology of vaginal smears, male mammary glands, and pituitary; also 
measurement  of  circulating  levels  of  T3,  T4  and  TSH).  The  extended  one  generation  assay 
reproductive  assay  (TG  443)  was  designed  on  a  modular  „trigger‟  basis  specifically  to  address 
reproductive/developmental (but also immune and neurotoxicity) endocrine endpoints not covered in 
the two generation assays. In particular, it addresses reproductive endpoints that require the interaction 
of males and females, females with conceptus, females with offspring, and the F1 generation until 
after sexual maturity. Endocrine relevant endpoints include for example the anogenital distance and 
the presence of nipples/areolae in male pups.  
Examples of endocrine relevant non mammalian toxicity TGs and guidance include the amphibian 
metamorphosis assay (TG 231), the fish screening assay (TG 230), the fish short-term reproduction 
assay (TG 229) the androgenised female stickleback screen (OECD GD 140), and the fish sexual 
development test (TG 234).  
As the work will continue to deliver more suitable TGs, the following ongoing activities within OECD 
are relevant for EASs:  
VMG-NA has provided TG 456 on steroidogenesis (that is already included in the CF) and is carrying 
out further related work to support TG development: AOPs, HTS, metabolism, species differences, 
new endpoints, Ad Hoc QSAR group. 
The  OECD  described  in  its  Work  plan  of  the  Test  Guideline  Programme  (OECD,  2012d),  the 
following projects relevant for screening/testing chemicals for endocrine disruption:  
Related to health effects and endocrine disruption:  
Project 4.31: EDTA Activity - New TG: Human Recombinant Estrogen Receptor Alpha Binding Assays 
(hrERA,  2  protocols).  Lead:  United  States +  European  Commission  +  Germany  +  Japan.  Project  status  and 
milestones: Validation plan discussed the meeting of the VMG-NA (2007); Validation (complete) was presented at 
the meeting of the VMG-NA (2010); Data analysis and compilation completed in 2011; Work ongoing. 
 
Project 4.33: EDTA Activity - New TG: Stably Transfected Transcriptional Activation (STTA). Assay for 
the  detection  of  androgenic  and  anti-androgenic  activity  of  chemicals.  Lead:  Japan.  Project  status  and 
milestones:  Draft  validation  report  and  draft  TG  submitted  to  the  Secretariat  in  2010;  Draft  validation  report 
submitted to the VMG-NA in December 2010; Peer review report available in February 2011; Draft peer review 
report (with draft WNT Statement on the follow-up to the peer review) endorsed/agreed at the 2011 WNT meeting; 
Discussion of chemicals to be included in an additional validation at the VMG-NA meeting; Work ongoing. 
 
Project  4.34:  EDTA  Activity  -  New  TG  for  a  stably  Transfected  Transactivation  (STTA) Assay  for  the 
detection  of  anti-estrogenic  activity  of  chemicals.  Lead:  Japan.  Project  status  and  milestones:  Collection  of 
validation data expected in 2nd quarter 2012; Work ongoing. Identification/Characterisation of EDs: scientific criteria and test methods 
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Project 4.47: EDTA Activity - TG for an MCF-7 Cell Proliferation Assay for the Detection of Estrogen 
Receptor Agonist and Antagonist. Lead: United States. Project status and milestones: Information on the added 
value, scope, and possible place in an endocrine disruptor assessment scheme expected to be provided by the 
VMG-NA  before  the  first  commenting  round;  Validation  study  completed  in  January  2011; Validation  report 
expected end of March 2012; US expected to make a decision on whether a Peer Review will be conducted and a 
draft test guideline developed.  
 
Project 4.48: EDTA Activity - TG for a Chimpanzee Recombinant Androgen Receptor Binding Assay. 
Lead: United States. Project status and milestones: Information on the added value, scope, and possible place in an 
endocrine disruptor assessment scheme expected to be provided by the VMG-NA before the first commenting 
round; Pre-validation ongoing; Pre-validation report expected when the pre-validation is completed. This project is 
not expected to be continued after that stage. 
 
**Project  4.55:  GD  on  internal  triggers  for  US/Canada  (GD  117)  and  GD  Supporting  the  TG  for  an 
Extended One Generation Reproductive Toxicity Study (draft GD 151). Lead: Secretariat. Project status and 
milestones: Preliminary draft GD supporting the Extended One Generation Reproductive Toxicity Study developed 
in parallel with the draft TG; Draft GD on internal triggers approved at the 2011 WNT meeting; GD published as 
No 117; Request for WNT comments on the draft GD 151 in September 2011; Discussion of draft GD 151 at an 
expert meeting on 25-26 January 2012 in Arlington (VA, United States); WNT Comments on a revised draft GD 
requested in April 2012; GD expected to be approved at the 2013 WNT meeting. 
Note: This work on an extended one-generation reproductive toxicity study TG 443 & GD 151 has the 
objective to evaluate specific life stages not covered by other types of toxicity studies and test for effects that may 
occur as a result of pre- and postnatal chemical exposure, e.g. on reproduction, on the developing nervous system 
or on the developing immune system. This study evaluates endocrine endpoints in the juvenile and adult F1, which 
are not included in the 2-generation study (OECD TG 416) adopted in 2001.  
 
**Project 4.64: Transcriptional Assay for the Detection of Estrogenic and Anti-Estrogenic Compounds using 
the MELN Cells. Lead: European Commission. Project status and milestones: In vitro transactivation assay (2 
protocols: one for a manual test method and one for a high throughput test method); Under validation; Expected to 
be integrated to TG 455 and TG 457 (BG1Luc ER TA).  
 
 
Related to effects on biotic systems, that may also include endocrine disruption effects: 
 
Project 2.1: EDTA Activity: New TG for Copepod Reproduction and Development. Lead: Sweden. Project 
status and milestones: Pre-validation completed, expert group meeting on 3-4 November 2005; Revised detailed 
ring-test plan circulated in November 2005; Ring-test between November 2005 and mid-2006; Submission of the 
draft report to the invertebrate expert group and the VMG-eco; Additional experimental work (plus report and 
statistical analysis) completed in 2007 Validation report (Phase 1) published in 2007; Expert group agreement on 
another ring test. Validation plan developed by Sweden and the US; Validation report (phase 2) endorsed at the 
2011 WNT meeting; The US took the lead of an additional interlaboratory study; Outcome of additional work 
discussed  at  the  VMG-eco  meeting  (November  2011)  Comparison  review  between  copepod  and  mysid; 
Experimental work expected to be completed in 2nd quarter 2012; Integrated Summary Report expected to be 
available end 3rd quarter 2012. Work ongoing.  
 
Project 2.4: New TG 2-Generation Avian Toxicity. Lead: United States. Project status and milestones: Initial 
draft TG in 1999; decision to conduct an avian dosing study to be considered after DRP approval (Project 2.5 
completed); Species comparison study circulated to the expert group in April 2005; Avian dosing study (July 2005) 
and revised draft TG (November 2005) presented at VMG-eco meeting in December 2005; Revised draft TG used 
in developing a protocol for a demonstration study; Report of the demonstration study expected before the end of 
3rd quarter 2010; Revised Special Programme for Food Security (SPSF) expected to be submitted for the 2011 
WNT meeting; Progress report at the VMG-eco in November 2011; Experimental work expected to be completed 
in May 2012; Post study/histopathology expected end 2012; Validation report expected in 2013.  
 
Project 2.12: EDTA Activity: TG on a Medaka Life Cycle / Multi-generation Test (MMT). Lead: United 
States + Germany + Japan. Project status and milestones: Biateral work in Japan and the United States on medaka 
FLC/2-Gen in 2005-2006; Germany is working on a parallel project; 2007: preparation of a report comparing the 
various results available,  based  on  2  to  3  substances;  Review  of  statistical  issues  circulated  for  comments  in 
September 2007 to the fish drafting group and the VMG-eco; Revised review of statistical issues submitted to the 
VMG-eco meeting in January 2008; Development of a TG by Japan and the United States expected at a later stage; 
Revised SPSF submitted by the US and Japan agreed at the 2009 WNT meeting; Discussion of the approaches 
proposed and best course of action by the VMG-eco in December 2009 and by the fish expert group at a meeting in 
June  2010;  Consensus Japan/USA  27  week-Medaka  Multigeneration  Test  presented  at  the  fish drafting  group 
meeting held on 9-10 February 2011 in Japan; Progress report at the VMG-eco meeting in November 2011; Data Identification/Characterisation of EDs: scientific criteria and test methods 
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expected to be available for discussion by the Validation Management Group for Ecotoxicity Testing in December 
2012 in Paris. 
 
Project 2.13: EDTA Activity: New TG for Mysid Life Cycle Toxicity Test. Lead: United States. Project status 
and milestones: First proposal for a TG submitted in 2004; Pre-validation work completed in the U.S. in July 2005; 
Issue discussed at the 2nd Meeting of the invertebrate expert group, on 3-4 November 2005, and progress report at 
the VMG-eco in December 2005; Preliminary ring test results available. More validation needed; Optimization; US 
may  pursue  a  national  development  of  the  test  method  depending  on  the  interest  of  other  member  countries; 
Secretariat asked the WNT whether other countries than the US were interested in the project. If no country was 
interested, the project would be moved to Annex 1; Germany expressed interest in the project; Depending on the 
validation outcome, the SPSF will be revised and other partners will be invited to participate; Validation work 
completed (At that time there may be a need for a study comparing the copepod reproduction and development test 
(Project 2.1) with the mysid test; Comparison review between copepod and mysid; Outcome of additional work 
expected discussed at the VMG-eco meeting (November 2011); Experimental work expected to be completed in 
2nd quarter 2012; Integrated Summary Report expected to be available end 3rd quarter 2012.  
 
Project 2.31: EDTA Activity - TG on a Larval Amphibian Growth and Development Assay. Lead: United 
States + Japan. Project Status and milestones: Report at the VMG-eco meeting in November 2011; Validation 
expected to be completed in 2nd quarter 2012; Validation report expected to be available end 2012.  
 
Project  2.36:  EDTA  Activity  -  New  TG(s):  Mollusc  Reproductive  Toxicity  Tests  –  Development  and 
Validation  of  Test  Guidelines.  Lead:  Germany,  United  Kingdom,  France,  Denmark.  Project  Status  and 
milestones: Annual meetings of lead countries; Pre-validation and Ring test under the oversight of the VMG-eco; 
Report on the pre-validation of Potymopyrgus and Lymnea tests at the VMG-eco in 2011 and2012; First draft TG 
expected to be ready for a WNT commenting round by the end of 2014. 
 
Project 2.39: EDTA Activity – New TG: Xenopus Embryonic Thyroid Signalling Assay. Lead: France. Project 
status  and  milestones:  Project  approved  by  written  procedure  on  1  June  2011;  Completion  of  a  document 
summarising results from different demonstration studies in 2011; Project discussed at the VMG-eco meeting in 
November 2011; Comprehensive written validation plan, including a detailed protocol, distributed to VMG-eco and 
participating laboratories in June 2012; Inter-laboratory trial in 2012. Work ongoing. 
 
**Project 2.7: New TG for Fish Embryo Toxicity test. Lead: Germany. Project status and milestones: First draft 
of  the  TG  and  comprehensive  background  paper  sent  to  the  WNT  for  comments  by  1  September  2006; 
Establishment of an expert group to address comments received; First teleconference of expert group on 29 January 
2007 (decision on further validation steps), followed by two other conference calls; Meeting of the expert group on 
9-11 October 2007 in Berlin; Expert group addressed the issue of performance; meeting arranged by ILSI/HESI at 
L‟Oreal in Paris in March 2008 with a session on the OECD FET; Progress reported at WNT 20 meeting in 2008; 
Meeting of the expert group on 14-15 May 2008 in Berlin; Validation Management Group established to oversee 
the validation study that was initiated in May 2009. Validation report (phase 1) endorsed at the 2011 WNT meeting 
and published in 2011; Validation (phase 2) initiated in October 2010 with additional testing of 13 chemicals in 8 
laboratories; Expert group meeting in Berlin on 16-17 February 2012; Phase 2 validation report will be submitted 
for endorsement at the WNT in April 2012; Phase 2 validation report endorsed by the WNT and submitted to the 
Joint Meeting for declassification before publication, 2nd draft TG sent to WNT for comments by 14 September 
2012. 
 
Adapted  from  OECD  (2012)  WORK  PLAN  FOR  THE  TEST  GUIDELINES  PROGRAMME  (TGP) 
http://www.oecd.org/env/ehs/testing/August%20Work%20plan%20for%20the%20Test%20guidelines%20program
me%20June%202013.pdf. 
**= projects not mentioned by the OECD in the overview table 2 from document “Information on OECD Work 
related to Endocrine disruptors” (OECD, 2012f).  
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D.  EPIDEMIOLOGICAL, FIELD AND (ECO)TOXICOLOGICAL INFORMATION  
This annex describes types of studies that can be used to inform Level 1 of the OECD CF, OECD GD 
150, (OECD, 2012a), and that may already be available in scientific literature prior to specifically 
conducting regulatory tests in subsequent levels of the CF.  
 
D.1   Use  of  epidemiological  information when  characterising  the  hazards for humans of 
exposure to endocrine active substances 
Because the main concern of EAS exposure and potential adverse effects relate to humans (e.g. as 
reviewed in the report on early development effects (WHO, 2012)), the conduct of epidemiological 
studies appears to be a logical and necessary complement to non-clinical studies to better characterise 
the nature and magnitude of the risk of endocrine disruption in humans.  
However, general difficulties of epidemiological studies are related to their observational nature which 
is  prone  to  a  number  of  selection  biases  and  methodological  difficulties.  More  specifically, 
epidemiological studies aiming at deciphering a plausible causal relation between EAS exposure and 
various adverse effects should account for the following: 1) Environmental EASs are numerous and 
ubiquitous, 2) Humans are generally exposed to low levels and multiple substances and, 3) Other 
„environmental‟ conditions such as lifestyle factors may come into play (Main et al., 2010; Martina et 
al., 2012). 
Precise estimates of the exposure together with the identification of the critical developmental stage(s) 
to a particular EAS or combined exposure to multiple EASs are major challenges in studies aimed at 
assessing the effects of EASs in humans. 
Designing relevant exposure measurements 
A number of studies have focused on EAS perinatal exposure due to the possible irreversible 
impact of an exposure during this critical developmental period. In this particular case, the 
exposure  of  the  individual  at  the  time  of  disease  manifestation  is  not  important,  but  the 
exposure of the parents at time of conception and/or prenatal period is the one that needs to be 
assessed. Since accurate exposure data of the parents are hardly available it is consequently 
difficult to establish any causal association between early life exposures and adverse health 
effects in adulthood.  
A unique measurement of exposure e.g. in urine, provides a snap-shot of exposure, but is not a 
good surrogate marker to estimate any long term exposure to ubiquitous substances that do not 
accumulate in the human body (e.g. phthalates). In addition, the total exposure may involve a 
repeated exposure to very low doses of different EASs. 
Perhaps partly due to the above difficulties, several studies which have tried to quantify the exposure 
to various EASs have failed to find a link between exposure and adverse effects (e.g. Swan et al., 
2005). 
Health effects currently attributed to EAS exposure are often multifactorial, highly prevalent in the 
general population (e.g. obesity, diabetes, breast or prostate cancer, decreased fertility or congenital 
malformations), making the identification of an increased risk associated with the exposure to EASs 
only possible via the conduct of cohort studies with a very large sample size due to the need of 
controlling for a very wide range of possible confounding factors; e.g. diet, exercise, smoking status, 
social status (Vrijheid et al., 2012; Gehring et al., 2013) are examples of such studies. Significant 
changes in nutrient and food intake over the recent years also needs to be taken into account. Identification/Characterisation of EDs: scientific criteria and test methods 
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The problem of defining adequate study groups and to find controls in humans studies 
It is often impossible to find negative controls, i.e. subjects who have not been or are not 
exposed to EASs and other substances. The absence of proven effects observed in humans 
following EAS exposure might be related to the low exposure levels but also to the difficulty 
to account for the multiple exposures from the environment. 
Occupationally exposed workers represent an interesting group of subjects to assess the effects 
of  some  EASs  in  humans  due  to  the  predominant  high  levels  of  exposure  to  specific 
substances compared to environmental exposures. However, due to the ubiquitous nature of 
many of these substances finding control groups poses an important methodological problem. 
Inaccurate  biomonitoring  data  could  lead  to  misclassification  (i.e.  wrongly  consider  that 
subjects have not been exposed to EASs despite the fact that they have actually been), which 
in turn will induce a bias towards finding no effect between the active and the control groups. 
A  lack  of  adequate  biomonitoring  data  is  a  major  limiting  factor  in  preventing  the 
identification of causal associations.  
Independent  of  these  difficulties,  wide  population  surveys  in  combination  with  specific 
epidemiological  studies  will  still  be  the  most  important  approaches  to  identify  adverse  effects  of 
endocrine disruption in the human population. Criteria for objectively evaluating the level of causality 
of associations observed in epidemiology have been formulated by Bradford Hill (1965) and include 
consistency, strength of association, dose response, time order, specificity, consistency of replication, 
predictive  performance,  biological  plausibility  (including  evidence  from  non-clinical  studies)  and 
coherence.  
Considering the uncertainties surrounding the effects of EASs on human health and limitations of 
extrapolation from non-clinical data, it can be concluded that the conduct of epidemiological studies, 
in spite of their inherent challenges, remains an essential component of the evaluation of possible 
human effects of EASs in large populations.  
Advances in our understanding of critical windows of susceptibility (see section 4.7.2) and of the 
cumulative effects of multiple EASs acting in synergy (see section 4.7.3) add to existing concerns 
about the health impacts of EASs. The increased level of knowledge shows that the possible impacts 
of EASs on human health cannot be dismissed and should be taken into account in risk assessment 
(EEA, 2012).  
 
D.2   Use of field information when characterising the hazards for wildlife of exposure to 
endocrine active substances 
Laboratory studies have shown that a broad range of species from vertebrate and invertebrate taxa are 
susceptible to EASs; for many species, strong evidence exists to indicate that endocrine disruption is a 
widespread phenomenon in wildlife populations. Clear examples of male and female reproductive 
dysgenesis and of thyroid hormone disruption that can be linked, quite convincingly, to ED exposure 
have been reported in some wildlife (non-target) species. The causal relationship is, however, difficult 
to establish (EEA, 2012). For example, although an extensive number of studies have demonstrated 
endocrine disruption in wild freshwater and marine fish e.g. by Allen et al. (1999), the causality of the 
worldwide decline in amphibian populations and the possible effects and contribution of endocrine 
disruption to such decline remains uncertain (EEA, 2012). 
In principle, there is no major difference between the evaluation of effects in the field of EDs and non-
EDs. However, in view of the need to be confident that an adverse effect of an ED is likely to have 
consequences  at  the  population  level, the  use  of  field  data,  if  available,  may  be  valuable.  In  the 
absence of such data, regulators must be confident of being able to extrapolate from laboratory data on Identification/Characterisation of EDs: scientific criteria and test methods 
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such  endpoints  as  growth  and  reproduction  to  potential  effects  on  populations,  ideally  but  not 
necessarily through the use of population modelling. It is acknowledged that some effects, particularly 
those affecting individual behaviour, may not easily be apparent when observed at a population or 
subpopulation level. 
There  are  two  types  of  field  information  –  field  experiments,  and  monitoring  data.  The  former 
approach involves the study of animal populations in treated artificial ponds (mesocosms), cages or 
field  plots  (e.g.  Kidd  et  al.,  2007).  Through  the  use  of  replication  and  defined  dosing  with  the 
substance of interest, this is essentially a field extension of laboratory experiments, and can provide 
reliable population-level data which firmly link the treatment with an adverse effect. In the case of 
EASs/EDs, it may also be desirable to measure biomarkers of exposure and/or mechanism in the 
exposed organisms (e.g. vitellogenin – VTG - induction in male fish as a response to oestrogens) so as 
to  provide  further  evidence  that  the  observed  population-level  impact  is  indeed  associated  with 
postulated endocrine activity. The main drawback of mesocosm, cage or plot experiments is their cost, 
and the complexity of evaluating the results. By contrast, effects on some aspects of animal behaviour, 
particularly those which are best expressed in the environment of a natural experimental arena, may be 
studied more effectively in the field than in the laboratory. 
Field monitoring is probably the most powerful tool in establishing impacts at the population-level 
(e.g.  population  declines).  Historically,  field  monitoring  has  been  instrumental  in  illustrating  the 
environmental  hazards  of  chemicals  like  dichlorodiphenyltrichloroethane  (DDT),  Polychlorinated 
Biphenyls (PCBs) and mercury and their negative impacts on wildlife populations. Field monitoring is 
usually combined with chemical monitoring of the environment and the food chain. Correlation and 
multifactorial  analysis  are  employed  to  assess  the  results.  Such  data  are  similar  to  human 
epidemiological  information,  and  it  may  become  necessary  to  employ  the  Bradford  Hill  criteria 
(Bradford Hill, 1965) to decide by WoE whether the substance of interest is likely to be responsible 
for the observed effects. Ultimately, this may involve returning to the laboratory or mesocosm to 
conduct replicated experiments to test hypotheses derived from the field evidence. For an example of 
field monitoring, see the case of tributytin antifouling paints (Matthiessen and Gibbs, 1998). It should 
be noted that while field studies can provide confidence that an ED is indeed able to cause population-
level adverse impacts, there may be practical difficulties associated with this type of approach. In 
many cases, a judgement about whether test endpoints such as impaired reproduction are likely to 
cause population damage in the field will have to be made in the absence of field data or even of 
population modelling. In these circumstances, the expert judgement of the regulator or assessor will 
need to be deployed. A key question, for example, may be the degree of reproductive impairment (or 
other altered endpoint) which is likely to have consequences for populations. In other words, it may be 
insufficient merely to demonstrate a statistically significant effect on (say) fecundity – the effect must 
also be of sufficient magnitude so as to have biological relevance for the population (EFSA Scientific 
Committee, 2011). 
 
D.3   Use of in vitro and animal studies when characterising the hazards  for humans or 
wildlife of exposure to endocrine active substances 
There is a wealth of in vitro studies based on cellular systems or isolated receptors. As information 
accumulates the strength of different in vitro assays in predicting endocrine disruption related health 
effects is becoming more and more evident. The US EPA ToxCast programme is using receptor assays 
and enzyme assays in a high throughput system (HTS) for screening chemicals for endocrine activity 
(U.S. EPA, 2012b). The OECD Guidance Document 150 (OECD, 2012a) lists a number of in vitro 
screens and tests (Level 2) to evaluate substances for potential endocrine disruption, discussing their 
applicability and limitations.  
Animal  studies  have  contributed  considerably  to  our  understanding  of  health  disorders  as  a 
consequence of endocrine disruption in humans and wildlife. Reproduction-related disorders continue 
to dominate this area (for example, several EDs, either anti-androgenic or oestrogenic, can induce Identification/Characterisation of EDs: scientific criteria and test methods 
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various developmental anomalies of the male genital tract in experimental animals (Toppari, 2008), 
mirroring  what  has  been observed in  DES exposed  humans)  but  neurodevelopmental  and  thyroid 
hormone–mediated  disorders  have  also  joined  the  list.  The  WHO  report  (WHO,  2012)  on  early 
development  effects,  lists  more  than  100  examples  of  endocrine  disruption  related  effects  in 
experimental  animals  caused  by  pharmaceuticals  and  industrial  chemicals.  Without  doubt  this 
constitutes a body of evidence that substances cause endocrine disruption resulting in adverse effects. 
Since the animal models so clearly show such effects, this is a strong indication that humans could 
also be at risk provided the exposure is adequate. These animal experiments were reported in general 
scientific literature (i.e. were not performed under a regulatory framework) and they may often be 
carried  out  with  high  exposure  levels  that  are  not necessarily  relevant to  humans.  For  regulatory 
purposes,  whilst  maintaining  a  full  dose  response  curve,  in  vivo  toxicological  studies  should  be 
conducted at exposure levels relevant to human exposures.  
The requirement for demonstrating adverse effects of an ED is manifest in the OECD conceptual 
framework for ED testing in the provision for higher Level in vivo tests (i.e. Levels 4 and 5) with the 
capacity  to  demonstrate  effects  on  apical  endpoints  relevant  to  protection  goals  (e.g.  population-
relevant for ecotoxicological species). This obviously places a burden on animal testing in the near 
term, which cannot be avoided in the absence of robust methods for extrapolating data from in silico, 
in vitro or ex vivo methods to predict adverse effects in vivo. 
In conclusion, experimental and mechanistic studies will continue to be the key sources of information 
when judging if a substance could act as an ED, and which by extrapolation could lead to adverse 
health effects in humans and wildlife. The fact that a substance in an in vitro assay is binding to an 
endocrine receptor, then interfering with the intracellular messenger system connecting receptor to 
target or resulting in an endocrine related response in a target cell must be taken as strong indication 
for endocrine activity. If a suitable animal model provides further indication for an endocrine-related 
adverse effect, this substance should be considered an ED. 
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GLOSSARY 
 
Adverse effects  Change  in  the  morphology,  physiology,  growth,  development, 
reproduction, or life span of an organism, system, or (sub)population that 
results  in  an  impairment  of  functional  capacity,  an  impairment  of  the 
capacity  to  compensate  for  additional  stress,  or  an  increase  in 
susceptibility to other influences. 
IPCS 
Androgens  Androgens are steroidhormones that help to develop sex organs in men. 
They also contribute to sexual function in men and women. 
Endocrine 
Society 
Apical endpoints  Results of an in vivo assay which describe a response by the organism as a 
whole, (e.g. fecundity or growth) which have possible implications for its 
biological fitness, rather than a response of the endocrine system alone 
(including physiological changes dependent on the endocrine system, such 
as Vitellogenin induction). Apical responses may or may not result from 
endocrine changes (e.g. fecundity may be affected both by some EDs and 
by some non-EDs). 
OECD 
Critical effect  The first adverse effect, or its known precursor, that occurs to the most 
sensitive species as the dose rate of an agent increases. 
EPA 
Glossary 
Dose response 
relationship 
Relationship between the amount of an agent administered to, taken up by 
or absorbed by an organism system or (sub)population and the change 
developed in that organism, system or (sub)population in reaction to the 
agent. 
IPCS 
Expert system  A database of rules compiled by specialists (see section 4.2.2.6).  EFSA 
Grouping of 
substances and 
read-across 
approach 
Substances  whose  physicochemical,  toxicological  and  ecotoxicological 
properties are likely to be similar or follow a regular pattern as a result of 
structural  similarity  may  be  considered  as  a  group,  or  „category‟  of 
substances.  Application  of  the  group  concept  requires  that 
physicochemical  properties,  human  health  effects  and  environmental 
effects or environmental fate may be predicted from data for reference 
substance(s) within the group by interpolation to other substances in the 
group (read-across approach). This avoids the need to test every substance 
for every endpoint. 
JRC/IHCP 
Hazard  Inherent property of an agent or situation having the potential to cause 
adverse effects when an organism, system, or (sub)population is exposed 
to that agent. 
IPCS 
Hazard 
characterisation 
The  qualitative  and,  wherever  possible,  quantitative  description  of  the 
inherent property of an agent or situation having the potential to cause 
adverse  effects.  This  should,  where  possible,  include  a  dose–response 
assessment and its attendant uncertainties. Hazard characterisation is the 
second stage in the process of hazard assessment and the second of four 
steps in risk assessment. 
IPCS 
Hazard 
identification 
The identification of the type and nature of adverse effects that an agent 
has  an  inherent  capacity  to  cause  in  an  organism,  system,  or 
(sub)population.  Hazard  identification  is  the  first  stage  in  hazard 
assessment and the first of four steps in risk assessment. 
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Hormone  Made by endocrine glands, hormones are chemical messengers that travel 
in  the  bloodstream  to  tissues  or  organs.  They  affect  many  processes, 
including growth, metabolism, sexual function, reproduction, and mood. 
Endocrine 
Society 
HTS  High-throughput  screening  (HTS)  is  a  method  for  scientific 
experimentation  especially  used  in  drug  discovery  and  relevant  to  the 
fields  of  biology  and  chemistry.  Using  robotics,  data  processing  and 
control software, liquid handling devices, and sensitive detectors, HTS 
allows a researcher to quickly conduct millions of biochemical, genetic or 
pharmacological  tests.  Through  this  process  one  can  rapidly  iden tify 
active  compounds,  antibodies  or  genes  which  modulate  a  particular 
biomolecular pathway. The results of these experiments provide starting 
points for drug design and for understanding the interaction or role of a 
particular biochemical process in biology. 
JRC/IHCP 
In silico methods  The expression in silico is used to mean „performed on computer or via 
computer simulation‟. The phrase was coined in 1989 as an analogy to the 
Latin phrases in vivo and in vitro which are commonly used in biology 
and refer to experiments done in living organisms and outside of living 
organisms, respectively. 
JRC/IHCP 
Intact organism  Not in vitro systems, or castrated or ovariectomised test animals  EFSA 
In vitro assay  Assay where whole live animals are not used. Systems used may include 
cell lines or subcellular preparations from untreated animals. 
JRC/IHCP 
In vivo assay  Assay where a whole live animal is treated. This may be a mammalian 
assay where individual animals are treated or a wildlife assay where a 
population of animals is treated. 
JRC/IHCP 
(Endocrine) 
Modality 
A  modality  is  an  axis,  pathway,  signalling  process  or  hormonal 
mechanism within the endocrine system. 
EFSA 
Mode of Action  A biologically plausible sequence of key events leading to an observed 
effect  supported  by  robust  experimental  observations  and  mechanistic 
data. A mode of action describes key cytological and biochemical events – 
that is, those that are both measurable and necessary to the observed effect 
– in a logical framework. 
IPCS 
No observed 
adverse effect 
level (NOAEL) 
Greatest concentration or amount of a substance, found by experiment or 
observation, that causes no adverse alteration of morphology, functional 
capacity,  growth,  development  or  lifespan  of  the  target  organism 
distinguishable from those observed in normal (control) organisms of the 
same species and strain under the same defined conditions of exposure. 
IPCS 
Oestrogens  Oestrogens are a group of steroid compounds that are the primary female 
sex hormones. They promote the development of female secondary sex 
characteristics and control aspects of regulating the menstrual cycle. 
Endocrine 
Society 
(Q)SAR  (Q)SARs are methods for estimating properties of a chemical from its 
molecular  structure  and  have  the  potential  to  provide  information  on  
hazards  of  chemicals,  while  reducing  time,  monetary  cost  and  animal 
testing currently needed. 
JRC/IHCP 
Read-across  „Read-across‟ is a technique of filling data gaps. To „read-across‟ is to 
apply data from a tested chemical for a particular property or effect (e.g. 
cancer, reproductive toxicity) to a similar untested chemical. The read-
across  technique  is  often  applied  within  groups  of  similar  chemicals 
assembled for assessment using either analog approach (grouping based 
on a very limited number of chemicals) or category approach (grouping 
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based on a larger number of chemicals). In an analog/category approach, 
not every chemical needs to be tested for every endpoint. Source: EPA, 
Glossary of Terms, Methods of Toxicity Testing and Risk Assessment. 
Risk assessment   A  process  intended  to  calculate  or  estimate  the  risk  to  a  given  target 
organism,  system,  or  (sub)population,  including  the  identification  of 
attendant uncertainties, following exposure to a particular agent, taking 
into account the inherent characteristics of the agent of concern as well as 
the  characteristics  of  the  specific  target  system.  The  risk  assessment 
process includes four steps: hazard identification, hazard characterisation 
(related term: dose–response assessment), exposure assessment, and risk 
characterisation. It is the first component in a risk analysis process. 
IPCS 
Risk management   Decision-making  process  involving  considerations  of  political,  social, 
economic, and technical factors with relevant risk assessment information 
relating to a hazard so as to develop, analyse, and compare regulatory and 
non-regulatory options and to select and implement appropriate regulatory 
response to that hazard. Risk management comprises three elements: risk 
evaluation; emission and exposure control; and risk monitoring. 
IPCS 
Thyroid hormone  The thyroid gland makes T3 (triiodothyronine) and T4 (thyroxine), which 
together are considered thyroid hormone. T3 and T4 have identical effects 
on  cells.  Thyroid  hormone  affects  heart  rate,  blood  pressure,  body 
temperature, and weight. T3 and T4 are stored as thyroglobulin, which can 
be converted back into T3 and T4.  
National 
Cancer 
Institute 
dictionary 
Validated Assay  A  test  method  for  which  validation  studies  have  been  completed  to 
determine the relevance (including accuracy) and reliability for a specific 
purpose. It is important to note that a validated test method may not have 
sufficient performance in terms of accuracy and reliability to be found 
acceptable for the proposed purpose (OECD, 2005a).  
OECD 
Weight-of-
evidence 
A process in which all of the evidence considered relevant to a decision is 
evaluated and weighted. 
IPCS 
Wild life  Non-target  species.  This  term  does  not  cover  wildlif e  intended  to  be 
controlled by the application of regulated products (i.e. target species). 
EFSA 
 
ABBREVIATIONS 
 
A 
ADI 
Apical 
Acceptable Daily Intake 
ADME  Absorption, Distribution, 
Metabolism, Excretion 
ANSES  French Agency for Food, 
Environmental and Occupational 
Health & Safety 
AOP  Adverse Outcome Pathway 
AR  Androgen receptor 
CF  Conceptual Framework 
CMR  Carcinogenic, Mutagenic or toxic 
for Reproduction 
DES  Diethylstilbestrol  
DRP  Detailed Review Paper 
EAS  Endocrine active substance 
EATS  Oestrogen, androgen, thyroid or 
steroidogenic 
EC  European Commission 
ECETOC  European Centre for 
Ecotoxicology and Toxicology of 
Chemicals 
ECHA  European Chemical Agency 
ED  Endocrine disruptor 
EDTA  Endocrine Disruptors Testing and 
Assessment 
EDTA TF  Endocrine Disrupters Testing and 
Assessment Task Force 
EEA  European Environment Agency  
EMA  European Medicines Agency 
ENVI  Committee on the Environment, Identification/Characterisation of EDs: scientific criteria and test methods 
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Public Health and Food Safety 
(European Parliament) 
EP  European Parliament 
EQSD  Directive on Environmental 
Quality Standards 
ER  Oestrogen receptor 
EU  European Union 
FFLC  Fish full life cycle 
FP  Framework Programme 
GD  Guidance document 
HEAL  Health and Environment Alliance, 
NGO 
HPA  Hypothalamus-pituitary-
adrenocortical 
HTS  High Throughput Screening 
IPCS  International Programme on 
Chemical Safety 
JRC  Joint Research Centre 
M  Mechanistic 
MCF-7  Michigan Cancer Foundation-7 
MG  Multi-generation 
MMGT  Medaka Multi-generation Test 
NMDRC  Non-monotonic dose response 
curves 
NOAEL  No Observed Adverse Effect 
Level 
NOEC  No Observed Effect 
Concentration 
NRC  National Research Council 
NTP  US National Toxicology Program 
OECD  Organisation for Economic Co-
operation and Development 
PAN 
Europe 
Pesticide Action Network Europe, 
NGO 
PBT  Persistent, Bioaccumulative and 
Toxic 
PPAR  Peroxisome Proliferator-Activated 
Receptor 
PPP  Plant Protection Products 
(Q)SAR  (Quantitative) Structure Activity 
Relationship 
RBA  Relative binding affinity 
REACH  Regulation on Registration, 
Evaluation, Authorisation and 
Restriction of Chemicals 
rtER  rainbow trout oestrogen receptor 
SAAED  State of the Art Assessment of 
Endocrine Disrupters 
SAR  Structure Activity Relationship 
SCCS  Scientific Committee on 
Consumer Safety 
SCENIHR  Scientific Committee on 
Emerging and Newly Identified 
Health Risks 
SCHER   Scientific Committee on Health 
and Environmental Risks 
SPSF  Special Programme for Food 
Security 
STOT-RE  Specific Target Organ Toxicity-
Repeated Exposure 
STTA  Stably Transfected 
Transcriptional Activation 
SVHC  Substances of Very High Concern 
TDI 
TG 
Tolerable Daily Intake 
test guidelines 
TH  Thyroid hormone 
ToR  Terms of reference 
TR  Thyroid receptor 
UNEP  United Nations Environment 
Programme 
US EPA  The United States Environmental 
Protection Agency 
VMG–
Mamm 
The OECD Validation 
Management Group for 
mammalian toxicity testing 
VMG-eco  The OECD Validation 
Management Group for 
ecotoxicology testing 
VMG-NA  The OECD Validation 
Management Group on non-
animal testing 
vPvB  Very persistent and very 
bioaccumulative 
WFD  Water Framework Directive 
WHO  World Health Organization 
WNT  The OECD Working Group of 
National Co-ordinators of the Test 
Guidelines Programme  
WoE  Weight-of-evidence 
 
 
 